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During	  my	  PhD	  I	  worked	  on	  a	  project,	  that	  I	  started	  during	  my	  Master	  of	  Science	  internship,	  about	  
the	  functional	  cooperation	  between	  Sox6	  and	  Nfix	  during	  murine	  prenatal	  myogenesis.	  The	  results	  
of	   this	  project	  have	  been	   recently	  published	  on	  Cell	   Reports	  where	   I	   am	   first	   author.	   This	  work	  
addressed	  the	  role	  of	  Sox6,	  during	  embryonic	  myogenesis,	  in	  regulating	  the	  expression	  of	  the	  slow	  
myosin	   heavy	   chain	   (MyHC-­‐I).	   We	   demonstrated	   that	   Sox6,	   which	   is	   a	   well-­‐known	   inhibitor	   of	  
MyHC-­‐I	  during	  fetal	  myogenesis,	  is	  instead	  responsible	  for	  MyHC-­‐I	  activation	  during	  the	  embryonic	  
myogenesis	   via	   Mef2C-­‐dependent	   mechanism.	   Notably,	   we	   reported	   that	   the	   switch	   in	   Sox6	  
function	  at	  the	  onset	  fetal	  myogenesis	  occurs	  through	  the	  interaction	  with	  the	  transcription	  factor	  
Nfix.	   Finally,	  we	   demonstrated	   that	   the	   functional	   cooperation	   of	   Sox6	   and	  Nfix	   is	   evolutionary	  
conserved	  in	  mouse	  and	  zebrafish	  (Part	  II).	  Across	  this	  project,	  I	  started	  to	  work	  on	  my	  PhD	  project	  
about	  the	  identification	  of	  the	  molecular	  mechanisms	  involved	  in	  the	  regulation	  of	  Nfix	  expression	  
during	   fetal	   myogenesis.	   The	   data	   obtained	   are	   now	   collected	   in	   manuscripts	   one	   already	  
























Skeletal	  muscle	  development	  occurs	  through	  successive	  developmental	  phases,	  named	  embryonic	  
and	   fetal	   myogenesis,	   involving	   the	   differentiation	   of	   distinct	   myogenic	   populations:	   the	  
embryonic	  and	  fetal	  myoblasts.	  An	  important	  work	  developed	  in	  2007	  identified	  specific	  features	  
of	   embryonic	   and	   fetal	   myoblasts,	   demonstrating	   that	   these	   two	   populations	   of	   muscle	  
progenitors	   represent	   intrinsically	   different	   myogenic	   lineages.	   The	   identification	   of	   the	  
transcriptional	   factor	   Nfix	   was	   the	   major	   step	   in	   understanding	   how	   muscle	   progenitor	   fate	  
decisions	  are	  mediated.	  Nfix,	  expressed	  in	  fetal	  but	  not	  in	  embryonic	  muscles,	  is	  necessary	  for	  the	  
acquisition	  of	  fetal	  myogenic	  identity,	  activating	  fetal-­‐specific	  genes	  and	  repressing	  the	  expression	  
of	  embryonic	  one,	  such	  as	  slow	  myosin	  heavy	  chain	  (MyHC-­‐I).	  Another	  repressor	  of	  MyHC-­‐I,	  during	  
fetal	  myogenesis,	   is	   the	  transcription	  factor	  Sox6,	  which	   inhibits	  MyHC-­‐I	  by	  direct	  binding	  to	  the	  
proximal	   promoter	   of	   MyHC-­‐I	   gene.	   Interestingly,	   Sox6	   at	   variance	   with	   Nfix	   is	   also	   expressed	  
during	  embryonic	  myogenesis,	  when	  embryonic	  myoblasts	   form	  fibers	   that	  express	  high	   level	  of	  
MyHC-­‐I.	  We	  demonstrated	  that	  Sox6	  has	  opposite	  roles	  in	  regulating	  MyHC-­‐I	  expression	  between	  
embryonic	   and	   fetal	   myogenesis.	   Specifically,	   during	   embryonic	   myogenesis,	   Sox6	   indirectly	  
promotes	  MyHC-­‐I	  expression	  via	  transcriptional	  activation	  of	  Mef2C.	  On	  the	  contrary,	  during	  fetal	  
myogenesis,	  Nfix	  allows	  the	  proper	  binding	  of	  Sox6	  to	  the	  MyHC-­‐I	  promoter	  with	  the	  consequent	  
repression	  of	  MyHC-­‐I	  expression.	  In	  addition,	  we	  provide	  evidence	  that	  the	  functional	  interplay	  of	  
Nfix	  and	  Sox6	  is	  conserved	  also	  in	  zebrafish.	  Although	  Nfix	  functions	  were	  partially	  characterized,	  
nowadays	  the	  mechanisms	  that	  regulate	  its	  expression	  during	  fetal	  myogenesis	  are	  still	  unknown.	  
Another	   transcription	   factor	  more	  expressed	  during	   fetal	  myogenesis	   is	   JunB.	  We	  assessed	   that	  
JunB	  is	  required	  and	  sufficient	  to	  induce	  the	  expression	  of	  Nfix,	  acting	  as	  direct	  activator	  of	  it.	  To	  
better	  elucidate	  this	  pathway,	  we	  started	  to	  study	  the	  possible	  involvement	  of	  RhoA	  and	  its	  major	  
kinase	  ROCK,	  since	  growing	   investigations	  have	  shown	  that	  RhoA/ROCK	  regulate	  skeletal	  muscle	  
differentiation.	  We	  demonstrated	  that	  RhoA/ROCK	  are	  active	  only	  during	  embryonic	  myogenesis	  
and	  their	   inhibition	   in	  embryonic	  myoblasts	   increased	  the	  expression	  of	  both	  Nfix	  and	  JunB.	  The	  
interference	  with	  the	  RhoA/ROCK	  signalling	  led	  also	  to	  the	  increased	  activation	  of	  the	  ERK	  kinases,	  
which	  we	  show	  are	  necessary	  for	  Nfix	  and	  JunB	  up-­‐regulation.	  In	  summary,	  we	  have	  identified	  the	  
RhoA/ROCK	  axis	  as	  an	  important	  negative	  regulator	  of	  JunB	  and	  Nfix	  expression	  during	  embryonic	  
myogenesis,	   through	  the	   inhibition	  of	  ERK	  activity.	  Conversely,	  during	   fetal	  myogenesis,	   the	  ERK	  
kinases	  are	  active	  and	  allow	  JunB	  and	  Nfix	  expression.	  Finally,	  Nfix	  is	  sufficient	  to	  activate	  the	  fetal	  











1.	  Skeletal	  muscle	  organization	  and	  function	  
1.1	  Cellular	  physiology	  and	  contraction	  
Skeletal	  muscle	  is	  the	  most	  abundant	  tissue	  in	  our	  body	  and	  it	  is	  responsible	  for	  all	  the	  voluntary	  
movements,	  breathing,	  the	  storage	  of	  nutrient	  reserves	  and	  for	  the	  maintenance	  of	  posture	  and	  
body	  temperature.	  Each	  skeletal	  muscle	  is	  made	  up	  of	  a	  large	  number	  of	  syncytial	  cell,	  known	  as	  
myofibers.	   A	   myofiber	   is	   a	   multinucleated	   single	   muscle	   cell,	   formed	   from	   the	   fusion	   of	   many	  
precursor	  cells.	  Each	  muscle	  fiber	  is	  surrounded	  by	  a	  cell	  membrane	  or	  sarcolemma,	  composed	  by	  
a	  lipid	  bilayer,	  that	  is	  in	  contact	  with	  numerous	  thin	  collage	  fibrils	  and	  specialized	  proteins	  such	  as	  
laminin,	  which	  functions	  as	  a	  scaffold	  for	  the	  myofiber.	  Inside	  each	  muscle	  fibers,	  the	  cytoplasm	  is	  
mainly	   composed	   by	   myofibrils,	   which	   constitute	   the	   contractile	   apparatus.	   The	   myofibrils	   are	  
composed	  by	   repeated	   segments,	  named	   sarcomers,	   formed	  by	  parallel	   actin	   (thin)	   and	  myosin	  
(thick)	  filaments,	  thus	  representing	  the	  core	  of	  muscle	  contraction.	  Our	  current	  understanding	  of	  
muscle	   contraction	   derives	   from	  A.F.	  Huxley	   and	  R.	  Niedergerke	   (1954)	   and	  H.	   E.	  Huxley	   and	   J.	  
Hanson	   (1954),	   that	   observed	   a	   sarcomere	   shortening	   during	   contraction	   (Figure	   1).	   The	  
shortening	  is	  due	  to	  change	  in	  length	  of	  actin	  filaments,	  while	  the	  thick	  filaments	  of	  myosin	  remain	  
constant	  in	  length.	  These	  observations	  led	  them	  to	  propose	  a	  sliding	  filament	  theory,	  which	  state	  
that	  the	  sliding	  of	  actin	  on	  myosin	  generates	  a	  shortening	  of	  actin	  filament	   length,	  resulting	   in	  a	  
shortening	  of	  the	  sarcomere	  and	  thus	  of	  the	  muscle.	  The	  sliding	  is	  due	  to	  the	  capability	  of	  myosin	  
to	   pull	   upon	   actin	   to	   shorten	   the	   sarcomere,	   thanks	   to	   the	   power	   stroke	   of	   myosin,	   obtained	  
through	  the	  hydrolysis	  of	  ATP.	  Skeletal	  muscle	  contractions	  are	  neurogenic,	  as	  motor	  neuron	  input	  
is	   required	   to	   produce	  muscle	   contractions.	   The	  motor	   neuron	   excitation	   provokes	   the	   release	  
from	   the	   sarcoplasmatic	   reticulum	   of	   calcium	   ions,	   which	   interact	   with	   troponin	   of	   the	   thin	  
filament,	   causing	   a	   movement	   of	   the	   tropomyosin	   molecules.	   All	   these	   movements	   allow	   the	  























Figure	  1:	  Scheme	  of	  a	  sarcomere.	  The	  diagram	  shows	  the	  structure	  of	  a	  relaxed	  and	  contracted	  sarcomere,	  
composed	  by	  thick	  myosin	  filaments	  (in	  light	  blue)	  and	  thin	  actin	  filaments	  (in	  red).	  The	  thin	  actin	  filaments	  
are	   tethered	   at	   the	   Z-­‐discks	   and	   interdigitated	   between	  myosin	   filaments.	   The	   contracted	   sarcomere	   is	  









Skeletal	   muscles	   are	   heterogeneous	   tissues	   to	   fulfill	   different	   functional	   demands	   such	   as	  
continuous	  low-­‐intensity	  activity	  (posture),	  repeated	  submaximal	  contractions	  (locomotion)	  or	  fast	  
and	  strong	  maximal	  contractions	  (jumping,	  kicking).	  The	  heterogeneity	  of	  skeletal	  muscles	  is	  due	  
to	  different	   fiber	   types	   that	   compose	  each	  muscle.	  Nowadays,	   the	   fibers	  are	  classified	   into	   four	  
major	   types	   (Table	   1),	   marked	   by	   the	   expression	   of	   different	   isoforms	   of	   myosin	   heavy	   chain	  
(MyHC):	  MyHC-­‐I,	  MyHC-­‐2a,	  MyHC-­‐2x	  and	  MyHC-­‐2b	  (DeNardi	  et	  al.	  1993;	  Chakkalakal	  et	  al.	  2012).	  
Specific	  MyHC	  isoforms	  are	  also	  present	  in	  developing	  muscle:	  embryonic	  MyHC	  (MyHC-­‐emb)	  and	  
perinatal	   or	   neonatal	   MyHC	   (MyHC-­‐neo),	   encoded	   by	   Myh3	   and	   Myh8	   respectively.	   The	  
developing	   MyHC	   isoforms	   are	   expressed	   during	   prenatal	   development	   and	   in	   regenerating	  
muscles,	   which	   recapitulate	   the	   molecular	   processes	   involved	   during	   embryonic	   development	  
(Eusebi	  et	  al.,	  1986;	  Schiaffino	  et	  al.,	  1986;	  Whalen	  et	  al.,	  1990).	  The	  power	  and	   the	  velocity	  of	  
shortening	  of	  each	  muscle	  are	  determined	  by	  the	  type	  of	  myosin,	  that	  is	  present	  in	  the	  fiber,	  and	  
both	   decrease	   in	   the	   order	   MyHC-­‐I	   <	   MyHC-­‐2a	   <	   MyHC-­‐2x	   <	   MyHC-­‐2b	   (Reiser	   et	   al.,	   1985;	  
Bottinelli	  et	  al.,	  1996).	  These	  observations	  lead	  to	  subdivide	  the	  fibers	  in	  slow-­‐twitching	  fibers	  or	  
type	  I	   fibers,	  which	  express	  MyHC-­‐I,	  and	  fast-­‐twitching	  fibers	  expressing	  MyHC-­‐2a,	  MyHC-­‐2x	  and	  
MyHC-­‐2b	   (Schiaffino	   and	  Reggiani,	   2011).	   Slow	  and	   fast-­‐twitching	   fibers	   differ	   also	   in	  metabolic	  
properties.	   Slow	   fibers	  are	  able	   to	  generate	  ATP	  by	  oxidative	  mitochondrial	  processes	  and	   their	  
ATP	  consumption	  during	  contraction	  is	  not	  high,	  allowing	  them	  to	  maintain	  contractile	  activity	  for	  
long	   time	   without	   showing	   fatigue.	   Conversely,	   fast	   fibers	   generate	   ATP	   very	   rapidly	   through	  
glycolytic	   processes,	   setting	   a	   limit	   to	   the	   duration	   of	   their	   contractile	   activity	   (Schiaffino	   and	  
Reggiani,	   2011).	   Based	   on	   their	   metabolic	   properties,	   myofibers	   can	   be	   subdivided	   into	   slow-­‐
oxidative	   (S),	   fast-­‐oxidative-­‐glycolitic	   (FOG)	   and	   fast-­‐glycolitic	   (FG)	   fibers	   (Ashmor	   et	   al.,	   1972;	  
Peter	  et	  al.,	  1972).	  The	  FOG	  fibers	  are	  the	  type	  2a	  fibers,	  expressing	  MyHC-­‐2a	  isoform,	  and	  they	  
possess	   both	   oxidative	   and	   glycolytic	   enzyme	   complement	   (Barnard	   et	   al.,	   1971),	  while	   type	   2x	  
and	   2b	   fibers	   have	   only	   a	   high	   content	   of	   glycolytic	   enzymes	   (Nemeth	   et	   al.,	   1981;	   Park	   et	   al.,	  
1987).	  The	  heterogeneity	  of	  skeletal	  muscles	  is	  early	  established	  during	  prenatal	  development	  and	  
can	  be	  regulated	  by	  extrinsic	  signals	  during	  adulthood.	  	  
	  
	   Type	  I	  fibers	   Type	  2a	  fibers	   Type	  2x	  fibers	   Type	  2b	  fibers	  
Contraction	  time	   Slow	   Moderately	  Fast	   Fast	   Very	  fast	  











Power	  produced	   Low	   Medium	   High	   Very	  High	  
Mitochondrial	  density	   High	   Intermediate	   Low	   Low	  
Glycolytic	  capacity	   Low	   High	   High	   High	  
Myosin	  Heavy	  Chain	   Myh7	   Myh2	   Myh1	   MYH4	  
	  
Table	  1:	  Characteristics	  of	  muscle	  fiber	  types	  





2.	  Skeletal	  muscle	  development	  
2.1.	  The	  onset:	  somitogenesis	  	  
Mesoderm	  is	  anatomically	  divided	  into	  paraxial,	  intermediate,	  and	  lateral	  mesoderm,	  with	  respect	  
to	   position	   from	   the	   midline.	   During	   prenatal	   development,	   the	   myogenic	   progenitors,	   named	  
myoblasts,	   derive	   from	   presomitic	  mesoderm	   (PSM)	   and	   they	   give	   rise	   to	   all	   the	   body	   skeletal	  
muscles	  (Christ	  and	  Ordahl,	  1995),	  while	  the	  head	  and	  neck	  muscles	  derived	  from	  anterior	  paraxial	  
unsegmented	  mesoderm	  and	  from	  prechordal	  mesoderm	  (Buckingham	  et	  al.,	  2003).	  In	  the	  course	  
of	  development,	  PSM	  gives	   rise	   to	   somites	   through	  segmentation	  around	  embryonic	  day	   (E)	  8.0	  
and	  E13.5	  in	  mouse	  (Pourquié,	  2003).	  Somites	  are	  bilaterally	  paired	  cellular	  spheres,	  that	  develop	  
in	   a	   rostral-­‐to-­‐caudal	   direction	   flanked	   the	   neural	   tube.	   The	   segmentation	   of	   the	   paraxial	  
mesoderm	   is	   a	   tight	   regulated	  process	   that	   depends	  on	   clock	  mechanisms	   known	  as	   clock-­‐and-­‐
wave	   front	   model.	   On	   the	   basis	   of	   this	   model	   the	   segmentation	   is	   controlled	   by	   an	   oscillator	  
(clock),	  which	  gives	  the	  periodicity	  of	  the	  process,	  and	  a	  wave	  front,	  that	  is	  a	  gradient	  of	  signaling	  
molecules.	   This	   model	   is	   supported	   by	   numerous	   experimental	   observations,	   which	   show	   that	  
genes	  activated	  by	  Notch,	  Wnt	  and	  FGF	  signaling	  pathways	  are	  expressed	   in	  a	   time-­‐fashion	  way	  
and	  the	  crosstalk	  of	  these	  signaling	  cause	  the	  oscillation	  in	  the	  expression	  of	  segmentation	  genes	  
(Hofmann	  et	  al.,	  2004).	  The	  manipulation	  of	   the	  wave	  front,	  constituted	  by	  a	  gradient	  of	  Notch,	  
Wnt	  and	  FGF,	  results	  in	  an	  altered	  segmentation	  because	  of	  the	  lack	  of	  the	  oscillatory	  expression	  
of	   a	   network	   of	   genes	   controlling	   the	   rhythmic	   specification	   of	   the	   future	   segments	   (Aulehla	  &	  
Pourquié	  2006;	  Wahl	  et	  al.,	  2007;	  Goldbeter	  &	  Pourquié,	  2008;	  Hubaud	  &	  Pourquié,	  2014).	  The	  
somites,	  formed	  through	  segmentation,	  are	  initially	  composed	  by	  epithelial	  cells,	  which	  undergo	  a	  
high	   number	   of	   morphological	   changes,	   leading	   the	   formation	   of	   somatic	   compartments.	   The	  
ventral	   portion	   of	   each	   somite	   is	   the	   sclerotome,	   which	   is	   formed	   through	   the	   epithelial-­‐to-­‐
mesenchimal	  transition	  and	  contributes	  to	  cartilage	  and	  bone	  (Verbout,	  1985;	  Christ	  and	  Wilting	  
1992).	   The	   dorsal	   part	   of	   each	   somites	   is	   the	   dermamyotome,	   which	   maintains	   the	   epithelial	  
composition	  and,	  during	  development,	  yield	  skeletal	  and	  smooth	  muscles	  (Huang	  and	  Christ	  2000;	  
Yusuf	  and	  Brand-­‐Saberi	  2006;	  Ben-­‐Yair	  and	  Kalcheim	  2008),	  dermis	  (Kalcheim	  et	  al.,	  1999;	  Ben-­‐Yair	  
et	  al.,	  2003;	  Ben-­‐Yair	  and	  Kalcheim	  2005)	  and	  nearby	  cartilage	  (Huang	  and	  Christ	  2000).	   	   In	  turn,	  
the	   dermamyotome	   can	   be	   subdivided	   into	   two	   portions:	   the	   dorso-­‐medial	   or	   epaxial	   and	   the	  
ventro-­‐later	   or	   hypaxial	   part.	   The	   dorsal	  muscles	   derive	   from	   the	   epaxial	   domain,	  while	   ventral	  





Christ	   2000).	   The	   hypaxial	   muscles	   are	   generated	   through	   an	   extensive	   migration	   of	   myogenic	  
precursor	  cells	  to	  enrich	  their	  final	  destination	  (Vasyutina	  and	  Birchmeier,	  2006).	  The	  delamination	  
from	   the	   lips	   of	   the	   dermamyotome	   is	   controlled	   by	   different	   key	   molecules,	   such	   as	   scatter	  
factor/hepatocyte	   growth	   factor	   (SF/HGF)	   and	   its	   receptor	   c-­‐Met,	   and	   by	   many	   transcription	  
factors	  as	  Lbx1	  and	  Six	  factors.	  	  In	  mouse	  mutant	  for	  c-­‐Met	  (Bladt	  et	  al.,	  1995)	  or	  HGF	  (Schmidt	  et	  
al.,	   1995)	   the	   limb	  bud	  and	  diaphragm	  are	  not	   colonized	  by	  myogenic	   cells,	  demonstrating	   that	  
this	  paracrine	  signaling	  is	  required	  for	  the	  migration	  of	  muscle	  precursors.	  Lbx1	  is	  also	  involved	  in	  
the	  regulation	  of	  delamination,	  because	  the	  inactivation	  of	  Lbx1	  causes	  the	  lack	  of	  muscles	  in	  both	  
forelimbs	  and	  hindlimbs	   (Schafer	  and	  Braun,	  1999),	  while	  Six1	  and	  Six4	  control	   the	  proliferation	  
and	   the	   survival	   of	  migrating	   cells	   (Li	   et	   al.,	   2003;	   Laclef	   et	   al.,	   2003).	  When	   the	  precursor	   cells	  
reach	   their	   target	   sites,	   they	   start	   to	   differentiate	   and	   to	   fuse	   into	   multinucleated	   myotubes,	  
constituting	  the	  embryonic	  skeletal	  muscles.	  Other	  precursors	  remain	  in	  an	  undifferentiated	  state	  
and	   continue	   to	   proliferate,	   to	   accomplish	   differentiation	   in	   the	   late	   stages	   of	   development,	  
allowing	  the	  complete	  maturation	  of	  prenatal	  skeletal	  muscles.	  Moreover,	  shortly	  after	  the	  onset	  
of	   somitogenesis,	   some	   muscle	   progenitors	   terminally	   differentiate	   in	   mononucleated	   muscle	  
cells,	  named	  myocytes.	  The	  myocytes	  form	  the	  primary	  myotome,	  located	  in	  the	  ventral	  portion	  of	  
dermamyotome	  and	  elongated	  along	  the	  axis	  of	  the	  embryo.	  	  
	  
	  
2.2.	  The	  patterns	  of	  somitogenesis:	  extrinsic	  factors	  	  
The	  dermamyotome	  domains	  are	  established	  by	  morphogene	  gradients.	  The	  tissues	  surrounding	  
the	   somites,	   such	   as	   the	   dorsal	   ectoderm,	   the	   neural	   tube,	   the	   notochord	   and	   the	   lateral	  
mesoderm,	  produce	  different	   signaling	  molecules,	  which	   control	   the	  activation	  of	   the	  myogenic	  
program	  (Figure	  2).	  Sonic	  hedgehog	  (Shh),	  secreted	  from	  the	  notochord	  and	  floor	  plate	  of	  neural	  
tube,	  is	  involved	  in	  the	  positive	  specification	  of	  epaxial	  domain.	  Shh	  is	  essential	  for	  the	  formation	  
of	   the	   sclerotome,	   but	   also	   for	   the	  maturation	   of	   dermomyotomal	   cells.	   In	   the	   absence	   of	   Shh	  
there	  is	  somite	  cell	  death,	  most	  sclerotomal	  cells	  are	  lost	  (Chiang	  et	  al.,	  1996;	  Zhang	  et	  al.,	  2001)	  
and	  myogenic	   lineage	  progression	   is	   prevented	   (Feng	  et	   al.,	   2006;	  Hammond	  et	   al.,	   2007).	  Wnt	  
factors	  (Wnt	  -­‐1,	  -­‐3a	  and	  -­‐4)	  are	  expressed	  in	  the	  dorsal	  half	  of	  the	  neural	  tube	  and	  play	  a	  crucial	  





myogenic	  progenitor	  population	  (Parr	  et	  al.,	  1993;	  Hollyday	  et	  al.,	  1995;	  Munsterberg	  et	  al.,	  1995;	  
Cauthen	  et	  al.,	  2001).	  Mouse	  mutants	  for	  Wnt-­‐1	  do	  not	  develop	  the	  dermomyotome	  and	  lack	  the	  
expression	  of	  the	  myogenic	  genes	  (Ikeya	  and	  Takada,	  1998),	  and	  experiments	  of	  explant	  cultures	  
of	  mouse	  mesoderm	  demonstrate	  that	  Wnt-­‐1	  strongly	  induce	  myogenesis	  (Tajbakhsh	  et	  al.,	  1998).	  	  
Conversely,	   Wnt-­‐7a	   induces	   the	   development	   of	   hypaxial	   dermomyotome	   in	   a	   ventro-­‐later	  
position	  of	   each	   somites	   and	   it	   emerges	   from	   the	   ventral	   half	   of	   the	   neural	   tube	   and	   from	   the	  
surface	   ectoderm	   (Kenny-­‐Mobbs	   and	   Thorogood,	   1987;	   Parr	   et	   al.,	   1993;	   Cossu	   et	   al.,	   1996;	  
Pourquié	  et	  al.,	  1996).	  The	  correct	  spatio-­‐temporal	  specification	  of	  hypaxial	  progenitors	  is	  also	  due	  
to	   BMP4	   by	   the	   lateral	   mesoderm.	   BMP4	   retains	   muscle	   cells	   in	   an	   undifferentiated	   state	  
(Pourquié	  et	  al.,	  1995),	  contributing	  to	  the	  expansion	  of	  myogenic	  pool	  through	  the	  prevention	  of	  
differentiation.	  Wnt	  and	  BMP	  proteins	  are	  secreted	  in	  overlapping	  gradients	  (Itasaki	  and	  Hoppler,	  
2010)	   and	   it	   is	   known	   that	   Wnts	   antagonize	   BMP	   signals	   in	   the	   dorsomedial	   lip	   of	   the	  
dermomyotome	   through	   the	   activation	   of	  Noggin	   (Hirsinger	   et	   al.,	   1997;	  Marcelle	   et	   al.,	   1997).	  
This	   antagonism	   controls	   the	   timing	   and	   pattern	   of	  myogenic	   phenotype	   (Reshef	   et	   al.,	   1998).	  
Another	   pathway	   critical	   for	  muscle	   development	   is	  mediated	   by	  Notch.	  Notch	   is	   a	   cell-­‐surface	  
receptor,	   that	   may	   initiate	   an	   intracellular	   signaling	   cascade,	   when	   activated	   by	   its	   ligands:	  
Jagged1,	  Jagged2,	  Delta-­‐like	  1,	  Delta-­‐like	  3	  and	  Delta-­‐like	  4	  (Artavanis-­‐Tsakonas	  et	  al.,	  1995).	  The	  
activation	  of	  Notch	   causes	   sequential	   proteolytic	   cleavage	  events,	  which	   result	   in	   the	   liberation	  
from	  the	  plasma	  membrane	  of	  Notch	  intracellular	  domain	  (NICD).	  Once	  liberated,	  NICD	  enters	  the	  
nucleus,	  where	  it	  activates	  transcription	  of	  target	  genes	  (Kopan	  and	  Ilagan,	  2009).	  Activated	  Notch	  
signaling	  is	  fundamental	  during	  prenatal	  myogenesis	  for	  the	  maintenance	  of	  the	  undifferentiated	  
state	  of	  muscle	  progenitors,	  preserving	   the	  pool	  of	  myoblasts.	  On	   the	   contrary	   the	   cessation	  of	  








Figure	  2:	  Model	  of	  early	  phases	  of	  myogenesis	  in	  mouse	  at	  E10.5.	  	  The	  model	  illustrates	  the	  morphogenes	  
secreted	  by	  the	  tissus	  surrounding	  the	  somites,	  which	  influence	  the	  commitment	  of	  myogenic	  precursors.	  
DM	  dermomyotome,	  DE	  dorsal	  ectoderm,	  NC	  notochord,	  LM	  lateral	  mesoderm,	  MRFs	  myogenic	  regulatory	  
factors	  (Rossi	  and	  Messina,	  2014).	  
2.3.	  The	  control	  of	  myogenic	  specification,	  determination	  and	  differentiation	  	  
Myogenesis	   in	   the	   embryo	   is	   initially	   orchestrated	   by	   the	   myogenic	   regulatory	   factors,	   MRFs,	  
together	   with	   the	   paired-­‐homeobox	   transcription	   factors,	   Pax3	   and	   Pax7.	   Pax3	   is	   required	   for	  
myogenic	  specification	  (Tajbakhsh	  et	  al.,	  1997),	  while	  the	  MRFs	  control	  muscle	  cell	  determination	  
and	  differentiation	  (Tajbakhsh	  and	  Buckingham,	  2000).	  Cells	  in	  the	  mouse	  dermamyotome	  express	  
Pax3	  and	  Pax7.	  However,	  Pax3,	  unlike	  Pax7,	  is	  expressed	  in	  the	  hypaxial	  portion,	  where	  it	  plays	  an	  
important	   role	   in	   regulating	   the	   survival	   of	  myogenic	   progenitor	   cells	   (Borycki	   et	   al.,	   1999),	   the	  
limb	  musculature	  development	  (Franz,	  1993;	  Bober	  et	  al.,	  1994;	  Goulding	  et	  al.,	  1994;	  Relaix	  et	  al.,	  
2004),	  and	  MRFs	  expression	  (Maroto	  et	  al.,	  1997;	  Bajard	  et	  al.,	  2006).	  Moreover,	  Pax3	  controls	  the	  
delamination	  and	  the	  migration	  of	  muscle	  precursor	  cells,	  because	  Pax3	  activates	  the	  expression	  
of	  c-­‐met,	  receptor	  of	  SF/HGF.	  SF/HGF	  are	  factors	  that	  delineate	  the	  migratory	  route	  of	  migrating	  





embryonic	   muscle	   development,	   but	   it	   plays	   a	   fundamental	   role	   in	   the	   maintenance	   of	   adult	  
muscle	   stem	   cells,	   the	   satellite	   cells	   (Seale	   et	   al.,	   2000;	   Relaix	   et	   al.,	   2006).	   Transgenic	   mice	  
carrying	   Pax	   mutation	   better	   elucidate	   the	   functions	   of	   these	   transcription	   factors.	   In	   Pax3	  
mutants	   the	   hypaxial	   domain	   is	   lost,	   leading	   to	   the	   absence	   of	   limb	   and	   diaphragm	   muscles	  
(Tajbakhsh	   &	   Buckingham	   2000),	   while	   epaxial-­‐derived	   muscles	   are	   less	   affected	   (Bober	   et	   al.,	  
1994;	  Daston	  et	   al.,	   1996;	   Tremblay	  et	   al.,	   1998).	   The	  mice	  mutant	   for	   Pax7	  do	  not	   exhibit	   any	  
embryonic	  muscle	  phenotype	  (Mansouri	  et	  al.,	  1996),	  because	  of	  a	  probable	  compensation	  due	  to	  
Pax3.	   Indeed,	  muscle	  formation	  is	  more	  defective	   in	  Pax3-­‐Pax7	  double-­‐knockout	  embryos,	  when	  
compared	  with	   the	   single	  mutant	   alone	   (Relaix	   et	   al.,	   2005).	   Skeletal	  muscle	  determination	  and	  
differentiation	  depend	  on	  MRFs	  expression.	  The	  MRF	  family	  is	  a	  group	  of	  four	  related	  basic-­‐helix-­‐
loop-­‐helix	  proteins	  (bHLH):	  MyoD	  (Davis	  et	  al.,	  1987),	  Myf-­‐5	  (Braun	  et	  al.,	  1989),	  Myogenin	  (Wright	  
et	  al.,	  1989),	  and	  MRF4	  (Rhodes	  and	  Konieczny,	  1989).	  MRFs	  are	  master	  regulators	  of	  myogenic	  
lineage,	  because	  the	  expression	  of	  any	  one	  of	   them	   in	  several	  non-­‐myogenic	  cell	   types	  converts	  
those	  cells	  into	  skeletal	  muscle	  (Weintraub,	  1993).	  The	  protein	  structure	  of	  MRFs	  is	  characterized	  
by	   a	   basic-­‐helix-­‐loop-­‐helix	   domain	   (bHLH	   doman),	   that	   is	   high	   conserved.	   The	  main	   function	   of	  
bHLH	   domain	   is	   the	   dimerization	   and	   the	   binding	   of	   E-­‐box	   (enhancer	   box),	   a	   DNA	   motif	   with	  
CANNTG	  as	  core	  sequence	  (Jones,	  2004;	  Berkes	  and	  Tapscott,	  2005).	  	  The	  crucial	  role	  of	  MRFs	  in	  
regulating	  myogenesis	  was	  further	  revealed	  by	  models	  of	  MRF	  null	  mice.	  Based	  on	  knock-­‐out	  data,	  
it	  was	  possible	  reveal	  a	  hierarchy	  and	  the	  functions	  of	  MRF	  network.	  Mice	  lacking	  MyoD	  or	  Myf5	  
have	  no	  long-­‐term	  effects	  on	  muscle	  development,	  that	  appears	  normal	  but	  delayed	  if	  compared	  
with	  wild-­‐type	  embryos.	   	   In	  Myf5-­‐null	   embryos	  were	  observed	  only	   some	  epaxial	  defects,	  while	  
MyoD-­‐null	   embryos	   have	   primary	   hypaxial	   defects	   (Rudnicki	   et	   al.,	   1992;	   Braun	   et	   al.,	   1992;	  
Tajbakhsh	   et	   al.,	   1997).	   Knock-­‐out	  model	   for	   both	  MyoD	   and	  Myf5	   is	   devoid	   of	  myoblasts	   and	  
myofibers,	   demonstrating	   that	   both	   factors	   are	   required	   for	   the	   determination	   of	   muscle	  
progenitors	  and	  that	  they	  act	  upstream	  of	  MRF4	  and	  Myogenin	  (Rudnicki	  et	  al.,	  1993).	  Mutations	  
in	  the	  gene	  encoding	  for	  Myogenin	  cause	  drastic	  defects	   in	  myoblast	  differentiation,	  despite	  the	  
correct	  expression	  of	  MyoD	  (Hasty	  et	  al.,	  1993).	  Moreover,	  the	  double	  mutant	  for	  both	  Myogenin	  
and	  Myf5	  or	  Myogenin	  and	  MyoD	  have	  the	  same	  phenotype	  with	  the	  mice	  lacking	  only	  Myogenin,	  
confirming	   that	  Myf5	  and	  MyoD	  are	  upstream	  of	  Myogenin	   (Rawls	  et	   al.,	   1995).	  MRF4-­‐mutants	  
have	   different	   phenotypes	   due	   to	   the	   various	   functions	   of	   MRF4,	   which	   is	   involved	   both	   in	  
myogenic	   determination	   and	   also	   in	  myofiber	   differentiation	   and	  maturation	   (Hinterberg	   et	   al.,	  





reflect	  also	  their	  expression	  pattern	  during	  development.	  Myf5	  and	  MyoD	  are	  the	  first	  expressed	  
MRFs	   for	   the	   commitment	   of	  myoblasts,	   followed	   by	   the	   expression	   of	  Myogenin	   and	  MRF4	   in	  
differentiating	   myoblasts	   (Hannon	   et	   al.,	   1992;	   Pownall	   &	   Emerson,	   1992).	   In	   particular,	   Myf5	  
appears	   early	   in	   the	  epaxial	   domain,	  while	  MyoD	   is	   expressed	   later	   in	   the	  hypaxial	   portion	   in	   a	  
Pax3-­‐dependent	  way.	   This	   suggests	   that	   axial	  muscles	   activate	  myogenesis	   through	  Myf5,	  while	  
dorso-­‐later	  myogenesis	  depends	  on	  Pax3	  and	  MyoD	  activated	  pathways	  (Cossu	  et	  al.,	  1996b).	  	  
The	   myocyte	   enhancer	   factor	   2	   (Mef2)	   family	   is	   another	   family	   of	   transcription	   factors	   crucial	  
during	  skeletal	  muscle	  myogenesis.	  Vertebrates	  have	  four	  Mef2	  genes	  (Mef2A,	  Mef2B,	  Mef2C	  and	  
Mef2D),	  that	  belong	  to	  the	  evolutionarily	  ancient	  MADS	  family	  of	  transcription	  factors	  (Shore	  and	  
Sharrocks,	  1995).	  Mef2	  factors	  have	  a	  conserved	  MAD-­‐box	  and	  a	  Mef2	  domain	  in	  the	  N-­‐terminal	  
portion.	   The	  Mef2	  domain	   is	   necessary	   for	   the	  homo-­‐	   or	   hetero-­‐	   dimerization	   and	   for	   the	  DNA	  
binding	  to	  the	  consensus	  DNA	  sequence	  CAT(A/T)4TAG	  (Andres	  et	  al.,	  1995;	  Gossett	  et	  al.,	  1989;	  
Molkentin	   and	   Olson,	   1996;	   McKinsey	   et	   al.,	   2002a;	   Sebastian	   et	   al.,	   2013).	   Whereas	   the	   C-­‐
terminus	   contains	   the	   transcriptional	   activation	   domain,	   that	   is	   divergent	   among	   the	   different	  
Mef2	  members	  (Potthoff	  and	  Olson,	  2007).	  Mef2	  factors	  play	  a	  role	  in	  the	  hierarchical	  regulation	  
of	  muscle-­‐specific	   gene	   expression,	   although	  Mef2	   do	   not	   have	  myogenic	   activity.	  Only	   the	   co-­‐
expression	   of	   Mef2	   with	   MRFs	   proteins	   leads	   to	   amplification	   of	   myogenic	   differentiation	  
program,	   increasing	   the	  expression	  of	  myosin	  heavy	   chain	   isoforms	  and	  other	  muscle	   structural	  
genes	  (Molkentin	  et	  al.,	  1995;	  Wang	  et	  al.,	  2001).	  The	  four	  Mef2	  genes	  are	  expressed	  in	  different	  
tissues	  as	  endothelium	  and	  bone	  (Arnold	  et	  al.,	  2007)	  with	  higher	  expression	  in	  striated	  muscles	  
and	  brain	   (Edmondson	  et	  al.,	  1994).	  During	  prenatal	  skeletal	  muscle	  development,	  Mef2	  mRNAs	  
and	   proteins	   were	   detected	   in	   both	   fetal	   and	   embryonic	   muscles,	   with	   the	   exception	   of	   the	  
Mef2D1b	  isoform,	  which	  is	  restricted	  to	  fetal	  muscle	  (Ferrari	  et	  al.,	  1997).	  In	  particular,	  Mef2C	   is	  
the	  first	  Mef2	  gene	  expressed	  around	  E9	  in	  mouse,	  while	  Mef2A	  and	  Mef2D	  are	  expressed	  a	  day	  
later	  (Edmondson	  et	  al.,	  1994).	  Moreover,	  it	  is	  known	  that	  MRFs	  activate	  the	  expression	  of	  Mef2	  
genes	  and	  in	  turn	  Mef2	  factors	  stimulate	  the	  expression	  of	  MRFs	  and	  their	  own	  expression	  (Cheng	  
et	  al.,	  1993;	  Yee	  and	  Rigby,	  1993;	  Dodou	  et	  al.,	  2003;	  Wang	  et	  al.,	  2001),	  establishing	  an	  auto-­‐	  and	  
cross-­‐	   regulatory	  circuits,	   that	  maintain	  muscle	  phenotype	   (Penn	  et	  al.,	  2004;	  Blais	  et	  al.,	  2005).	  
Moreover,	   it	   was	   demonstrated	   a	   negative-­‐feedback	   loop	   between	   Mef2C	   and	   the	   histone	  
deacetylase	  9	  (HDAC9);	  in	  fact,	  Mef2C	  activates	  the	  expression	  of	  HDAC9,	  which,	  once	  expressed,	  
restrain	   Mef2C	   from	   excessive	   activity	   (Haberland	   et	   al.,	   2007).	   The	   understanding	   of	   Mef	  





out	  mice	  have	  no	  observable	  phenotype	  in	  skeletal	  muscles	  (Potthoff	  et	  al.,	  2007a;	  Potthoff	  et	  al.,	  
2007b),	  while	  Mef2C-­‐null	  mice	   exhibit	   lethality	   at	   E9.5	   due	   to	   cardiovascular	   defects	   (Lin	   et	   al.,	  
1997).	   For	   this	   reason,	   there	   were	   generated	   skeletal	   muscle	   specific	  Mef2C	   knock-­‐out	   under	  
Myogenin	   and	  muscle	   creatin	   kinase	   (MCK)	   promoters.	   The	  deletion	  of	  Mef2C	  under	  Myogenin	  
promoter	  causes	  lethality	  at	  postnatal	  day	  1	  (P1)	  with	  myofiber	  disarray	  and	  defects	  in	  sarcomere	  
assembly.	   In	  contrast,	   the	  mice	  with	  the	  deletion	  on	  Mef2C	  under	  the	  control	  of	  MCK	  promoter	  
are	   viable	  without	   the	   disruption	   of	  myofiber	   organization	   (Potthoff	   et	   al.,	   2007b).	   In	   addition,	  
Mef2C	   regulates	   fiber	   type	   specification,	   because	  muscle-­‐specific	   deletion	   of	  Mef2C	   in	   a	  mixed	  
mouse	  genetic	  background	  results	   in	  a	  decrease	  of	  slow–twitch	  fibers,	  while	  the	  over-­‐expression	  
of	   a	   super	   active	   form	  of	  Mef2C	   (MEF2C-­‐VP16)	   promotes	   slow-­‐fiber	   phenotype	   (Potthoff	   et	   al.,	  
2007).	   More	   recently,	   Anderson	   et	   al.	   confirm	   that	   Mef2C	   is	   required	   for	   normal	   fiber	   type	  
composition	  and	  discover	  a	  new	  function	  of	  Mef2C	  in	  regulating	  glucose	  uptake	  (Anderson	  et	  al.,	  
2015).	  	  
Once	  committed	  to	  myogenic	  lineage	  by	  the	  expression	  of	  MRFs,	  Pax	  and	  Mef	  factors,	  myoblasts	  
undergo	  differentiation.	   The	  differentiation	   requires	  prior	   irreversible	   cell	   cycle	  withdrawal.	   The	  
cell	  cycle	  exit	  is	  a	  high	  regulated	  process	  that	  involves	  the	  down-­‐regulation	  of	  cell	  cycle	  activators,	  
such	  as	  cyclins	  and	  cyclin-­‐dependent	  kinases	  (CDK),	  and	  the	  up-­‐regulation	  of	  cell	  cycle	  inhibitors,	  
such	  as	  Retinoblastoma	  (Rb),	  p21	  and	  p27.	  The	  induction	  of	  growth	  arrest	  is	  mediated	  by	  MyoD	  by	  
activation	   of	   the	   cyclin-­‐dependent	   kinase	   inhibitor	   p21	   (Guo	   et	   al.,	   1995;	   Halevy	   et	   al.,	   1995),	  
which	  inhibits	  a	  wide	  range	  of	  CDKs	  essential	  for	  cell	  cycle	  progression	  (Sherr	  and	  Roberts,	  1999).	  
MyoD	   also	   induces	   the	   expression	   of	   Retinoblastoma,	   ensuring	   the	   inhibition	   of	   cell	   cycle	  
progression	  (Martelli	  et	  al.,	  1994).	  When	  myoblasts	  leave	  the	  cell	  cycle,	  muscle	  cell	  fusion	  begins,	  
allowing	  the	  formation	  of	  muscle	  fibers.	  	  
	  
	  
2.4.	  Waves	  of	  differentiation:	  embryonic	  and	  fetal	  myogenesis	  
During	   prenatal	   myogenesis,	   different	   types	   of	   myofibers	   develop	   from	   different	   lineage	   of	  
myogenic	   progenitors	   and	   in	   a	   striking	   time	   regulated	   manner	   (Millet	   and	   Stockdale	   1986).	   In	  
vertebrates,	   skeletal	  myofibers	   prenatally	   develop	   in	   two	   distinct	   waves,	   which	   depend	   on	   the	  





(Stockdale,	  1992;	  Biressi	  et	  al.,	  2007a;	  Tajbakhsh,	  2009).	  Embryonic	  myoblasts	  are	  responsible	  for	  
embryonic	   or	   primary	   myogenesis,	   which	   starts	   in	   mouse	   around	   embryonic	   day	   10.5	   (E10.5),	  
giving	   rise	   to	   primary	   myofibers.	   Embryonic	   myogenesis	   establishes	   the	   basic	   muscle	   pattern,	  
while	  fetal	  myogenesis	  allow	  the	  growth	  and	  the	  complete	  maturation	  of	  prenatal	  muscles.	  During	  
fetal	  myogenesis,	  which	  occurs	  between	  E14.5	  and	  E17.5,	   fetal	  myoblasts	   fuse	   to	  each	  other	  or	  
with	   primary	   fibers,	   forming	   secondary	   fibers.	   These	   two	   waves	   of	   differentiation	   need	   the	  
determination	  of	  muscle	  progenitors,	   through	   the	  expression	  of	  Myf5,	  MyoD	  and	  MRF4	   (MRFs),	  
the	  commitment	  to	  the	  differentiation	  and	  the	  maturation	  of	  myofibers,	  through	  the	  expression	  of	  
Myogenin	  and	  myosin	  heavy	  chain	  (MyHC)	  isoforms.	  Embryonic	  and	  fetal	  myoblasts	  derive	  from	  a	  
common	   progenitor	   population	   that	   co-­‐expresses	   Pax3	   and	   Pax7	   (Pax3+/Pax7+	   cells)	   during	  
somitogenesis	  (Kassar-­‐Duchossoy	  et	  al.,	  2005;	  Relaix	  et	  al.,	  2005).	  The	  Pax3+/Pax7+	  population	  at	  
the	   beginning	   of	   embryonic	   myogenesis	   down-­‐regulates	   Pax7,	   generating	   a	   population	   of	  
Pax3+/Pax7-­‐	  cells.	  	  Pax3+/Pax7-­‐	  cells	  are	  bipotent	  and	  contribute	  to	  the	  formation	  of	  primary	  fibers	  
and	   endothelium,	   while	   Pax7	   is	   required	   for	   fetal	   myogenesis.	   The	   progenitors	   that	   terminally	  
differentiate	   during	   embryonic	   myogenesis	   are	   only	   a	   fraction	   (Kassar-­‐Duchossoy	   et	   al.,	   2005;	  	  
Relaix	  et	  al.,	  2005).	  The	  remaining	  committed	  but	  undifferentiated	  progenitors	  express	  Pax7	  but	  
not	  Pax3	  and	  are	  called	  Pax3-­‐derived	  Pax7+	  cells.	  	  Pax3-­‐derived	  Pax7+	  cells	  are	  responsible	  for	  fetal	  
myogenesis,	  starting	  from	  E14.5	  (Figure	  3)	  (Hutcheson	  et	  al.,	  2009;	  Messina	  and	  Cossu,	  2009).	  	  
Embryonic	   and	   fetal	   myoblasts	   are	   intrinsically	   distinct	   populations,	   which	   were	   initially	  
characterized	   according	   to	   their	   in	   vitro	   features.	   They	   deeply	   differ	   in	   terms	   of	   morphology,	  
responses	  to	  extracellular	  signals	  and	  myofibers	  that	  they	  generate	  (Stockdale	  et	  al.,	  1992;	  Biressi	  
et	  al.,	  2007b).	  The	  phenotypic	  diversity	   is	  revealed	   in	  vitro,	  when	  embryonic	  and	  fetal	  myoblasts	  
were	   cultured	   under	   differentiating	   conditions,	   to	   allow	   their	   fusion	   and	   the	   formation	   of	  
myotubes.	   Embryonic	   myoblasts	   generate	   small	   myotubes	   with	   few	  myonuclei	   (<20	   nuclei	   per	  
myotube),	   while	   fetal	   myoblasts	   form	   large	   myotube	   with	   significantly	   more	   nuclei	   (>20)	   if	  
compared	   with	   the	   embryonic	   ones.	   Moreover,	   if	   these	   two	   population	   were	   cultured	   under	  
conditions	   that	   promote	   proliferation,	   embryonic	   myoblasts	   are	   less	   proliferating,	   because	   are	  
more	  prone	  to	  differentiate,	  if	  compared	  with	  fetal	  myoblasts	  (Biressi	  et	  al.,	  2007b).	  The	  prenatal	  
muscle	  progenitors	  have	  also	  different	   sensitivity	   to	  different	  growth	   factors,	   such	  as	  TGF-­‐β1	  or	  
BMP4	   (Cossu	   et	   al.,	   1988;	   Cusella-­‐DeAngelis	   et	   al.,	   1994).	   In	   particular,	   embryonic	   myoblast	  
differentiation	  is	  unaffected	  by	  TGF-­‐β1	  or	  BMP4,	  that	  inhibit	  the	  differentiation	  of	  fetal	  myoblasts	  





primary	   and	   secondary	   fibers,	   which	   have	   different	   speed	   of	   contraction	   and	   metabolisms.	  
Primary	  fibers	  are	  programmed	  for	  a	  mainly	  oxidative	  and	  slow	  phenotype,	  because	  they	  express	  
high	  levels	  of	  slow	  myosin	  heavy	  chain	  isoform	  (MyHC-­‐I)	  and	  low	  level	  of	  fast	  MyHC	  isoforms.	  On	  
the	  contrary,	   secondary	   fibers	  adopt	  a	  glycolitic	  and	   fast	  phenotype,	  being	  negative	   for	  MyHC-­‐I,	  
but	   expressing	   perinatal	   and	   fast	   isoforms	   of	   myosin	   heavy	   chain	   (Stockdale	   et	   al.,	   1992).	   The	  
phenotypic	   diversity	   of	   embryonic	   and	   fetal	   myoblasts	   depends	   on	   a	   different	   transcriptome,	  
which	  was	  revealed	  by	  genome-­‐wide	  gene	  expression	  assays,	  by	  analyzing	  freshly	  purified	  Myf-­‐5	  
positive	   embryonic	   and	   fetal	   myoblasts	   (Biressi	   et	   al.,	   2007).	   The	   array	   analysis	   shows	   that	   a	  
significant	   number	   of	   genes	   involved	   in	   signaling	   transduction	   are	   differentially	   expressed.	   This	  
observation	  explains	  the	  divergent	  response	  of	  embryonic	  and	  fetal	  progenitors	  to	  the	  TGF-­‐β1	  and	  
BMP4	   treatment.	   In	   particular,	   the	   inhibitory	   Smad6	   and	   Smad7,	   negative	   regulator	   of	   TGF-­‐β	  
signaling,	   are	   more	   expressed	   in	   embryonic	   myoblasts,	   while	   genes	   that	   are	   involved	   in	   the	  
transduction	  of	  TGF-­‐β	  pathway,	   such	  as	  PKCθ,	  Decorin	  and	  Biglycan	  are	  more	  expressed	   in	   fetal	  
myoblasts	   (Biressi	   et	   al.,	   2007b).	   Moreover,	   many	   cell	   adhesion	   molecules,	   genes	   encoding	  
metabolic	   and	   structural	   protein	   and	   transcription	   factors	   are	   differentially	   expressed.	  
Interestingly,	  Nfix	  and	  JunB,	  two	  crucial	  transcription	  factors	  important	  for	  muscle	  differentiation	  
and	  maturation,	  were	  found	  to	  be	  more	  highly	  expressed	  in	  fetal	  myoblasts	  (Biressi	  et	  al.,	  2007b,	  
Messina	  et	  al.,	  2010).	  The	  diverse	  gene	  expression	  profile	  of	  embryonic	  and	  fetal	  myoblasts	  clearly	  















Figure	   3:	   Scheme	   of	   prenatal	   myogenic	   lineages	   responsible	   for	   embryonic	   and	   fetal	   myogenesis.	  
Embryonic	  myoblasts	  (Pax3+-­‐Pax7-­‐)	  differentiate	  around	  E10.5	  in	  primary	  slow-­‐twitching	  fibers,	  while	  fetal	  
myoblasts	   (Pax3-­‐derived	  Pax7+),	   starting	   from	  E14,	  give	   rise	   to	  secondary	   fast-­‐twitching	   fibers.	  Nfix	   is	   the	  
transcription	   factor,	  which	   regulates	   the	   transition	   from	  embryonic	   to	   fetal	  myogenesis.	  d.p.c	   days	   post-­‐
coitum	  (modified	  from	  Rossi	  and	  Messina,	  2014).	  
2.5.	  Postnatal	  development	  and	  regeneration	  
Postnatal	  muscle	  growth	  is	  achieved	  by	  an	  increase	  in	  size	  of	  each	  myofibers	  by	  fusion	  of	  postnatal	  
myoblasts.	  The	  muscle	  progenitors	  responsible	   for	  the	  postnatal	  muscle	  growth	  are	  the	  Satellite	  
cells	  (SCs),	  the	  resident	  stem	  cells	  of	  skeletal	  muscle	  (Seale	  et	  al.,	  2000).	  Satellite	  cells	  are	  the	  third	  
population	  of	  muscle	  progenitors	  and	  they	  are	  responsible	  not	  only	  for	  postnatal	  growth	  but	  also	  
for	   repair	   and	   regeneration	   of	   skeletal	   muscle	   tissue	   in	   response	   to	   stress,	   induced	   by	   weight	  
bearing	  or	  by	  damage,	  such	  as	  injury	  or	  extensive	  exercise	  (Grounds	  and	  Yablonka-­‐Reuveni,	  1993;	  
Charge	  and	  Rudnicki,	  2004).	  SCs	  were	  first	  identified	  by	  their	  unique	  anatomical	  position,	  situated	  
underneath	  the	  basal	  membrane	  of	  myofibers	  and	  outside	  the	  sarcolemma	  (Mauro,	  1961).	  Beside	  
their	   unique	   anatomical	   position,	   SCs	   can	   be	   identified	   by	   expression	   of	   several	   molecular	  
markers,	  including	  Pax7	  (Seale	  et	  al.,	  2000),	  M-­‐cadherin	  (Irintchev	  et	  al.,	  1994),	  Syndecan-­‐3	  and	  -­‐4	  
(Cornelison	  et	  al.,	  2001),	  CD34	  (Beauchamp	  et	  al.,	  2000),	  α7-­‐integrin	  (Burkin	  and	  Kaufman,	  1999)	  
and	  Calcitonin	   receptor	   (Fukada	  et	  al.,	  2007).	   In	  normal	  physiological	   conditions,	  SCs	  are	  mostly	  
quiescent	  and	  they	  can	  be	  activated	  in	  response	  to	  damage,	  to	  regenerate	  muscle	  tissues.	  Muscle	  
regeneration	   occurs	   in	   distinct	   phases:	   degeneration	   of	   myofibers	   (necrosis),	   inflammation,	  
regeneration,	  and	  functional	   repair	   (Musarò,	  2014).	  Myofiber	  necrosis	   involves	  the	  disruption	  of	  
sarcolemma,	   influx	   of	   calcium	   ions	   and	   cellular	   organelles	   destruction,	   which	   stimulates	   a	   host	  
inflammatory	   response.	   The	   inflammatory	   response	   is	   a	   coordinate	   process,	   critical	   for	  
regeneration	  and	  for	  the	  activation	  of	  SCs	  (Teixeira	  et	  al.,	  2003;	  Summan	  et	  al.,	  2006;	  Tidball	  and	  
Wehling-­‐Henricks,	  2007).	  	  The	  first	  wave	  of	  inflammation	  is	  mainly	  composed	  by	  neutrophils,	  then	  
a	  major	   role	   is	  played	  by	  macrophages,	  which	  eliminate	   cellular	  debris	   in	   the	  necrotic	   area	  and	  
sustain	   SC	   proliferation	   and	   differentiation	   (Tidball	   and	   Villalta,	   2010).	   Once	   activated	   upon	  
exposure	   to	   signals	   from	   a	   damaged	   environment,	   SCs	   enter	   the	   cell	   cycle,	   proliferate	   and	  





(Tajbakhsh	  &	  Cossu,	  1997).	  Thus,	  SCs	  start	  to	  proliferate	  and	  activate	  the	  expression	  of	  Myf5	  and	  
MyoD	  (Cooper	  et	  al.,	  1999;	  Zammit	  et	  al.,	  2002),	  generating	  an	  amplified	  population	  of	  myoblasts,	  
called	  myogenic	  precursors	  cell	  (mpc).	  The	  myogenic	  precursors	  cells	  undergo	  cell-­‐to-­‐cell	  fusion	  to	  
rapair	   damaged	  myofiber	   or	   to	   form	  de	   novo	  multinucleated	  myofibers,	   differentiating	   through	  
the	  expression	  of	  Myogenin	  and	  MRF4	  (Smith	  et	  al.,	  1994;	  Yablonka-­‐Reuveni	  &	  Rivera,	  1994).	   In	  
addition	   to	   generate	   muscle	   precursors	   cells	   for	   differentiation,	   SCs	   maintain	   also	   their	   own	  
population	  by	  self-­‐renewal	  (Collins	  et	  al.,	  2005).	   Indeed,	  they	  can	  be	  classified	  as	  myogenic	  stem	  
cells	   (Church	   et	   al.,	   1966;	   Moss	   &	   Leblond,	   1971).	   SCs	   derive	   from	   Pax3+/Pax7+	   embryonic	  
progenitor	   cells	   during	   prenatal	   development	   and	   they	   can	   be	   visible	   at	   the	   end	   of	   fetal	  
myogenesis,	   when	   basal	   lamina	   is	   formed	   and	   SCs	   assume	   their	   peculiar	   position	   (Gros	   et	   al.,	  
2005;	  Relaix	  et	  al.,	  2005;	  Sambasivan	  et	  al.,	  2013).	  	  
2.6.	  Muscle	  development	  in	  zebrafish	  	  	  
The	   process	   of	   prenatal	  muscle	   development	   in	   teleosts,	   in	   particular	   in	   zebrafish,	   is	   similar	   to	  
mammals	   but	   the	   timing	   and	   the	   specification	   of	   myogenic	   progenitors	   show	   particular	  
differences.	  In	  zebrafish,	  the	  first	  cells	  committed	  into	  myogenic	  lineage	  arise	  before	  the	  onset	  of	  
somitogenesis,	  which	  starts	   immediately	  after	  gastrulation	   (Kimmel	  et	  al.,	  1995).	  The	  presomitic	  
population	  of	  muscle	  progenitors	  is	  composed	  by	  adaxial	  cells	  (Stickney	  et	  al.,	  2000).	  Adaxial	  cells	  
express	  Myf5	  and	  MyoD,	  before	  the	  formation	  of	  dermamyotome,	  and	  migrate	  radially	  from	  the	  
notochord,	   generating	   a	   single	   layer	  of	   superficial	   slow-­‐twitching	   fibers,	   positive	   for	   slow	  MyHC	  
isoform	  (sMyHC1)	  and	  for	  the	  transcription	  factor	  Prox1a	  (Figure	  4)(Devoto	  et	  al.,	  1996;	  Stickney	  
et	  al.,	  2000).	  In	  particular,	  adaxial	  cells	  are	  specified	  by	  notochord-­‐derived	  Hedgehog	  (Hh)	  signals,	  
which	   lead	   to	   the	   expression	   of	   Prdm1,	   a	   PR-­‐domain-­‐containing	   protein	   (Blagden	   et	   al.,	   1997;	  
Barresi	   et	   al.,	   2000;	   Roy	   et	   al.,	   2001).	   Prdm1	   is	   necessary	   and	   sufficient	   to	   drive	   slow-­‐twitch	  
differentiation	   (Roy	   et	   al.,	   2001;	   Baxendale	   et	   al.,	   2004),	   by	   inhibiting	   the	   expression	  of	   sox6,	   a	  
repressor	  of	   slow-­‐specific	   gene	   transcription,	   and	  by	   acting	   as	   a	  direct	   repressor	  of	   fast-­‐specific	  
genes	  (von	  Hofsten	  et	  al.,	  2008).	  This	  mechanism	  is	  not	  conserved	  in	  mouse	  development	  (Vincent	  
et	   al.,	   2012).	   Fast	   fibers	   originate	   from	   dermamyotomal	   progenitors,	   which	   form	   the	   second	  
component	  of	  the	  primary	  myotome	  (Blagden	  et	  al.,	  1997;	  Stellabotte	  et	  al.,	  2007).	  Fast	  fibers	  are	  
multinucleated	  and	  they	  specifically	  express	  the	  fast	  MyLC	  isoform,	  Mylpfa	  (Figure	  4)	  (Roy	  et	  al.,	  
2001;	  Liew	  et	  al.,	  2008).	  After	  this	  embryonic	  period,	  the	  second	  wave	  of	  skeletal	  muscle	  growth	  





cells	   of	   the	   dermomyotome	   (Devoto	   et	   al.,	   1996;	   Hollway	   et	   al.,	   2007;	   Elworthy	   et	   al.,	   2008;	  









Figure	   4:	   A)	   Scheme	   of	   transverse	   section	   of	   successively	   older	   zebrafish	   embryos.	   The	   representation	  
shows	  the	  lateral	  migration	  of	  adaxial	  cells	  (in	  green),	  generating	  a	  monolayer	  of	  slow-­‐twitching	  fibers.	   In	  
yellow	  is	  represented	  the	  fusion	  of	  fast-­‐twitching	  myoblasts	   in	  the	  central	  part	  of	  embryos.	  B)	  Transverse	  
section	  at	  the	  truck	  level	  of	  a	  48	  hours	  old	  zebrafish	  embryo.	  The	  immunofluorescence	  shows	  the	  fiber	  type	  
composition	  of	  myotome.	  The	  slow	  fibers	  (in	  red)	  form	  a	  sub-­‐cutaneous	  layer,	  while	  fast-­‐twitching	  fibers	  (in	  
green)	  make	  up	  the	  bulk	  of	  the	  myotome	  (modified	  from	  Jackson	  and	  Ingham,	  2013).	  
	  
	  
3.	  Molecular	  regulation	  of	  myogenic	  diversity	  during	  pre-­‐natal	  
myogenesis	  
3.1.	  The	  role	  of	  Nfix	  
The	  main	  regulator	  of	  the	  transition	  from	  embryonic	  to	  fetal	  myogenesis	  is	  the	  transcription	  factor	  
Nfix	  (Messina	  et	  al.,	  2010).	  Nfix	  belongs	  to	  the	  nuclear	  factor	  I	  (NFI)	  family,	  which	  is	  composed	  by	  
four	   closely	   related	  genes:	  Nfia,	  Nfib,	  Nfic	   and	  Nfix	   (Gronostajski,	   2000).	   The	  NFI	   factors	  have	  a	  
highly	   conserved	   N-­‐terminal	   domain,	   which	   mediates	   the	   DNA-­‐binding	   and	   the	   dimerization	  





consensus	  binding	  sequence	  5’-­‐PyTGGCA-­‐N3-­‐TGCCAPu-­‐3’	  as	  homodimers	  or	  heterodimers	  (Goyal	  
et	   al.,	   1990;	   Kruse	   &	   Sippel,	   1994b).	   The	   C-­‐terminal	   portion,	   that	   exhibits	   a	   high	   variability,	   is	  
composed	   by	   a	   transcriptional	   modulation	   domain	   for	   both	   activation	   and	   repression	   of	  
transcription.	   Additional	   variability	   between	   NFI	   factors	   is	   due	   to	   alternative	   splicing,	   encoding	  
more	   splice	   isoforms	   (Kruse	   and	   Sippel,	   1994a).	   NFI	   consensus	   binding	   sites	   were	   found	   in	  
promoters	  and	  enhancers	  of	  genes	  specific	  for	  different	  tissue,	  including	  brain	  (Martynoga	  et	  al.,	  
2013),	   lung	   (Bachurski	   et	   al.,	   1997),	   liver	   (Jackson	   et	   al.,	   1993),	  muscle	   (Spitz	   et	   al.,	   1997)	   and	  
skeletal	  elements	  (Artlett	  et	  al.,	  1998;	  Gronostajski	  et	  al.,	  2000).	  Indeed,	  NFI	  factors	  are	  expressed	  
in	  different	   tissue	  both	  during	  development	  and	   in	  adulthood	  and	   their	  expression	  patterns	  are	  
restricted	  in	  some	  specific	  tissue	  and	  fine	  regulated	  in	  time	  (Chaudhry	  et	  al.,	  1997).	  The	  analysis	  of	  
mouse	   mutant	   for	   each	   of	   the	   NFI	   factors	   reveals	   that	   they	   have	   distinct	   and	   crucial	   roles	   in	  
different	  organs.	  Nfia	   -­‐/-­‐	  mice	  have	  severe	  brain	  defects	  with	  a	  lack	  of	  genesis	  of	  corpus	  callosum	  
and	   ventricular	   dilation,	   causing	   early	   hydrocephalus.	   The	   neurological	   deformity	   causes	   a	   high	  
prenatal	  mortality	  in	  Nfia	  -­‐/-­‐	  embryos	  (das	  Neves	  et	  al.,	  1999).	  Nfib-­‐deficient	  mice	  possess	  lung	  and	  
forebrain	  defects	  (Steele-­‐Perkins	  et	  al.,	  2005),	  whereas	  Nfic	  mutants	  have	  agenesis	  of	  tooth	  roots	  
and	   aberrant	   incisor	   development	   (Steele-­‐Perkins	   et	   al.,	   2003).	   Finally,	  Nfix-­‐/-­‐	  mice	   have	   growth	  
retardation	   and	   die	   postnatally	   between	   postnatal	   day	   21	   (P21)	   and	   P28.	   They	   present	  
enlargement	  of	  brain	  ventricles	  and	  partial	  agenesis	  of	  corpus	  callosum.	  Moreover,	  Nfix-­‐mutants	  
show	   spine	   deformation	   with	   impaired	   endochondral	   ossification	   and	   skeletal	   muscle	   defects	  
(Driller	  et	  al.,	  2007;	  Messina	  et	  al.,	  2010).	  The	  phenotypes	  of	  NFI-­‐deficient	  mice	  suggest	  that	  these	  
factors	  have	  both	  overlapping	  functions,	  for	  example	  in	  the	  regulation	  of	  brain	  development,	  and	  
tissue	   specific	   functions	   essential	   for	   prenatal	   development.	   	   The	  NFI	   factor	  more	   expressed	   in	  
skeletal	   muscle	   during	   myogenesis	   is	   Nfix	   (Messina	   et	   al.,	   2010),	   and	   its	   expression	   is	   rapidly	  
increased	  during	   fetal	  myogenesis,	   being	   virtually	   absent	   in	   embryonic	  myoblasts	   (Biressi	   et	   al.,	  
2007b).	   Once	   expressed,	   Nfix	   is	   able	   to	   drive	   the	   complete	   maturation	   of	   prenatal	   muscles,	  
allowing	   the	  switch	   from	  embryonic	   to	   fetal	  myogenesis.	   In	  particular,	  Nfix	   represses	  embryonic	  
specific	  genes	  and	  activate	  fetal	  ones	  (Messina	  et	  al.,	  2010).	  	  
Fetal	  myoblasts	  silenced	  for	  Nfix	  have	  an	  impaired	  fusion	  and	  generate	  small	  myotubes,	  acquiring	  
a	   more	   embryonic-­‐like	   phenotype.	   Moreover,	   silencing	   of	   Nfix	   in	   fetal	   progenitors	   causes	   the	  
down-­‐regulation	   of	   fetal	   specific	   genes,	   such	   as	  MCK	   and	   β-­‐enolase,	   and	   the	   up-­‐regulation	   of	  
embryonic	  markers,	  such	  as	  MyHC-­‐I.	  On	  the	  contrary,	  embryonic	  myoblasts	  over-­‐expressing	  Nfix,	  





Interestingly,	  Nfix	  over-­‐expressing	  cells	  don’t	  up-­‐regulate	  MCK,	  suggesting	  a	  requirement	  of	  other	  
cofactors.	  Deeper	   analysis	   demonstrates	   that	  Nfix	   is	   able	   to	   induce	  MCK	  expression,	   acting	   in	   a	  
complex	  with	  Mef2A	  and	  PKCθ.	   In	  particular,	   	   the	  expression	  of	  MCK	   is	  dependent	  on	  Mef2A,	  a	  
transcription	  factor	  that	   is	  equally	  expressed	  during	  all	  the	  prenatal	  development.	  The	  capability	  
of	  Mef2A	  to	  bind	  MCK	  promoter	  is	  dependent	  on	  a	  post-­‐translational	  phosphorylation,	  that	  occurs	  
specifically	  during	  fetal	  myogenesis	  (Ferrari	  et	  al.,	  1997)	  and	  the	  phosphorylation	  of	  Mef2A	  is	  due	  
to	  PKCθ,	  whose	  expression	   is	   fetal-­‐specific	   (Biressi	   et	   al.,	   2007b).	  Nfix	   acts	   as	   a	  bridge	  between	  
Mef2A	   and	   PKCθ,	   allowing	   Mef2A	   phosphorylation	   and	   the	   consequent	   activation	   of	   MCK.	  
Moreover,	   Nfix	   is	   able	   to	   repress	   MyHC-­‐I	   expression	   both	   indirectly,	   through	   the	   inhibition	   of	  
Nfatc4	   (Messina	  et	  al.,	  2010),	  and	  directly,	  acting	   in	  a	  complex	  with	  Sox6	   (Taglietti	  et	  al.,	  2016).	  
Interestingly,	  during	   fetal	  myogenesis,	  Nfix	  cooperates	  with	  Sox6	   in	   the	   inhibition	  of	  slow	  MyHC	  
and	   this	   cooperation	   is	   necessary	   for	   the	   switch	   of	   Sox6	   activity	   between	   embryonic	   and	   fetal	  
myogenesis	  (Taglietti	  et	  al.,	  2016).	  The	  Nfix	  negative	  regulation	  of	  slow	  MyHC	  is	  conserved	  during	  
vertebrate	  evolution.	   Indeed,	   in	  zebrafish,	  the	  ortholog	  of	  Nfix,	  nfixa,	  negatively	  regulate	  nfatc4,	  
which	  in	  turn,	  is	  responsible	  for	  the	  physiological	  expression	  of	  slow	  MyHC,	  as	  in	  mouse	  (Pistocchi	  
et	  al.,	  2013).	  Also,	  the	  functional	  cooperation	  between	  Nfix	  and	  Sox6	  is	  conserved	  during	  zebrafish	  
myogenesis	  and	   is	   required	   for	   the	  proper	   regulation	  of	   slow	  MyHC	   (Taglietti	  et	  al.,	  2016).	   	  The	  
role	  of	  Nfix	  in	  mouse	  was	  also	  characterized	  in	  embryos	  (E12.5)	  over-­‐expressing	  Nfix	  under	  muscle	  
specific	  promoter,	  Tg:Mlc1f-­‐Nfix2,	  and	  in	  fetuses	  (E16.5)	  with	  a	  skeletal	  muscle-­‐specific	  deletion	  of	  
Nfix	  (Messina	  et	  al.,	  2010),	  demonstrating	  that	  Nfix	  is	  required	  and	  sufficient	  for	  the	  induction	  of	  
fetal	   program	   of	   muscle	   gene	   expression	   (Figure	   5).	   Moreover,	   skeletal	   muscle-­‐specific	   Nfix-­‐
deficient	  muscles	  (E16.5)	  have	  a	  delayed	  assembly	  of	  sarcomeres	  and	  the	  diameter	  of	  myofibers	  is	  
reduced,	  suggesting	  that	  Nfix	  may	  be	  involved	  in	  the	  regulation	  of	  many	  other	  genes.	  Nowadays,	  
the	  mechanisms	  that	  temporally	  regulate	  the	  up-­‐regulation	  of	  Nfix	  specifically	  at	  the	  beginning	  of	  
fetal	  myogenesis	  are	  not	  fully	  known.	  Indeed,	  Pax7	  is	  sufficient	  to	  activate	  Nfix,	  because	  its	  over-­‐
expression	   in	  embryonic	  myoblasts	  causes	  a	  precocious	  activation	  of	  Nfix,	  but	  Pax7-­‐null	  muscles	  
normally	  express	  Nfix.	  These	  observations	  corroborate	  the	  idea	  that	  other	  genes	  can	  be	  involved	  
in	  the	  regulation	  of	  Nfix	  expression	  (Messina	  et	  al.,	  2010).	  Finally,	  it	  was	  recently	  clarified	  the	  role	  
of	  Nfix	  also	  during	  post-­‐natal	  myogenesis.	  As	  observed	  during	  prenatal	  development,	  adult	  Nfix-­‐
null	  muscles	  have	  altered	  homeostasis	  and	  morphology,	  characterized	  by	  a	  reduced	  muscle	  fiber	  
size	  and	  over-­‐expression	  of	  slow	  MyHC	  isoform	  (Rossi	  et	  al.,	  2016).	  Moreover,	  Nfix-­‐null	  mice	  have	  





inhibitor	  of	  myogenesis	  and	  satellite	  cell	  activation	  (Taylor	  et	  al.,	  2001;	  McCroskery	  et	  al.,	  2003).	  
Myostatin	   expression	   is	   directly	   represses	   by	   Nfix,	   influencing	   the	   proper	   timing	   of	   muscle	  











Figure	   5:	   Scheme	   of	   Nfix	   mechanisms	   of	   action	   in	   regulating	   the	   transition	   from	   embryonic	   to	   fetal	  
myogenesis.	  During	   fetal	  myogenesis,	  Nfix	  directly	   represses	  Nfatc4,	   causing	   the	   inhibition	  of	   slow	  MyHC	  
expression,	  and	  directly	  promotes	  β-­‐enolase	  activation.	  Nfix	  acts	  also	  as	  a	  bridge	  between	  PKCθ	  and	  Mef2a,	  
allowing	  MCK	  up-­‐regulation	  (Messina	  et	  al.,	  2010).	  	  
	  
	  





3.2.	  The	  role	  of	  Sox6	  
The	   SRY-­‐related	   HMG	   box	   (Sox)	   family	   in	  mammals	   is	   composed	   by	   22	   genes,	   divided	   in	   eight	  
groups	   (SoxA-­‐SoxH)	   (Schepers	   et	   al.,	   2002).	   All	   the	   Sox	   factors	   have	   a	   highly	   conserved	   high-­‐
mobility	  group	  (HMG)	  domain,	  which	  mediates	  DNA	  binding	  to	  ATTGTT	  or	  related	  sequence	  motifs	  
(Badis	   et	   al.,	   2009;	   Kondoh	   and	  Kamachi,	   2010;	   Kamachi	   and	  Kondoh,	   2013).	   The	  HMG	  domain	  
allows	   also	   the	   interaction	   with	   cofactors	   (Yamashita	   et	   al.,	   2000)	   and	   it	   contains	   two	   nuclear	  
localization	  signals	  (NLS),	  required	  for	  the	  shuttling	  between	  cytoplasm	  and	  nucleus	  (Malki	  et	  al.,	  
2010).	   The	   shuttling,	   but	   also	   the	   transcriptional	   activity	   of	   Sox	   factors,	   is	   regulated	   post-­‐
translationally	   by	   modifications	   including	   phosphorylation	   (Huang	   et	   al.,	   2000),	   acetylation	  
(Thevenet	  et	  al.,	  2004)	  and	  sumoylation	  (Gill,	  2005;	  Hattori	  et	  al.,	  2006).	  SoxD	  group	  includes	  Sox5,	  
Sox6	   and	   Sox13	   genes,	   whose	   expression	   has	   been	   demonstrated	   in	   different	   cell	   lineages	   as	  
chondrocytes	   (Lefebvre	   et	   al.,	   1997),	   vessels	   (Roose	   et	   al.,	   1998),	   oligodendrocytes	   (Stolt	   et	   al.,	  
2006),	   erythrocytes	   (Dumitriu	   et	   al.,	   2006)	   and	   skeletal	   muscle	   (Hagiwara	   et	   al.,	   2000).	   SoxD	  
factors	   do	   not	   possess	   a	   transactivation/repression	   domain,	   indicating	   that	   the	   recruitment	   of	  
cofactors	   is	   necessary	   to	   elicit	   transcriptional	   activation	   or	   repression	   activity	   (Kamachi	   et	   al.,	  
2001).	  Sox6	  has	  important	  roles	  in	  the	  development	  of	  different	  organ	  and	  tissues.	  Sox6-­‐deficient	  
mice	  die	  after	  birth,	  failing	  to	  breathe.	  Those	  that	  survive	  die	  in	  early	  life,	  because	  of	  the	  stop	  to	  
feed	   (Smits	   et	   al.,	   2001).	   During	   skeletal	   muscle	   development,	   Sox6	   plays	   a	   crucial	   role	   in	  
regulating	   fiber	   type	   differentiation	   in	   secondary	   fibers.	   Fetal	   Sox6-­‐mutant	   muscles	   have	   a	  
significantly	  higher	  expression	  of	  slow	  fiber	  type-­‐specific	  genes,	  whereas	  fast	  fiber-­‐specific	  genes	  
are	  decreased	  (Hagiwara	  et	  al.,	  2005),	  suggesting	  that	  Sox6	  functions	  as	  a	  transcriptional	  repressor	  
of	  slow-­‐twitching	  phenotype.	  In	  particular,	  Sox6	  acts	  as	  a	  direct	  repressor	  of	  a	  specific	  marker	  of	  
slow	   fibers:	  MyHC-­‐I.	   Sox6	   is	  able	   to	  directly	  bind	   the	  proximal	   cis-­‐regulatory	  element	  of	  MyHC-­‐I	  
promoter	  (350-­‐bp	  upstream	  of	  the	  transcription	  start	  site)	  and	  a	  distal	  enhancer	  (between	  -­‐3.5	  kb	  
and	   -­‐2.5	   kb	   from	   the	   transcription	   start	   site),	  which	   are	  both	  necessary	   for	   the	  optimal	  MyHC-­‐I	  
expression	   in	   skeletal	   muscle	   (Shimizu	   et	   al.,	   1992;	   Giger	   et	   al.,	   2000;	   Hagiwara	   et	   al.,	   2005).	  
Furthermore,	   Sox6	   function	   was	   elucidated	   through	   genome-­‐wide	   ChIP-­‐seq	   analysis	   in	   fetal	  
(E18.5)	  myotubes	  differentiated	   in	  vitro.	   Interestingly,	  the	  comparison	  of	  Sox6	  ChIP-­‐seq	  with	  the	  
phosphorylated	  form	  of	  Pol	  II	  ChIP-­‐seq,	  which	  is	  considered	  to	  be	  a	  transcriptionally	  active	  form	  of	  
Pol	  II,	  associated	  with	  highly	  transcribed	  gene	  (Brookes	  and	  Pombo,	  2009),	  reveals	  that	  the	  84%	  of	  





et	   al.,	   2011).	   Gene	   Ontology	   (GO)	   analysis	   reveals	   that	   Sox6	   target	   genes	   show	   the	   highest	  
enrichment	  for	  genes	  relevant	  for	  myofibril	  establishment.	   In	  particular,	  Sox6	  regulates	  proteins,	  
which	  define	  the	  fiber	  types	  but	  it	   is	  not	  directly	  involved	  in	  the	  transcriptional	  regulation	  of	  the	  
fastest	   MyHC	   isoforms	   (An	   et	   al.,	   2011).	   Sox6	   is	   implicated	   in	   fiber	   type	   specification	   also	   in	  
zebrafish.	   In	   zebrafish	   embryos	   lacking	   Prdm1a,	   adaxial	   cells	   differentiate	   into	   fast-­‐twitching	  
fibers,	  because	  they	  ectopically	  express	  sox6.	  This	   transformation	   is	  suppressed	  by	  the	  transient	  
knock-­‐down	  of	  sox6,	  suggesting	  that	  sox6	  also	  during	  zebrafish	  development	  acts	  to	  repress	  slow-­‐
twitching	  genes	  (von	  Hofsten	  et	  al.,	  2008;	  Jackson	  et	  al.,	  2015).	  
	  
	  
3.3.	  The	  role	  of	  JunB	  
Jun	  (c-­‐Jun,	  JunB	  and	  JunD),	  Fos	  (c-­‐Fos,	  FosB,	  Fra1	  and	  Fra2)	  and	  ATF	  proteins	  are	  members	  of	  AP-­‐1	  
family.	   AP-­‐1	   is	   a	   complex	   of	   heterodimers	   or	   homodimers,	  which	   determine	   the	   transcriptional	  
regulation	  of	   different	   target	   genes	   (Angel	   and	  Karin,	   1991;	  Aronheim	  et	   al.,	   1997;	  Bakiri	   et	   al.,	  
2000).	  The	  members	  of	  AP-­‐1	  family	  are	  basic	  leucine-­‐zipper	  (bZIP)	  proteins,	  because	  they	  interact	  
and	  dimerize	  through	  a	  leucine-­‐zipper	  motif,	  and	  they	  contain	  a	  basic	  domain	  for	  the	  binding	  with	  
the	  DNA	   in	   specific	  DNA	   response	  element,	   named	  TPA-­‐responsive	  element	   (TRE).	   In	  particular,	  
Fos	  proteins	  can	  only	  heterodimerize	  with	  Jun	  factors,	  while	  the	  Jun	  proteins	  can	  both	  homo-­‐	  and	  
hetero-­‐dimerize	  to	  form	  transcriptionally	  active	  complexes	  (Nakabeppu	  et	  al.,	  1988;	  Smeal	  et	  al.,	  
1989;	  Jochum	  et	  al.,	  2001).	  Moreover,	  AP-­‐1	  members	  can	  interact	  with	  other	  factors	  through	  the	  
leucine-­‐zipper	   domain,	   expanding	   their	   regulatory	   potential	   (Deng	   &	   Karin,	   1992).	   The	   AP-­‐1	  
proteins	  differ	  considerably	   in	  their	   trans-­‐regulation	  abilities	   (Chiu	  et	  al.,	  1989;	  Bos	  et	  al.,	  1990),	  
but	   they	   exhibit	   similar	  DNA-­‐binding	   specificity	   (Nakabeppu	   et	   al.,	   1988).	   In	   spite	   of	   the	   similar	  
DNA-­‐binding	   specificity,	   it	   is	   known	   that	   different	   dimers	   preferentially	   bind	   to	   different	   DNA	  
elements,	  as	  the	  cAMP-­‐response	  element	  (CRE),	  the	  MAF-­‐recognition	  elements	  (MAREs)	  and	  the	  
antioxidant-­‐response	   elements	   (AREs)	   (Chinenov	   and	   Kerppola,	   2001;	   Eferl	   and	  Wagner,	   2003).	  
The	  AP-­‐1	  main	  function	  is	  the	  transduction	  of	  extracellular	  stimuli	  into	  the	  cells,	  converting	  growth	  
factor	  signals	  into	  changes	  in	  expression	  of	  specific	  target	  genes	  (Passegue	  et	  al.,	  2002;	  Eferl	  and	  





and,	   during	   myogenesis,	   it	   is	   more	   highly	   expressed	   during	   fetal	   myogenesis	   compared	   with	  
embryonic	  myogenesis,	  as	  Nfix	  (Wilkinson	  et	  al.,	  1989;	  Biressi	  et	  al.,	  2007b).	  JunB	  is	  essential	  for	  
prenatal	  development,	  because	  the	  inactivation	  of	  JunB	  results	  in	  embryonic	  lethality	  around	  E9.5	  
because	  of	  defects	  in	  vasculogenesis	  in	  the	  extra-­‐embryonic	  tissues	  (Schorpp-­‐Kistner	  et	  al.,	  1999;	  
Jochum	   et	   al.,	   2001).	   To	   rescue	   the	   embryonic	   lethality,	   it	   was	   generated	   JunB-­‐/-­‐	   Ubi-­‐JunB	  
transgenic	  mouse,	  which	   expresses	   JunB	   under	   the	   human	   ubiquitin	   C	   promoter,	   resulting	   in	   a	  
reduced	  expression	  of	  JunB	  (Schorpp-­‐Kistner	  et	  al.,	  1999;	  Passegue	  et	  al.,	  2001;	  Hartenstein	  et	  al.,	  
2002).	   JunB-­‐/-­‐	  Ubi-­‐JunB	  mice	   have	   a	   decrease	   in	   body	   size	   and	   reduced	   length	   of	   appendicular	  
bones,	  due	  to	  impaired	  endochondral	  bone	  growth	  (Hess	  et	  al.,	  2003).	  The	  role	  of	  JunB	  in	  skeletal	  
muscle	  was	   characterized	  only	   in	  adult	  muscles.	   In	  normal	  adult	   tissue,	   JunB	   is	   required	   for	   the	  
maintenance	  of	  muscle	  mass	  and	   its	  down-­‐regulation	   induces	  muscle	  atrophy.	  Conversely,	   JunB	  
over-­‐expression	   causes	   hypertrophy	   by	   enhancing	   protein	   synthesis	   and	   myosin	   expression	  
(Raffaello	   et	   al.,	   2010).	  Moreover,	   JunB	   can	   specifically	   reduce	   the	   stimulation	   of	   proteasomal-­‐
dependent	   protein	   degradation	   by	   reducing	   the	   activity	   of	   FoxO3,	   a	   transcription	   factor	   that	  
induces	   atrophy	   through	   the	  activation	  of	   atrogenes	   (Sandri	   et	   al.,	   2004;	  Raffaello	   et	   al.,	   2010).	  
Thus,	  it	  is	  clear	  that	  JunB	  plays	  an	  important	  role	  in	  skeletal	  muscle	  maintenance	  and	  its	  strong	  up-­‐
regulation	  specifically	  during	  fetal	  myogenesis	  leads	  to	  speculate	  that	  JunB	  may	  be	  important	  also	  
for	  prenatal	  muscle	  development.	  
	  
	  
4.	  From	  the	  extracellular	  signal	  to	  the	  signaling	  pathways	  
4.1.	  ERK	  kinases	  
The	  extracellular	  regulated	  kinase	  1	  and	  2	  (ERK1	  and	  ERK2)	  belong	  to	  MAPK	  family	  that	   includes	  
also	   JNK	   and	   p38	  MAPKs.	   The	   ERKs	   are	   known	   to	   be	   one	   of	   the	   principal	   kinases	   activated	   by	  
growth	   factors	   and	   the	   constitutive	   activation	   of	   ERKs	   is	   associated	   with	   alterations	   in	   cell	  
proliferation,	  differentiation,	  and	  apoptosis	  (Scholl	  et	  al.,	  2005).	  ERK	  kinases	  can	  be	  activated	  by	  a	  
high	   number	   of	   ligand-­‐	   or	   self-­‐activated	   tyrosine	   kinase	   receptors,	   such	   as	   EGFR,	   FGFR,	   IGFR,	  
PDGFR	   and	   insulin	   receptor	   (Chang	   et	   al.,	   2001;	   Karnoub	   and	  Weinberg,	   2008).	   The	   ERKs	   have	  
distinct	   biological	   functions	   in	   vivo.	   Erk1-­‐deficient	   mice	   are	   viable	   and	   fertile,	   with	   defect	   in	  





an	   up-­‐regulation	   of	   ERK2	   signaling	   in	   response	   to	   glutamate	   (Mazzucchelli	   et	   al.,	   2002).	   Erk2	  
mutant	  mice	  are	  embryonic	  lethal	  around	  E6.5	  and	  the	  embryos	  present	  alteration	  in	  mesoderm	  
differentiation	   (Yao	   et	   al.,	   2003).	   The	   signaling	   cascade	   of	   ERKs	   is	   usually	   initiated	   by	   Ras	  
activation,	   which	   transmits	   the	   signal	   by	   phosphorylating	   MAPKK	   proteins.	   MAPKK,	   in	   turn,	  
activate	   MAPK/ERK	   kinases,	   named	   MEK	   (Ahn	   et	   al.,	   1991;	   Gomez	   and	   Cohen,	   1991),	   that	  
specifically	  phosphorylates	  and	  activates	  ERK	  kinases	  (Seger	  and	  Krebs,	  1995).	  Nevertheless,	  it	  was	  
postulated	  the	  existence	  of	  MEK-­‐independent	  mechanisms	  involved	  in	  ERKs	  activation	  (Johnson	  et	  
al.,	   2005;	   Cuevas	   et	   al.,	   2007).	   Once	   activated,	   the	   ERKs	   phosphorylate	   a	   large	   number	   of	  
substrates	  (Yoon	  et	  al.,	  2006),	  that	  can	  be	  localized	  in	  the	  cell	  cytoplasm	  or	  in	  the	  nucleus	  (Seger	  et	  
al.,	  1991).	  Nowadays	  only	  some	  transcription	  factors,	  activated	  by	  the	  ERKs,	  were	  identified,	  such	  
as	  Elk1	  (Hipskind	  et	  al.,	  1991;	  Gille	  et	  al.,	  1992)	  and	  JunB	  (Textor	  et	  al.,	  2006;	  Cevik	  et	  al.,	  2008).	  
The	  ERK	  kinases	  control	  the	  caudo-­‐rostral	  maturation	  of	  PSM,	  allowing	  the	  correct	  segmentation	  
and	   somite	   formation	   in	   chick	   embryos.	   In	   particular,	   ERK	   activity	   FGF8-­‐dependent	   prevents	  
cellular	  epithelialization	  and	  regulates	  motility	  along	  the	  antero-­‐posterior	  axis	  of	  the	  PSM	  (Delfini	  
et	  al.,	  2005).	  Although	  ERK	   function	   is	  well	  characterized	  during	  early	  somitogenesis,	   the	  role	  of	  
ERKs	   in	   regulating	   myogenesis	   is	   controversial,	   because	   the	   available	   data	   are	   conflicting.	   It	   is	  
reported	  that	  the	  ERKs	  have	  different	  activities	  at	  early	  versus	  late	  stages	  of	  muscle	  differentiation	  
(Bennett	  and	  Tonks,	  1997).	  In	  vivo	  studies	  on	  chick	  embryos	  show	  that	  the	  ERK	  shuttling	  between	  
nucleus	   and	   cytoplasm	   provide	   the	   switch	   between	   the	   two	   cellular	   responses:	   myogenic	  
proliferation	  and	  differentiation	  (Michailovici	  et	  al.,	  2014).	  In	  particular,	  the	  activation	  of	  ERKs,	  due	  
to	  FGF	  activity,	  causes	  their	  translocation	  into	  the	  nuclei,	  where	  they	  promote	  the	  proliferation	  of	  
myogenic	  progenitors	  and	  the	  inhibition	  of	  differentiation.	   Indeed,	  the	  cytoplasmatic	   localization	  
of	  ERK	  correlates	  with	  the	  fusion	  and	  differentiation	  of	  myoblasts	  (Michailovici	  et	  al.,	  2014).	  Also	  in	  
vitro	  studies	  show	  that	  ERK	  signaling	  is	  crucial	  for	  both	  proliferation	  and	  fusion	  of	  myoblasts	  (Jones	  
et	  al.,	  2001).	  Furthermore,	  Li	  and	  Johnson	  in	  2006	  report	  that	  ERK1	  and	  ERK2	  play	  non	  redundant	  
functions,	   using	   C2C12,	  mouse	  myoblast	   cell	   line,	   silenced	   for	   ERK1	   (C2C12siERK1)	   or	   for	   ERK2	  
(C2C12siERK2).	  They	  demonstrate	  that	  C2C12siERK2	  cells	  grow	  lower	  and	  fail	  to	  fuse,	  if	  compared	  
with	  control	  cells	  or	  with	  C2C12siERK1	  myoblasts,	  suggesting	  that	  ERK2	  is	  necessary	  for	  myofiber	  
formation	  (Li	  and	  Johnson,	  2006).	  	  Consistently,	  the	  treatment	  of	  C2C12	  with	  ERK	  phosphorylation	  
inhibitor,	  U0126,	  inhibits	  myoblast	  fusion	  and	  differentiation	  (Jiang	  et	  al.,	  2015).	  On	  the	  contrary,	  
it	   is	   reported	   that	   23A2	   and	   L6	  myoblasts	   are	   committed	   to	   terminal	   differentiation	   upon	   ERK	  





terminal	  differentiation	  (Coolican	  et	  al.,	  1997;	  Weyman	  &	  Wolfman,	  1998).	  The	  reasons	  for	  these	  
controversial	  results	  are	  unclear	  but	  probably	  the	  reason	  depends	  on	  the	  different	  cell	  types	  and	  
conditions	  used.	  Moreover,	  ERK	  kinases	  may	  be	  only	  transiently	  activated	  and	  their	  function	  may	  
depend	  on	   their	   cellular	   localization	   and	  on	   the	   crosstalk	  with	  other	   signaling,	   complicating	   the	  




Rho-­‐related	  small	  GTPases	   is	  a	   family	  of	   low	  molecular	  weight	  GTPases	  divided	   into	  subfamilies:	  
Rho,	  Rac1,	  Cdc42	  and	  Rnd.	  The	  main	  function	  of	  Rho	  GTPases	  is	  the	  transduction	  of	  extracellular	  
signal	   into	   intracellular	  events,	   including	   remodeling	  of	   cytoskeleton,	   control	  of	   cell	  morphology	  
and	  motility	  and	  regulation	  of	  gene	  expression	  (Narumiya	  1996;	  Bar-­‐Sagi	  and	  Hall,	  2000;	  Takai	  et	  
al.,	  2001).	  The	  subfamily	  RhoA	  includes	  three	  members	  named	  RhoA,	  RhoB	  and	  RhoC,	  which	  share	  
high	   homology.	   They	   differ	   in	   the	   C-­‐terminal	   portion,	   which	   influence	   the	   interaction	   with	  
regulators	   and	   the	   subcellular	   localization	   (Hori	   et	   al.,	   1991).	  All	   the	  member	  of	   the	  Rho	   family	  
cycle	   between	   an	   inactive,	  Guanosine	   diphosphate	   (GDP)-­‐bound	   state	   and	   an	   active,	   guanosine	  
triphosphate	  (GTP)-­‐bound	  state.	  The	  oscillation	  between	  the	  GDP-­‐bound	  and	  GTP-­‐bound	  state	  is	  
regulated	  by	  different	  classes	  of	  proteins:	  GTPase	  activating	  proteins	   (GAPs),	  guanine	  nucleotide	  
exchange	   factors	   (GEFs)	   and	   GDP-­‐dissociation	   inhibitors	   (GDIs)(Figure	   6).	   The	   activation	   of	   Rho	  
effectors	  depends	  on	  GAP	  proteins,	  which	  accelerate	  the	  intrinsic	  GTPase	  activity	  of	  Rho	  GTPases,	  
promoting	  the	  transduction	  of	   the	  signal	   to	   their	   targets	   (Saras	  et	  al.,	  1997;	  Taylor	  et	  al.,	  1998).	  
The	  activation	  of	  Rho	  is	  regulated	  by	  GEFs	  proteins,	  which	  catalyze	  the	  exchange	  of	  GDP	  for	  GTP,	  
thanks	   to	   the	   DH	   domain	  with	   nucleotide	   exchange	   activity	   (Hart	   et	   al.,	   1996;	   Fukuhara	   et	   al.,	  
1999).	  On	  the	  contrary	  GDIs	  inhibit	  Rho	  activity,	  blocking	  the	  guanine	  nucleotide	  exchange	  (Figure	  







Figure	  6:	  Scheme	  of	  regulation	  of	  Rho	  GTPase.	  The	  Rho	  GTPase	  is	  anchored	  to	  the	  cell	  membrane,	  where	  
the	  GEF	  proteins	  catalyze	  the	  release	  of	  GDP,	  allowing	  the	  binding	  to	  GTP.	  The	  GAP	  proteins	   increase	  the	  
GTPase	  activity	  of	  Rho	  GTPases.	  The	  GDIs	  can	  sequestrate	  GDP-­‐bound	  Rho	  proteins,	  inhibiting	  the	  binding	  
of	  Rho	  GTPases	  to	  the	  cell	  membrane	  (Tybulewicz	  and	  Henderson,	  2009).	  
	  
The	  most	  characterized	  Rho	  GTPase	  is	  RhoA,	  which	  mediates	  intracellular	  responses	  by	  activating	  
downstream	   targets.	   The	   direct	   effectors	   of	   RhoA	   are	   the	   kinases	   ROCK	   and	   the	   non-­‐kinase	  
proteins	  as	  mDia,	  rhophilin	  and	  rhotekin	  (Watanabe	  et	  al.,	  1996;	  Reid	  et	  al.,	  1996;	  Matsui	  et	  al.,	  
1996).	  ROCK	  is	  a	  serine/threonine	  kinase,	  which	  has	  a	  kinase	  domain	  in	  the	  N-­‐terminal	  portion,	  a	  
middle	   coiled-­‐coil	   region	   and	   a	   Cys-­‐rich	   zinc	   finger-­‐like	  motif	   in	   the	   C-­‐terminus	   (Fujisawa	   et	   al.,	  
1996;	  Nakagawa	   et	   al.,	   1996).	   In	  mouse,	   two	   ROCK	   kinases	  were	   isolated,	   ROCK	   I	   and	   ROCK	   II,	  
which	   may	   have	   tissue-­‐specific	   functions	   because	   they	   are	   differentially	   expressed	   in	   distinct	  
tissues.	  In	  particular,	  ROCK	  I	  is	  ubiquitously	  expressed	  expect	  in	  the	  brain	  and	  muscle,	  while	  ROCK	  
II	   is	  abundant	   in	  the	  brain,	  muscle,	  heart,	   lung	  and	  placenta	  (Fujisawa	  et	  al.,	  1996).	   	  The	  cellular	  
responses	   of	   RhoA	   are	   studied	   with	   different	   approaches	   in	   vitro,	   because	   RhoA-­‐null	   mice	   die	  
during	   early	   embryogenesis.	   The	   role	   of	   RhoA	   in	   different	   cell	   types	   and	   processes	   has	   been	  
investigated	  using	  pharmacological	  inhibitors,	  such	  as	  C3	  exoenzyme,	  a	  non	  specific	  Rho	  inhibitor,	  





et	   al.,	   2000).	   Alternatively,	   there	   were	   identified	   different	   dominant	   negative	   (RhoG17V)	   and	  
constitutive	  active	  forms	  of	  RhoA	  (RhoV14),	  that	  are	  wildly	  used	  for	  in	  vitro	  studies.	  RhoA	  and	  its	  
kinases	   ROCK	   are	   required	   for	  myogenesis	   and	   their	   activity	  must	   be	   fine	   regulated	   in	   time	   to	  
allow	   muscle	   differentiation	   (Castellani	   et	   al.,	   2006).	   In	   skeletal	   muscle,	   RhoA	   is	   essential	   for	  
muscle	  development;	  indeed,	  the	  differentiation	  of	  muscle	  progenitors	  is	  blocked	  if	  RhoA	  signaling	  
is	   inhibited	   by	   treatment	   with	   ROCK	   inhibitor	   or	   by	   expressing	   the	   dominant	   negative	   form	   of	  
RhoA	  (Takano	  et	  al.,	  1998).	  In	  addition,	  RhoA	  activates	  MyoD	  and	  α-­‐actin	  gene	  expression	  (Carnac	  
et	  al.,	  1998;	  Wei	  et	  al.,	  1998)	  through	  an	  indirect	  mechanism,	  which	  involves	  the	  redistribution	  of	  
serum	  responsive	  factor	  (SRF)	  cofactors	  from	  the	  cytoplasm	  into	  the	  nucleus.	  In	  fact,	  SRF	  activity	  
correlates	   with	   the	   ration	   of	   F-­‐actin	   (polymerized	   actin)	   to	   G-­‐actin	   (un-­‐polymerized)	   in	   the	  
cytoplasm,	   because	   the	   SRF	   cofactor	   MAL	   in	   retained	   in	   the	   cytoplasm	   in	   presence	   of	   high	  
concentration	   of	   G-­‐actin.	   On	   the	   contrary,	   the	   increased	   polymerization	   of	   actin,	   promoted	   by	  
RhoA	  effectors,	   leads	   to	   the	  release	  of	  MAL	   from	  G-­‐actin	  and	  the	  consequent	   translocation	   into	  
the	  nucleus,	  where	   it	  mediates	  the	  transcriptional	  activation	  of	  SRF	  target	  genes	  (Miralles	  et	  al.,	  
2003).	  SRF	  is	  a	  MADS-­‐box	  transcription	  factor,	  which	  control	  growth	  factor	  regulated	  genes,	  such	  
as	   AP-­‐1	   factors	   and	   different	  muscle-­‐specific	   genes	   (Buckingham,	   1994;	   Soulez	   et	   al.,	   1996).	   In	  
muscle	  progenitors,	  RhoA	  can	  be	  activated	  by	  N-­‐cadherin-­‐dependent	  cell-­‐cell	  adhesion	  (Charrasse	  
et	  al.,	  2002),	  providing	  a	  link	  between	  cell-­‐cell	  adhesion	  and	  downstream	  signaling	  of	  RhoA-­‐SRF,	  to	  
induce	  muscle-­‐specific	  expression	  of	  MyoD.	  Instead,	  Sordella	  et	  al.	  demonstrate	  that	  mice	  lacking	  
the	  RhoA	   inhibitor	  p190-­‐Rho	  GAP	  are	  defective	   for	  adipogenesis	  but	   tend	   to	  undergo	  myogenic	  
differentiation	   (Sordella	   et	   al.,	   2003),	   suggesting	   that	  RhoA	  and	  ROCK	   regulates	   the	   adipogenic-­‐
myogenic	   switch	   during	   prenatal	   development	   (Sordella	   et	   al.,	   2003).	   Thus,	   RhoA	   seems	   to	   be	  
involved	   in	   the	   specification	   of	   myoblasts	   but	   down-­‐regulation	   of	   RhoA	   activity	   in	   committed	  
myoblasts	   is	   essential	   for	   cell	   cycle	   withdrawal	   and	   myoblasts	   fusion	   (Nishiyama	   et	   al.,	   2004),	  
concluding	  that	   its	  activity	  must	  be	  tightly	  regulated	  in	  a	  finely	  coordinated	  in	  a	  time-­‐dependent	  
manner	  to	  ensure	  skeletal	  muscle	  formation	  (Castellani	  et	  al.,	  2006;	  Charrasse	  et	  al.,	  2006).	  





Aim	  of	  the	  projects	  
Mammalian	  skeletal	  muscle	  is	  composed	  of	  different	  fiber	  types,	  whose	  identity	  is	  first	  established	  
during	   prenatal	   development	   (Schiaffino	  &	   Reggiani,	   2011).	   This	   heterogeneity	   of	  muscle	   fibers	  
depends	  on	  differentiation	  of	  distinct	  classes	  of	  myogenic	  progenitors,	  named	  embryonic	  and	  fetal	  
myoblasts.	   In	   particular,	   embryonic	   myoblasts	   differentiate	   into	   multinucleate	   muscle	   fibres,	  
primary	   fibers,	  around	  E11	   in	   the	  mouse,	  while	   the	  differentiation	  and	   fusion	  of	   fetal	  myoblasts	  
takes	   place	   between	   E14.5	   and	   E17.5,	   giving	   rise	   to	   secondary	   fibers.	   In	   general,	   it	   is	   well	  
established	  that	  mammalian	  primary	   fibers	  are	  programmed	  for	  a	  predominantly	  slow-­‐twitching	  
phenotype,	  whereas	   secondary	   fibers	   adopt	   a	   fast	   phenotype	   (Wigmore	  &	   Evans,	   2002).	   It	  was	  
demonstrated,	  through	  genome	  wide	  expression	  analysis	  carried	  on	  purified	  embryonic	  and	  fetal,	  
that	   the	   different	   phenotype	  of	   primary	   and	   secondary	   fibers	   depends	   on	   intrinsic	   factors.	   This	  
analysis	   identified	  many	  differentially	   expressed	   genes	   and	   clearly	   revealed	   that	   embryonic	   and	  
fetal	  myoblasts	  have	  distinct	   genetic	  programs,	   suggesting	   that	   the	  proper	   transition	  of	   skeletal	  
muscle	  from	  the	  embryonic	  to	  the	  fetal	  phenotype	  requires	  a	  switch	  in	  the	  transcriptional	  status	  
of	  differentiating	  myoblasts	   (Biressi	   et	   al.,	   2007b).	   The	   “master”	   regulator	  of	  embryonic	   to	   fetal	  
transition	  is	  the	  transcription	  factor	  Nfix	  (Messina	  et	  al.,	  2010).	  To	  drive	  fetal	  myogenesis,	  Nfix	  is	  
specifically	  activated	  around	  E14.5	  and	   it	   is	  virtually	  absent	  during	   the	  earlier	  phases	  of	   skeletal	  
muscle	  development.	  Nowadays,	  the	  mechanisms	  that	  temporally	  regulate	  its	  expression	  are	  still	  
unknown.	   Nfix,	   once	   expressed,	   allows	   the	   acquisition	   of	   fetal	   fiber	   phenotype,	   activating	   fetal	  
specific	   genes,	   and	   repressing	   embryonic	   ones,	   such	   as	   the	   slow	  myosin	   heavy	   chain	   (MyHC-­‐I)	  
(Messina	   et	   al.,	   2010).	   Another	  well-­‐known	   repressor	   of	  MyHC-­‐I	   during	   fetal	  myogenesis	   is	   the	  
transcription	  factor	  Sox6	  (Hagiwara	  et	  al.,	  2007;	  An	  et	  al.,	  2011).	  Interestingly,	  Sox6,	  at	  variance	  of	  
Nfix,	   is	   expressed	   also	   during	   embryonic	  myogenesis,	  when	   embryonic	  myoblasts	   form	   primary	  
fibers	  that	  express	  high	  level	  of	  MyHC-­‐I,	  despite	  its	  role	  of	  inhibitor	  of	  slow	  twitching	  program.	  
Therefore	  my	  phD	  work	  has	  been	  developed	  by	  addressing	  two	  main	  aims:	  
•	   The	   identifications	   of	   Sox6	   functions	   in	   regulating	  MyHC-­‐I	   during	   embryonic	  myogenesis	  
and	  the	  characterization	  of	  the	  interplay	  between	  Nfix	  and	  Sox6	  during	  fetal	  myogenesis.	  
•	   The	  elucidation	  of	  the	  molecular	  mechanisms	  involved	  in	  the	  regulation	  of	  Nfix	  expression	  










Main	  Results:	  	  
1.	  Nfix	  induces	  a	  switch	  in	  Sox6	  transcriptional	  activity	  to	  regulate	  MyHC-­‐I	  
expression	  in	  fetal	  muscle	  	  
During	  my	  PhD	  I	  worked	  on	  a	  project,	  that	  I	  started	  during	  my	  Master	  of	  Science	  internship,	  about	  
the	  functional	  cooperation	  between	  Sox6	  and	  Nfix	  during	  murine	  prenatal	  myogenesis.	  The	  results	  
of	  this	  project	  have	  been	  recently	  published	  on	  Cell	  Reports.	  Here	  below	  the	  main	  conclusions	  of	  
this	  work,	  whose	  paper	  is	  included	  in	  the	  present	  Thesis	  (Part	  II):	  
• during	  embryonic	  myogenesis,	  Sox6	  acts	  indirectly	  as	  a	  positive	  regulator	  of	  MyHC-­‐I	  via	  a	  
Mef2C-­‐dependent	  mechanism,	  in	  sharp	  contrast	  with	  its	  well-­‐known	  and	  characterized	  
function	  during	  fetal	  myogenesis	  	  
	  
• during	  fetal	  myogenesis,	  Sox6	  and	  Nfix	  phisically	  and	  functionally	  cooperate	  in	  the	  direct	  
inhibition	  of	  MyHC-­‐I	  expression	  
	  
• the	  functional	  cooperation	  of	  Sox6	  and	  Nfix	  is	  evolutionary	  conserved	  also	  in	  zebrafish	  and	  
it	  is	  required	  for	  proper	  skeletal	  muscle	  development	  
	  
2.	  RhoA-­‐ERK	  axis	  regulates	  secondary	  myogenesis	  through	  the	  control	  of	  JunB	  and	  
Nfix	  expression	  
The	   second	   project,	   that	   I	   developed	   during	   my	   PhD	   Thesis,	   	   aims	   to	   identify	   and	   define	   the	  
molecular	  signaling	  responsible	  for	  the	  expression	  of	  Nfix	  at	  the	  onset	  of	  fetal	  myogenesis.	  Here	  
below,	  the	  main	  results	  achieved,	  that	  are	  now	  collected	  in	  a	  manuscript	  in	  preparation	  (Part	  III).	  
• JunB	  and	  Nfix	  are	  both	  specifically	  expressed	  at	  the	  onset	  of	  fetal	  myogenesis	  
	  
• JunB	   is	   sufficient	   and	   necessary	   for	   Nfix	   activation,	   while	   Nfix	   does	   not	   control	   JunB	  






• JunB	  is	  not	  able	  to	  promote	  the	  switch	  from	  embryonic	  to	  fetal	  myogenesis,	  which	  is	  
strickly	  controlled	  by	  Nfix	  
	  
• The	  expression	  of	  JunB	  and	  Nfix	  is	  negatively	  regulated	  by	  RhoA/ROCK,	  during	  embryonic	  
myogenesis,	  through	  the	  inhibition	  of	  ERK	  kinase	  activity	  
	  











Conclusion	  and	  future	  perspective	  
Skeletal	  myogenesis	  occurs	  in	  successive	  developmental	  stages,	  which	  involve	  the	  differentiation	  
of	   two	   distinct	   populations	   of	   muscle	   progenitors:	   embryonic	   myoblasts	   and	   fetal	   myoblasts.	  
These	   two	   cell	   populations	   give	   rise	   to	   heterogeneous	   muscle	   tissues,	   which	   are	   composed	   of	  
different	  type	  of	  fibers	  in	  terms	  of	  shape,	  size,	  contractile	  activity	  and	  metabolism.	  	  In	  particular,	  
embryonic	  myoblasts	  fuse	  into	  multinucleated	  primary	  fibers,	  starting	  around	  E10.5	  in	  mouse.	  The	  
formation	  of	  primary	  fibers	  is	  considered	  the	  first	  wave	  of	  muscle	  differentiation,	  called	  embryonic	  
myogenesis.	  The	  second	  wave	  of	  myogenesis,	  named	  also	  fetal	  myogenesis,	  takes	  place	  between	  
E14.5	  and	  E17.5	  in	  mouse,	  when	  fetal	  myoblasts	  form	  secondary	  fibers.	  This	  multiphasic	  process	  
of	  differentiation	  gives	  rise	  to	  different	  fiber	  types.	  In	  particular,	  primary	  fibers	  are	  slow-­‐twiching	  
fibers,	   which	   express	   high	   level	   of	   the	   slow	   and	   embryonic	   isoforms	   of	   myosin	   heavy	   chain	  
(respectively	   MyHC-­‐I	   and	   MyHC-­‐emb);	   in	   contrast,	   secondary	   fibers	   are	   fast-­‐twitching	   fibers,	  
expressing	  fast	  and	  neonatal	   isoforms	  of	  myosin	  heavy	  chain	  (MyHC-­‐2a,	  MyHC-­‐2x,	  MyHC-­‐2b	  and	  
MyHC-­‐neo).	  In	  general,	  primary	  fibers	  are	  programmed	  for	  a	  mainly	  slow	  phenotype	  and	  oxidative	  
methabolism,	   whereas	   secondary	   fibers	   adopt	   a	   fast	   and	   glycolytic	   phenotype	   (Biressi	   et	   al.,	  
2007b;	  Stockdale,	  1992).	  The	  diversification	  of	  muscle	  fibers	  during	  embryonic	  and	  fetal	  stages	  is	  
independent	  from	  neural	  and	  hormonal	  influences.	  In	  the	  past	  years,	  some	  key	  factors,	  that	  may	  
regulate	  the	  fiber	  type	  specification,	  has	  been	  identified,	  such	  as	  Sox6	  (Hagiwara	  et	  al.,	  2005)	  and	  
Nfix	  (Messina	  et	  al.,	  2010).	  Sox6,	  belonging	  to	  group	  D	  of	  Sox	  factors,	  is	  a	  well	  known	  inhibitor	  of	  
slow-­‐twitching	   phenotype	   during	   fetal	   myogenesis	   (Hagiwara	   et	   al.,	   2005;	   An	   et	   al.,	   2011),	  
whereas	   Nfix	   is	   a	   transcription	   factor	   specifically	   expressed	   during	   fetal	   myogenesis,	   that	   is	   a	  
crucial	  activator	  of	   the	   fetal	  genetic	  program,	  allowing	  both	   the	   repression	  of	  embryonic	  genes,	  
such	  as	  MyHC-­‐I,	  and	  the	  activation	  of	  fetal	  ones,	  such	  as	  glycolytic	  enzymes	  (β-­‐enolase	  and	  MCK).	  	  





to	   fetal	   myogenesis.	   Our	   results	   show	   that,	   during	   fetal	   myogenesis,	   Nfix	   and	   Sox6	   are	  
coexpressed	  in	  fetal	  muscles	  and	  cooperate	  in	  inhibiting	  MyHC-­‐I	  expression.	  Indeed,	  we	  found	  that	  
Nfix	  acts	  as	  a	  fundamental	  co-­‐factor	  of	  Sox6,	  allowing	  its	  direct	  binding	  to	  the	  proximal	  promoter	  
of	  Myh7	   gene,	   critical	   for	   Sox6-­‐dependent	   fetal	   repression	   of	   MyHC-­‐I	   (Hagiwara	   et	   al.,	   2007).	  
Conversely,	   during	   embryonic	   myogenesis,	   when	   Nfix	   is	   not	   yet	   activated,	   Sox6	   is	   expressed	  
starting	  from	  E12.5,	  when	  embryonic	  progenitors	  form	  slow-­‐twitching	  fibers	  positive	  for	  MyHC-­‐I.	  
In	  embryonic	  myogenic	  progenitors,	  Sox6,	  through	  the	  direct	  activation	  of	  Mef2C,	  induce	  MyHC-­‐I	  
expression,	  contributing	  to	  the	  specification	  and	  maintenance	  of	  primary	  fibers.	  All	  together,	  our	  
data	  show	  that	   the	  reversal	   in	  Sox6	   functions	   from	  embryonic	   to	   fetal	  myogenesis	   is	  due	  to	   the	  
interplay	   with	   Nfix,	   that,	   once	   expressed,	   instructs	   Sox6	   for	   the	   direct	   repression	   of	   MyHC-­‐I.	  
Moreover,	   we	   provide	   evidence	   for	   a	   conserved	   cooperation	   of	   Sox6	   and	   Nfix	   orthologs	   in	  
zebrafish.	  The	  fetal-­‐specific	  expression	  of	  Nfix	  is	  known	  to	  be	  regulated	  by	  Pax7,	  that	  is	  sufficient	  
but	  not	  necessary	  for	  Nfix	  activation	  (Messina	  et	  al.,	  2010),	  corroborating	  the	  idea	  that	  additional	  
genes	   are	   responsible	   for	   Nfix	   expression.	  With	   the	   aim	   to	   identify	   the	   molecular	   and	   cellular	  
mechanisims	   by	   which	   Nfix	   expression	   is	   achieved	   during	   fetal	   myogenesis,	   we	   focused	   our	  
attention	   on	   JunB,	   the	   second	   transcription	   factor	  more	   highly	   expressed	   in	   fetal	   compared	   to	  
embryonic	  myogenesis	   (Biressi	   et	   al.,	   2007b).	  We	   demonstrate	   that	   JunB	   is	   both	   sufficient	   and	  
necessary	  for	  the	  direct	  induction	  of	  Nfix	  during	  prenatal	  skeletal	  myogenesis,	  starting	  from	  E14.5	  
in	   mouse.	   Therefore,	   we	   show	   that	   the	   activation	   of	   the	   fetal	   genetic	   program	   is	   strikingly	  
dependent	  on	  Nfix	  expression;	  indeed,	  JunB	  alone	  is	  not	  able	  to	  drive	  embryonic	  to	  fetal	  molecular	  
changes.	  	  Moreover,	  we	  identified	  the	  RhoA/ROCK	  pathway	  as,	  at	  least,	  one	  of	  the	  main	  signaling	  
involved	  in	  the	  maintenance	  of	  embryonic	  identity,	  thanks	  to	  their	  inhibitory	  effect	  on	  ERK	  kinase	  
activity,	  which	  is	  necessary	  for	  JunB	  and	  Nfix	  expression.	  	  During	  fetal	  myogenesis,	  we	  observed	  a	  





expression.	  	  Nowadays,	  it	  remains	  unknown	  the	  upstream	  inputs,	  which	  orchestrate	  the	  activity	  of	  
these	   signaling	   pathway	   and	   the	   clarification	   of	   them	   will	   let	   us	   to	   understand	   how	  myogenic	  
progenitors	  are	  instructed	  during	  skeletal	  myogenesis.	  Another	  crucial	  point,	  still	  unknown,	  is	  the	  
knowledge	  of	  Nfix	  functions	  during	  fetal	  myogenesis.	  We	  know	  that	  Nfix	  is	  sufficient	  to	  drive	  fetal	  
myogenesis,	   repressing	   directly	   and	   indirectly	   MyHC-­‐I	   expression	   and	   activating	   fetal-­‐	   specific	  
genes,	   such	  as	  β-­‐enolase	  and	  MCK	   (Messina	  et	  al.,	   2010),	  but	   the	   skeletal	  muscle	  phenotype	  of	  
Nfix-­‐null	  fetuses	  is	  more	  severe.	  The	  morphological	  changes	  of	  fetal	  muscles	  lacking	  Nfix,	  such	  as	  
sarcomere	  disorganization	  and	  misexpression	  of	  mature	  isoforms	  of	  contractile	  proteins	  (Messina	  
et	  al.,	  2010),	  strongly	  suggest	  that	  this	  transcription	  factor	  may	  regulate	  the	  expression	  of	  many	  
other	  genes.	  To	  better	  elucidate	  Nfix	  functions,	   it	  would	  be	  crucial	  to	  known	  all	   its	  target	  genes,	  
which	   still	   remain	   an	   unsolved	   issue.	   The	   comprehension	   of	   the	   mechanisms	   involved	   in	   the	  
achievement	  of	  the	  respective	  identities	  of	  the	  two	  populations	  of	  myoblasts	  and	  the	  clarification	  
of	   Nfix	   functions	   during	   fetal	   myogenesis	   will	   contribute	   to	   augment	   the	   knowledge	   of	   the	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Sox6 belongs to the Sox gene family and plays a
pivotal role in fiber type differentiation, suppressing
transcription of slow-fiber-specific genes during fetal
development. Here, we show that Sox6 plays oppo-
site roles in MyHC-I regulation, acting as a positive
and negative regulator of MyHC-I expression dur-
ing embryonic and fetal myogenesis, respectively.
During embryonic myogenesis, Sox6 positively regu-
lates MyHC-I via transcriptional activation of Mef2C,
whereas during fetal myogenesis, Sox6 requires
and cooperates with the transcription factor Nfix in
repressing MyHC-I expression. Mechanistically,
Nfix is necessary for Sox6 binding to the MyHC-I
promoter and thus for Sox6 repressive function,
revealing a key role for Nfix in driving Sox6 activity.
This feature is evolutionarily conserved, since the
orthologs Nfixa and Sox6 contribute to repression
of the slow-twitch phenotype in zebrafish embryos.
These data demonstrate functional cooperation be-
tween Sox6 andNfix in regulatingMyHC-I expression
during prenatal muscle development.
INTRODUCTION
In vertebrates, the process of skeletal muscle development oc-
curs in subsequent steps that involve distinct populations of
myogenic progenitors, the myoblasts, which arise from the der-
momyotomal domain of somitic mesoderm (Christ and Ordahl,
1995). The process of myogenic differentiation is initiated in
mesodermal cells by a family of basic-helix-loop-helix (bHLH)
transcription factors, named muscle regulatory factors (MRFs),
that are able to activate transcription of muscle-specific markers
such as the myosin heavy chain (MyHC) isoforms (Pinney et al.,
1988; Cao et al., 2010). Embryonicmyoblasts sustain a first wave
of myogenesis between embryonic day 10 (E10) and E12 in the
mouse and give rise to primarymyofibers that establish the prim-
itive shape of muscle and express high levels of the slow MyHC
isoform (MyHC-I, encoded by theMyh7 gene) and of the embry-
onic MyHC isoform (MyHC-emb, encoded by Myh3) (Schiaffino
et al., 1986; Stockdale, 1992). A secondwave of muscle differen-
tiation takes place between E15 and E18, driven by fetal myo-
blasts that form secondary fibers, characterized by low levels
of MyHC-I and high levels of neonatal MyHC (MyHC-neo, en-
coded by Myh8) (Eusebi et al., 1986; Lyons et al., 1990; Daou
et al., 2013). Eventually, primary fibers conserve the slow-twitch
phenotype typical of embryonic muscle, while secondary fibers
lose the expression of several embryonic-specific markers
such as MyHC-I and acquire expression of fast-twitch markers
(Ferrari et al., 1997; Biressi et al., 2007). Embryonic and fetal
myoblasts, once isolated from the embryo, are committed to a
specific fiber type, suggesting the involvement of intrinsic factors
rather than nerve activity in the establishment of fiber phenotype
(Page et al., 1992). These observations suggest that the proper
transition of skeletal muscle from the embryonic to the fetal/
post-natal phenotype requires a switch in the transcriptional sta-
tus of differentiating myoblasts.
In our previous study, we have shown that the transcription
factor Nfix, a member of the nuclear factor I (Nfi) family, has a
key role in the establishment of fetal muscle phenotype and in
the downregulation of slowMyHCboth in fetal and adult muscles
(Messina et al., 2010; Rossi et al., 2016). We have shown that
Nfix is strongly expressed in fetal myoblasts and indirectly re-
presses MyHC-I expression via the transcription factor Nfatc4,
a positive regulator of MyHC-I in skeletal muscle (Calabria
et al., 2009; Messina et al., 2010). We have also reported that
the zebrafish (Danio rerio) Nfix ortholog Nfixa has an evolution-
arily conserved role in the transition from slow-twitch to fast-
twitch myogenesis (Pistocchi et al., 2013). In the past few years,
it has been shown that Sox6, a member of the Sry-related HMG
box (Sox) factor family, which is highly conserved in vertebrates,
plays a critical role in fetal fiber specification through direct
repression of MyHC-I by binding to the 50-upstream region in
two different binding sites. The first is located !200 bp from
the transcription start site (TSS) in the proximal promoter and
is sufficient for Sox6-dependent MyHC-I repression in fetal my-
otubes (Hagiwara et al., 2007; An et al., 2011), and the second
2354 Cell Reports 17, 2354–2366, November 22, 2016 ª 2016 The Author(s).








is located !2,900 bp from the TSS in a distal muscle enhancer
that is required for full promoter activity (Giger et al., 2000;
Blow et al., 2010). As a consequence, Sox6-null mouse muscle
displays increased levels of MyHC-I and a general switch toward
a slower phenotype (Hagiwara et al., 2007; An et al., 2011; Quiat
et al., 2011). Of note, studies in zebrafish have shown that Sox6
is restricted to fast-twitch fibers during embryonic muscle devel-
opment and that ectopic Sox6 expression in adaxial cells (the
slow muscle progenitors in zebrafish) leads to the silencing of
slow-twitch genes (such as the slow MyHC isoform smyhc1
and the transcription factor prox1a) (von Hofsten et al., 2008;
Wang et al., 2011; Jackson et al., 2015).
Here, we observed that Sox6, at variance with Nfix, is ex-
pressed at comparable levels in embryonic and fetal myoblasts,
despite its role of inhibitor of slow twitching program. Intrigu-
ingly, we demonstrated that Sox6 has opposite roles in regu-
latingMyHC-I expression between embryonic and fetal myogen-
esis in mouse. Specifically, during embryonic myogenesis, Sox6
indirectly promotes MyHC-I expression via transcriptional acti-
vation of Mef2C. As a consequence, Sox6 deficiency in embry-
onic muscle leads to a strong downregulation of MyHC-I. On
the contrary, during fetal myogenesis, Sox6 cooperates with
Nfix to repress MyHC-I in a complex in which Nfix is necessary
for the proper binding of Sox6 to the MyHC-I promoter in fetal
myotubes. Finally, we show that Nfixa and Sox6 together regu-
late sMyHC in zebrafish embryos, revealing an evolutionarily
conserved mechanism that is required for the acquisition of
normal muscle phenotype.
RESULTS
Sox6 Transcriptionally Promotes MyHC-I Expression
during Embryonic Myogenesis
Sox6 has been intensively studied as an inhibitor of slow muscle
phenotype during the fetal period. However, we observed that
Sox6 is also expressed during embryonic myogenesis, which
is mainly characterized by the expression of typical slow genes
such as the slow MyHC isoform MyHC-I. Myf5GFP-P/+ embryos
and fetuses were collected at E12.5 or E16.5, and GFP-positive
myoblasts were isolated via fluorescence-activated cell sorting
(FACS) as previously described (Messina et al., 2010). Using
quantitative real-time PCR and western blot, we found that
Sox6 levels do not significantly change, whereas Nfix, as known,
is drastically upregulated in fetal progenitors (Figures 1A–1C).
Importantly, these data show that Sox6 and Nfix proteins are
co-expressed only during fetal myogenesis. We also performed
extensive immunofluorescence analysis on frozen mouse em-
bryo sections from E10.5 to E18.5 in order to follow Sox6 protein
expression throughout development. Notably, Sox6 is first ex-
pressed between E11.5 and E12.5 in primary fibers that express
high levels of MyHC-I (Figures S1A–S1H), whereas at E17.5, the
localization of Sox6 is almost completely associated with sec-
ondary fibers that are negative for MyHC-I (Figures S1I–S1L),
as previously described (An et al., 2011; Richard et al., 2011).
We therefore decided to investigate the possible function of
Sox6 during embryonic myogenesis, a function not apparently
linked to repression of MyHC-I. To this aim, we performed immu-
nofluorescence analysis on E12.5 muscle sections from homo-
zygous mice carrying the Sox6lacZ allele (hence referred to as
Sox6-null mice) (Smits et al., 2001). Surprisingly, the staining
for MyHC-I is strongly decreased in Sox6 null in comparison to
wild-type (WT) muscle (Figures 1D and 1E). Importantly, no dif-
ferences in total MyHC content were assessed in embryonic
muscle groups of Sox6-null embryos (Figures 1G and 1H),
implying that the decrease in MyHC-I expression is not due to
delayed or aberrant muscle differentiation. We also performed
western blot and quantitative real-time PCR on embryonic
muscle lysates to confirm the immunofluorescence data, and
our results showed a decrease of MyHC-I protein in Sox6-null
samples, without major changes in total MyHC content (Figures
1J and 1K). Interestingly, the phenotype of Sox6-null embryonic
muscle is reminiscent of the Tg:Mlc1f-Nfix2 gain-of-function em-
bryo (Figures 1F and 1I), in which the Nfix2 splice variant is
ectopically expressed in muscle cells from E11.5, leading to a
fetal-like muscle phenotype (Kelly et al., 1997; Messina et al.,
2010). Importantly, Nfix expression in embryonic skeletal muscle
is not altered in the absence of Sox6 at both the protein and
mRNA levels (Figures S2A–S2D). Taken together, these results
show that Sox6 is expressed at equal levels in skeletal muscle
during embryonic and fetal myogenesis and that deletion of
Sox6 during the embryonic period unexpectedly leads to down-
regulation of MyHC-I.
Sox6Positively Regulates theSlow-Twitch Phenotype of
Embryonic Myoblasts by Binding to Mef2C Promoter
In order to define a possiblemechanism bywhich Sox6 regulates
the transcription of MyHC-I during embryonic myogenesis, we
performed chromatin immunoprecipitation (ChIP) for Sox6 in
differentiated embryonic myoblasts. We found that Sox6 does
not significantly bind either to the proximal or to the distal regu-
lative regions upstream of MyHC-I (Figure 2A), thus suggesting
that Sox6 is not able to directly regulate MyHC-I transcription
in embryonic muscle. To confirm this hypothesis, we performed
luciferase assays on WT and Sox6-null embryonic differentiated
myoblasts with vectors containing the 3,500-bp MyHC-I full
50-upstream region (MyHC-I 3500), the 408-bpMyHC-I proximal
promoter sequence (MyHC-I 408), or the mutated forms of
the distal and proximal canonical Sox6 binding sites, MyHC-I
3500 m and MyHC-I 408 m (Figure S3A) (Hagiwara et al., 2007;
An et al., 2011). As expected, in the absence of Sox6, we found
a significant reduction of firefly luciferase activity in all the
conditions with the only notable exception of the 408 WT
construct (Figure 2B), suggesting that Sox6 is promoting
MyHC-I expression in embryonic myocytes without direct bind-
ing to its canonical binding sites. In order to identify a possible
indirect mechanism by which Sox6 enhances MyHC-I expres-
sion in embryonic muscle, we focused on the transcription factor
Mef2C, a known positive regulator of the slow phenotype (Wu
et al., 2000; Potthoff et al., 2007; Anderson et al., 2015). To verify
the interaction between Mef2C and theMyHC-I promoter in em-
bryonic myoblasts, we performed a ChIP assay, which showed
direct binding of Mef2C on the proximal MyHC-I promoter (Fig-
ure S3B). Interestingly, Mef2C mRNA is downregulated in
E12.5 Sox6-null muscle, at variance with the closely related
Mef2A (Figure 2C). By ChIP on embryonic differentiated myo-
blasts, we found that Sox6 directly binds to a region located in















Figure 1. Sox6 Acts a Positive Regulator of the Slow-Twitch Phenotype during Embryonic Myogenesis
(A) Quantitative real-time PCR analysis on freshly isolatedMyf5GFP-P/+ embryonic (E12.5) and fetal (E16.5) myoblasts showing relative expression ofSox6 andNfix
transcripts in the two populations.
(B) Western blot on lysates from freshly isolated Myf5GFP-P/+ embryonic and fetal myoblasts. b-Tubulin was used to normalize the amount of protein loaded.
(C) Quantitative densitometry of the protein expression levels of Sox6 and Nfix at E12.5 and E16.5.
(D–I) Immunofluorescence on E12.5 muscle sections fromWT (D and G), Sox6 null (E and H), and Tg:Mlc1f-Nfix2 (F and I) mice stained with anti-MyHC-I (D–F) or
anti-MyHCs (MF20) antibodies (G-I). Dashed lines highlight the forelimb anlagen contour. Scale bars, 100 mm.
(J) Western blot on E12.5 muscle samples from WT, Sox6 null, and Tg:Mlc1f-Nfix2 mice. Vinculin was used to normalize the amount of loaded proteins.
(K) Quantitative real-time PCR on E12.5 muscle tissue from WT and Sox6-null mice (*p < 0.05; **p < 0.01; n = 3).








the Mef2C promoter (Figure 2D), indicating that Sox6 is a direct
activator of Mef2C during embryonic myogenesis. In order to
validate a possible Mef2C-mediated mechanism of MyHC-I
regulation, we transfected WT and Sox6-null unpurified embry-
onic myoblasts with a vector overexpressing Mef2C. Mef2C
overexpression in Sox6-deficient cells (Figure S3C) leads to an
increase of MyHC-I expression when normalized on the levels
ofMyHC-emb to account for the total number of myogenic cells
(Figure 2E). To validate these data, we also transduced purified
embryonic myoblasts with a lentiviral vector expressing small
hairpin RNA (shRNA) against Sox6 to achieve in vitro Sox6
knockdown (Figure S3D). We then transfected cells with
Mef2C-overexpression vector (Figure S3D) and assessed the
levels ofMyHC-ImRNAbyquantitative real-timePCR (Figure 2F).
Strikingly, overexpression of Mef2C was able to partially rescue
MyHC-I expression in shSox6 cells (up to 30% of the levels of
scramble-transduced cells). These results show that during the
embryonic period, Sox6 acts indirectly as a positive regulator
ofMyHC-I via aMef2C-dependentmechanism, in sharp contrast
with its well-known and characterized function during fetal myo-





B Figure 2. Sox6 Indirectly Activates MyHC-I
Expression in Embryonic Myoblasts via a
Mef2C-Dependent Mechanism
(A) ChIP assay with anti-Sox6 antibody on E12.5 differ-
entiated myoblasts. Three different chromatin regions
were tested: a negative control region (intergenic)
located 15 kb upstream of MyHC-I TSS, the MyHC-I
proximalpromoter (!375bp;MyHC-Ipromoter),andthe
MyHC-I distal enhancer (!2,900 bp;MyHC-I enhancer).
(B) Luciferase report assay on WT and Sox6-null
E12.5 differentiated myoblasts transfected with
control pGL3-basic, MyHC-I 408, MyHC-I 408 m,
MyHC-I 3,500, and MyHC-I 3,500 m constructs (*p <
0.05; **p < 0.01; n = 2).
(C) Quantitative real-time PCR for Mef2C and Mef2A
on E12.5 muscle tissue from WT and Sox6-null mice
(**p < 0.01; n = 2).
(D) ChIP assay with anti-Sox6 antibody on E12.5
differentiated primary myoblasts showing binding of
Sox6 to a region located !1.1 kb upstream ofMef2C
TSS (***p < 0.001; n = 3). As negative control, we used
the MyHC-I !15 kb intergenic region.
(E) Quantitative real-time PCR forMyHC-I andMyHC-
emb (MyHC-I/MyHC-emb ratio) on WT and Sox6-null
differentiated embryonic myoblasts transfected with
a Mef2C-overexpressing vector (*p < 0.05; **p < 0.01;
n = 2).
(F) Quantitative real-time PCR for MyHC-I on embry-
onic myoblasts purified from Myf5GFP-P/+ mice, in-
fected with scramble or shSox6 virus. Myf5GFP-P/+
purified embryonic myoblasts infected by lentiviruses
expressing the shRNA for Sox6 were transfected with
Mef2C-overespressing vector (***p < 0.001; n = 2).
Sox6 Is Necessary for Nfix Binding to
theMyHC-I Promoter during the Fetal
Period
Since Sox6 has opposite roles in MyHC-I
regulation in embryonic and fetal muscle,
and since Nfix is only expressed during fetal myogenesis (Mes-
sina et al., 2010), we decided to investigate the possible cooper-
ation between Nfix and Sox6 during fetal myogenesis. We first
investigated Nfix expression and function in Sox6-null fetuses
(E16.5). As previously described in other Sox6-null mouse
models (Hagiwara et al., 2007; An et al., 2011; Quiat et al.,
2011), fetal fiber specification is completely disrupted in the
absence of Sox6. Indeed, in contrast to WT, Sox6-null fetal mus-
cle displays very high levels of MyHC-I by immunofluorescence,
quantitative real-time PCR, and western blot (Figures S4A–S4D).
We also looked at Nfix on sections from the Sox6-null mice and
found that despite the dramatic increase in MyHC-I expression,
Nfix is correctly expressed in the nuclei of muscle fibers in the
absence of Sox6 (Figures 3A–3D), and western blot analysis
did not reveal differences in Nfix protein content (Figure S4C).
These data suggest that Nfix is normally expressed in fetal mus-
cles lacking Sox6 but unable to properly repress MyHC-I. To
verify whether Sox6 is required for Nfix function, we performed
ChIP for Nfix in WT fetal myotubes, which revealed binding of
Nfix to MyHC-I promoter in the same region of the proximal
Sox6 binding site (!200 bp) (Figure 3E). Interestingly, we








observed that in Sox6-null fetal myotubes, the binding of Nfix to
the MyHC-I promoter is significantly reduced. Importantly, Nfix
binding to Nfatc4 promoter is not impaired in the absence of
Sox6 (Figure 3E), suggesting that Nfix is still able to bind to other
transcriptional targets in the absence of Sox6. We further vali-
dated the repressive role of Nfix on the MyHC-I proximal pro-





Figure 3. Sox6 Is Required for Normal Nfix
Function in Fetal Muscle
(A–D) Immunofluorescence with anti-Nfix (green)
and anti-MyHC-I (red) antibodies on E16.5 muscle
sections from WT (A and B) or Sox6-null (C and D)
mice. Arrows indicate Nfix-positive nuclei in
secondary (MyHC-I negative) fibers. Arrowheads
indicate Nfix-positive nuclei in MyHC-I-positive
fibers. Nuclei are counterstained with Hoechst.
Scale bars, 25 mm. Higher magnifications of Nfix-
positive fibers are shown in the insets.
(E) ChIP assay with anti-Nfix antibody on WT and
Sox6-null E16.5 myotubes on negative control
region (intergenic) located 15 kb upstream of
MyHC-I TSS, the MyHC-I proximal promoter
(!375 bp; MyHC-I promoter), and the Nfatc4
promoter region (!1.2 kb upstream of the Nfatc4
TSS) (*p < 0.05; **p < 0.01; n = 2).
(F) Luciferase report assay on WT and Nfix-null
differentiated fetal myoblasts (E16.5) transfected
with control pGL3-basic, MyHC-I 408, andMyHC-I
408 m vectors (**p < 0.01; n = 2).
MyHC-I 408 m vectors in WT and Nfix-
null fetal myotubes (Figure 3F). Our results
showed increased luciferase expression
in the absence of Nfix with the vector car-
rying the WT sequence, suggesting that
indeed Nfix represses MyHC-I by acting
on the proximal promoter regulative re-
gion, in spite of the absence of any Nfix
consensus sequences (data not shown).
Importantly, Nfix-dependent negative
regulation of MyHC-I is lost when the
proximal Sox6 binding sequence is
mutated, demonstrating that Sox6 is
required for Nfix binding to the proximal
MyHC-I promoter (Figure 3F). Overall,
these results suggest a possible crosstalk
between Nfix and Sox6 in regulating
MyHC-I expression at the proximal pro-
moter region.
Nfix Is Necessary and Sufficient for
Sox6 Regulation of MyHC-I
Expression
To better investigate a possible recip-
rocal interplay between Nfix and Sox6,
we performed immunofluorescence for
Sox6 and total MyHC on frozen muscle
sections from E16.5 WT and Nfix-null
mice (Campbell et al., 2008). We found
that Sox6 is expressed in both WT and Nfix-null muscles (Fig-
ures S4E and S4F), implying that Nfix is dispensable for normal
Sox6 expression in fetal muscle. Interestingly, immunofluores-
cence for Sox6 and MyHC-I on sections from the same mice
revealed that in the absence of Nfix, there is a marked increase
in the number of Sox6-positive fibers that co-express MyHC-I,
in contrast to WT muscles (Figures 4A–4D). We further








validated these data by western blot and quantitative real-time
PCR on differentiated fetal myotubes and observed that Nfix-
null myotubes express higher levels of MyHC-I than WT cells
(Figures 4E and 4F). These data show that in the absence of
Nfix, the repressive activity of Sox6 on MyHC-I is partially
impaired, even if the normal expression pattern of Sox6 is
maintained. The results obtained in both Sox6 and Nfix-null fe-
tuses led us to hypothesize a functional cooperation between
Nfix and Sox6 in MyHC-I regulation. Therefore, we tested the
ability of Nfix and Sox6 to bind to each other in a multi-protein
complex. To this aim, we used fetal myotubes transiently trans-
fected with an Nfix2 hemagglutinin (HA) vector (see Experi-
mental Procedures) and performed a co-immunoprecipitation
(coIP) assay from nuclear extracts for HA and Sox6. CoIP re-
vealed the presence of a complex containing both Sox6 and
Nfix2-HA, as shown in Figure 5A. Therefore, we wondered
whether, as observed for Nfix fetuses in absence of Sox6,
Nfix might be required for the binding of Sox6 to the MyHC-I
promoter as well. Hence, we performed ChIP for Sox6 in WT
and Nfix-null fetal myotubes. Our results showed a decrease





Figure 4. Nfix Is Necessary for the Correct Func-
tion of Sox6 in Fetal Muscle
(A–D) Immunofluorescence with anti-Sox6 (green) and
anti-MyHC-I (red) antibodies on fetal (E16.5) muscle
sections from WT (A and B) and Nfix-null (C and D) mice.
Arrows indicate secondary fibers, which present nuclear
Sox6 expression and low or absent staining for MyHC-I.
Arrowheads indicate fibers co-expressing nuclear Sox6
and MyHC-I. Nuclei are counterstained with Hoechst.
Scale bars, 25 mm. Higher magnifications are shown in
the insets.
(E) Western blot on lysates from WT and Nfix-null E16.5
myotubes. b-Tubulin was used to normalize the amount
of proteins loaded.
(F) Quantitative real-time PCR on WT and Nfix-null E16.5
myotubes (**p < 0.01; n = 3).
50-upstream region (Figure 5B). Notably, the
binding with the proximal promoter was
completely lost in the absence of Nfix,
whereas the binding with the distal enhancer
was reduced by 50%. Interestingly, ChIP for
Sox6 on the Mef2C promoter reveals that in
WT fetal myotubes, Sox6 is not able to bind
to the Mef2C promoter, at variance with
what happens during the embryonic stage.
On the contrary, Sox6 binding on the Mef2C
promoter still occurs in Nfix-null fetal myo-
tubes. These data indicate that Nfix is
required for the proper binding of Sox6 to
the MyHC-I promoter during fetal myogene-
sis. Finally, we performed ChIP for Sox6 on
WT and Tg:Mlc1f-Nfix2 embryonic myoblasts
(Figure 5C). Strikingly, Nfix overexpression
leads to a switch in the binding properties of
Sox6; indeed, we found that Sox6 is bound
to the MyHC-I promoter, but not to the
Mef2C promoter, in Tg:Mlc1f-Nfix2 embryonic myoblasts.
These data demonstrate that Nfix is necessary and sufficient
for the binding of Sox6 to the MyHC-I proximal promoter and
therefore for Sox6 repressive activity on MyHC-I.
Functional Cooperation of Sox6 and Nfixa Is
Evolutionarily Conserved in Zebrafish
It was previously demonstrated that both Sox6 and Nfixa have
an evolutionarily conserved role in the repression of slow-twitch
genes in zebrafish (von Hofsten et al., 2008; Pistocchi et al.,
2013; Jackson et al., 2015). We thus wondered whether a func-
tional interplay between Nfixa and Sox6 is conserved in zebra-
fish myogenesis. As a preliminary analysis, we performed quan-
titative real-time PCR on trunk and tail regions isolated from
zebrafish embryos at 1, 2, and 3 days post-fertilization (dpf)
and found that the sox6 transcript is expressed at high levels
at 1 dpf and is steadily downregulated up to 3 dpf (Figure S5A),
whereas the nfixa transcript peaks at 2 dpf (Figure S5B),
as shown previously (Pistocchi et al., 2013). Additionally, we
performed immunofluorescence for Sox6 and total MyHC
(MF20 antibody) or the slow MyHC isoform sMyHC (F59








antibody) on 2 dpf embryos and found that Sox6 protein is spe-
cifically expressed in the nuclei of fast muscle fibers that are
negative for sMyHC (Figures 6A and 6B), whereas the outer su-
perficial fibers positive for sMyHC are mostly negative for Sox6
(data not shown). Interestingly, we observed that a minority of
slow superficial fibers show cytoplasmic staining for Sox6 (Fig-
ures 6C–6J), suggesting that Sox6 subcellular localization might
be spatially regulated in the different muscle domains. In order
to elucidate the role of Sox6 in slow-twitch genes regulation, we
performed morpholino (MO)-mediated knockdown of sox6 (von
Hofsten et al., 2008). By quantitative real-time PCR analysis
(Figures S5C and S5D), we found that the expression of smyhc1
is markedly increased in sox6 morphants at 2 dpf, whereas the
fast-twitch gene mylpfa (fast myosin light chain isoform) is ex-




Figure 5. Nfix Is Required for Fetal-Spe-
cific Binding of Sox6 to MyHC-I Regulative
Regions
(A) Immunoprecipitation assay, from nuclear ex-
tracts, on fetal myoblasts transfected with Nfix2-
HA vector, showing the immunoprecipitation of
Sox6 (IP Sox6) and HA (IP HA). T, total lysate; IgG,
negative control; IP, immunoprecipitated. The
coIPs for Sox6 on Sox6-null myotubes and for HA
on fetal myoblasts transfected with the HA-only
expressing vector (pCH-HA) were used as nega-
tive controls.
(B) ChIP assay with anti-Sox6 antibody onWT and
Nfix-null E16.5 myotubes on the same chromatin
regions described in Figures 2A and 2D (*p < 0.05;
**p < 0.01; ***p < 0.001; n = 2). As a negative
control, we used only the MyHC-I !15 kb region.
(C) ChIP assay on unpurified embryonic myo-
blasts from WT or Tg:Mlc1f-Nfix2 to test Sox6
binding on MyHC-I and the Mef2C promoter. The
intergenic region was used as a negative control
and IgG as an unrelated antibody (**p < 0.01;
***p < 0.001; n = 2).
cally upregulated in sox6 morphants,
suggesting that Sox6 might negatively
regulate nfixa (Figure S5E). We conclude
that Sox6 is a critical repressor of the
slow-twitch phenotype in zebrafish and
that Nfixa is not able to compensate for
sox6 knockdown. To verify a possible
cooperation between Nfixa and Sox6,
we performed co-injections of morpholi-
nos against sox6 and nfixa at lower
doses with respect to those previously
described (von Hofsten et al., 2008; Pis-
tocchi et al., 2013) in order to minimize
their effect when injected separately
(see Experimental Procedures). Co-injec-
tion of these doses of MOs resulted in
synergistic defects in motility in touch-
response assays (Figure S6). Control em-
bryos and the vast majority of sox6 or
nfixa morphants readily swam away
when touch-stimulated. On the contrary, 66% of double partial
morphants were either shivering or bending their tails before
eventually moving away but within a shorter distance (Figures
S6A and S6C; Movie S1). The synergistic effect is more evident
when lowering the doses (see Figures S6B and S6D). Strikingly,
quantitative real-time PCR results show that smyhc1 is signifi-
cantly upregulated only in the double morphants at 48 hpf,
whereas the level of myl1, an early marker for differentiating
fast muscle cells (Burguie`re et al., 2011), does not change (Fig-
ure 6K). Moreover, we validated the increased expression of
sMyHC (F59 antibody) in sox6/nfixa double morphants by
western blot (Figure 6L). We thus conclude that functional
cooperation of Sox6 and Nfix is required for proper skeletal
muscle development and that this cooperation is evolutionarily
conserved in mouse and zebrafish.












Figure 6. Functional Cooperation of Sox6 and Nfixa Is Conserved in Zebrafish
(A–J) Immunofluorescence with anti-Sox6 antibody (green) and anti-MyHC antibody (red) (A, B, and G–J) or with anti-Sox6 (green) and anti-sMyHC (F59, red)
(C–F) on 2 dpf zebrafish muscle longitudinal sections. Arrowheads indicate Sox-positive nuclei in fast-twitch muscle fibers. Arrows indicate Sox6 staining in the
cytoplasm of superficial slow fibers. Approximately one-fifth of the sMyHC-positive superficial cells displayed cytoplasmic Sox6 staining, whereas fast fibers
negative for sMyHC only displayed nuclear Sox6 staining. Nuclei are counterstained with Hoechst. Scale bars, 25 mm.
(legend continued on next page)









Adult skeletal muscle is composed of two major fiber types pre-
senting a wide range of physiological and biochemical differ-
ences. Slow-twitch type I fibers use oxidative metabolism and
express the slow MyHC isoform MyHC-I; in contrast, fast-twitch
type II fibers present glycolytic or mixed metabolism and ex-
press three fast MyHC isoforms (MyHC-IIa, IIx/d, and IIb) (Peter
et al., 1972; Schiaffino et al., 1988; Chakkalakal et al., 2012). The
phenotype of post-natal muscle fibers is strictly regulated by
extrinsic signals such as muscle activity and hormones (But-
ler-Browne et al., 1982; Gambke et al., 1983; Russell et al.,
1988). Additionally, different factors controlling adult muscle
plasticity have been identified, including the Nfatc (Calabria
et al., 2009) and Mef2 (Wu et al., 2000; Potthoff et al., 2007; An-
derson et al., 2015) transcription factor families and PGC-1a (Li
et al., 2002). On the contrary, the molecular mechanisms by
which muscle fiber diversity is achieved during pre-natal devel-
opment are still poorly understood. It was shown that the
intrinsic transcriptional properties of embryonic and fetal
myogenic progenitors are important to set the fiber type in the
absence of nerve activity (Cho et al., 1993; Cusella-De Angelis
et al., 1994). Moreover, in recent years, several transcription
factors contributing to developmental muscle fiber specification
have been identified, including Sox6 (Hagiwara et al., 2007; An
et al., 2011), Nfix (Messina et al., 2010), Six1/Six4 (Richard et al.,
2011), and Nfatc2 (Daou et al., 2013). However, the network
of transcription factors controlling fiber specification during
embryogenesis is still far from being fully characterized, and
until now, functional interactions among the different regulators
were completely unknown.
In this work, we provided evidence for functional interplay be-
tween Nfix and Sox6 in controlling expression of the slow MyHC
isoform during mouse pre-natal muscle development.
In contrast to Nfix, which is a specific marker of fetal myogen-
esis (Messina et al., 2010; Mourikis et al., 2012), Sox6 is ex-
pressed in both embryonic and fetal purified myoblasts at the
mRNA and protein levels. Consistently, we found that Sox6 pro-
tein is expressed in skeletal muscle in vivo starting between
E11.5 and E12.5. This was unexpected, since Sox6 is known
to be a repressor of MyHC-I, which along with MyHC-emb is ex-
pressed in all embryonic fibers (Hagiwara et al., 2007; Hutche-
son et al., 2009). It is known that Sox6 transcript is absent in
mouse primary myotome between E9.5 and E10.75 (Vincent
et al., 2012), suggesting that Sox6 is quickly activated in embry-
onic myoblasts at the beginning of primary myogenesis. Unex-
pectedly, Sox6 deficiency during primary myogenesis leads to a
transient faster muscle phenotype with low levels of MyHC-I.
This is followed in Sox6-null fetuses by dramatic upregulation
of MyHC-I at the transcription level, consistently with previous
characterizations of the Sox6-null phenotype (Hagiwara et al.,
2007; An et al., 2011; Quiat et al., 2011). Our results demon-
strate that Sox6 plays opposite roles in MyHC-I expression dur-
ing development. Importantly, in embryonic myogenic cells,
Sox6 does not bind to the two canonical MyHC-I binding sites,
which are both dispensable for Sox6-dependent embryonic
regulation of MyHC-I, at least in our culturing conditions. These
data strongly suggest an indirect mechanism of regulation. We
found that Sox6 directly binds to the promoter ofMef2C and ac-
tivates its expression in primary myofibers. Mef2C is part of a
transcription factor family that is constitutively expressed in
muscle cells since early embryogenesis (Edmondson et al.,
1994) and plays an important role in the specification and main-
tenance of type I fibers (Chin et al., 1998; Wu et al., 2000; Ander-
son et al., 2015). Importantly, conditional deletion of Mef2C in
skeletal muscle leads to a drastic reduction in slow-twitch fibers
(Potthoff et al., 2007). Our rescue experiment, although partial,
clearly shows that one of the Sox6-dependent effects on
MyHC-I transcription in embryonic myofibers is mediated by
Mef2C, which is directly targeted by Sox6 in embryonic, but
not fetal, muscle. This function led us to hypothesize that the
binding ability of Sox6 is differentially regulated in discrete
myogenic progenitor populations or at different times during
development according to different co-factors, which contribute
to the high versatility of Sox6 functions. It is known that SoxD
factors, lacking trans-acting functional domains, have a critical
requirement for co-factors in order to regulate transcription of
target genes (reviewed in Hagiwara, 2011). Therefore, it is likely
that the reversal in Sox6 function is due to different factors that
are progressively recruited and activated during muscle devel-
opment. Indeed, we found that during fetal myogenesis, Nfix
acts as a fundamental co-factor of Sox6 and is able to form a
complex with Sox6, which is no longer able to bind to the
Mef2C promoter but can bind to MyHC-I regulative regions, in
particular the proximal promoter that was shown to be critical
for Sox6-dependent fetal repression of MyHC-I (Hagiwara
et al., 2007). In our previous study, we showed that Nfix nega-
tively regulates MyHC-I by repressing Nfatc4, a positive regu-
lator of MyHC-I (Messina et al., 2010). Interestingly, we have
now found that during fetal myogenesis, Nfix is also present
at the MyHC-I proximal promoter along with Sox6, suggesting
that a physical association between these two proteins may
be required for proper MyHC-I downregulation. Since Nfix pre-
sents both a trans-repression domain and a trans-activation
domain, we hypothesized that formation of a complex with
Sox6 might provide the basis for the transcriptional repression
at the MyHC-I locus (Figure 7). Indeed, Nfix and Sox6 were
found to be part of the same complex in fetal myotubes and
are both present at the MyHC-I proximal promoter. Moreover,
our study on Nfix-null and Sox6-null fetuses clearly shows that
Sox6 and Nfix are independently expressed during secondary
myogenesis and that neither Sox6 nor Nfix is able to correctly
downregulate MyHC-I expression when the other one is not pre-
sent. A scheme of the scenario in which Sox6 and Nfix behave
(K) Quantitative real-time PCR analysis on trunk and tail regions at 48 hpf from embryos injected with std-MO or suboptimal doses of nfixa-MO (0.25 pmol),
sox6-MO (0.1 pmol), or nfixa-MO + sox6-MO (**p < 0.01; N = 2).
(L) Western blot for sMyHC at 52 hpf on trunk and tail regions of embryos injected with std-MO or suboptimal doses of nfixa-MO, sox6-MO, or nfixa-MO + sox6-
MO. Vinculin was used to normalize the amount of loaded proteins.








and cooperate during pre-natal muscle development is shown
in Figure 7.
In this work, we have also provided evidence for a conserved
transcriptional cooperation of Sox6 and Nfixa in zebrafish. We
have shown that Sox6 is crucial for the regulation of smyhc1, in
line with the findings of Jackson et al. (2015). It was shown that
Sox6 expression is silenced in zebrafish slow fibers by the com-
bined effects of Prdm1a and miR-499 (von Hofsten et al., 2008;
Wang et al., 2011). We found that a minority of sMyHC-positive
cells display cytoplasmic staining for Sox6, suggesting that
Sox6 might also be regulated through subcellular localization
in different fiber types. Notably, our double partial knockdown
performed with suboptimal doses of sox6-MO (von Hofsten
et al., 2008) and nfixa-MO (Pistocchi et al., 2013) caused a severe
impairment in the touch-evoked escape response, suggesting
that Sox6 and Nfixa cooperate in proper muscle function. Molec-
ularly, our data suggest that the two transcription factors can act
together to repress smyhc1 expression in zebrafish embryos,
whereas the expression of a typical fast-twitch gene, such as
myl1 (Burguie`re et al., 2011), was unaffected in double partial
morphants.
In conclusion, we have presented a complex model of regula-
tion of embryonic to fetal MyHC-I regulation that involves a
functional interplay between Nfix and Sox6 that is conserved in
mammals and teleosts.
EXPERIMENTAL PROCEDURES
Mouse Strains and Fish Lines
The following murine lines were used: Myf5GFP-P/+ (Kassar-Duchossoy et al.,
2004), Nfix null (Campbell et al., 2008), Sox6lacZ/+ (Smits et al., 2001), and
Tg:Mlc1f-Nfix2 (Messina et al., 2010). For each of these lines, the genotyping
strategy has been described in the references. CD1 WT mice (Jackson Lab-
oratory) were used as well. Mice were kept in pathogen-free and controlled
conditions, and all procedures conformed to Italian law (D. Lgs n! 2014/26,
implementation of the 2010/63/UE) and were approved by the Animal Welfare
Body of the University of Milan and the Italian Minister of Health (1212/
2015PR). Zebrafish were raised and maintained according to established
techniques. The following line was used: AB (from Carole Wilson, UCL,
London, UK).
Figure 7. Model of Sox6 and Nfix Interplay
during Pre-natal Myogenesis
Scheme illustrating the functions of Sox6 and Nfix
during embryonic (E12.5) and fetal (E16.5) myo-
genesis. Transcription factors are represented by
circles, whereas the regulative region of MyHC-I is
indicated by rectangles that are green when tran-
scription is activated and red when transcription is
repressed.
Immunofluorescence on Sections
Mouse or zebrafish embryos were fixed in 4%
paraformaldehyde, extensively washed in PBS,
and incubated overnight in PBS containing 15%
sucrose. Samples were then frozen in nitrogen-
chilled isopentane and kept at "80!C until use.
Cryostat sections (8 mm thick) were permeabilized
in 1% BSA, 0.2% Triton X-100 in PBS for 30 min
at room temperature and then incubated for 1 hr
in blocking solution (10% goat serum in PBS) and
overnight with the primary antibody or with mock PBS. After incubation for
45 min with the fluorescent-conjugated secondary antibody (Jackson Immu-
noResearch Laboratories), sections were washed in PBS 0.2% Triton X-100
and mounted, and fluorescent immunolabeling was recorded with a DM6000
Leica microscope. The following primary antibodies were used: rabbit anti-
Sox6 (Abcam, 1:300), rabbit anti-Nfix (Novus Biological, 1:200), mouse anti-
MyHC-I (Sigma, 1:200), BAD5 (monoclonal, 1:2), MF20 (monoclonal, 1:2),
and F59 (monoclonal, 1:10). Nuclei were stained with Hoechst (1:1,000).
Cell Sorting and Culturing
Dissected Myf5GFP-P/+ embryonic or fetal muscles were digested by 0.15 mg/
mL Collagenase (Sigma), 1.5 mg/mL Dispase (GIBCO), and 0.1 mg/ml Dnase I
(Sigma) for 30min at 37!C in agitation as described in Biressi et al. (2007). After
centrifugation and filtration, cells were collected in DMEM, 20% fetal bovine
serum (FBS), 2 mM EDTA, and 20 mM HEPES. For cell sorting, we used the
Sorter BD FACSAria. GFP-positive cells were collected for mRNA and protein
extraction. For the preparation of unpurified fetal myoblasts after digestion of
tissue, cells were pre-plated for 30 min on a plastic dish to lose fibroblasts,
which normally adhere to plastic. Unpurified cells were kept in incubation
at 37!C in 20% HS (20% horse serum in DMEM) and 24 hr later allowed to
differentiate in DM (2% horse serum in DMEM) for 48 hr.
Lentivirus Production, Transduction, and Transfection
Preparation of viral particles were performed by co-transfecting pLKO.1-
shSox6 vectors (Thermo Fisher Scientific) or non-targeting shRNA vectors
(30 mg), together with the packaging plasmids pMDLg/p (16.25 mg),
pCMV-VSVG (9 mg), and pRSV-REV (6.25 mg), in HEK293T cells. Transfec-
tion was performed using the calcium phosphate transfection method.
Viral particles were collected 40 hr after transfection and subjected to
ultracentrifugation at 20,000 rpm for 2 hr at 20!C (Beckman Coulter, Optima
L-100 XP). The concentrated viral particles were re-suspended in PBS and
stored in aliquots at "80!C until further use. Embryonic myoblasts were
transduced by overnight incubation with viral preparation. These prepara-
tions were used to transduce embryonic myoblasts at an MOI of 10. The
day after transduction, embryonic myoblasts were transfected with Mef2C
(pCDNAI/A-Mef2C) or the empty vector as a negative control using Lipofect-
amine LTX (Invitrogen).
Protein Extraction and Western Blot
Cultured cells were washed twice in ice-cold PBS and then lysed (30min in ice)
with RIPA buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 1% Triton-X, 0.1%
sodium deoxycholate, 0.1% SDS, and 150 mM NaCl in deionized water)
plus protease inhibitors (1 mMPMSF). For zebrafish, only trunk and tail regions
were used, cutting out the head, and protein was extracted in Laemmli buffer








(3 mL per embryo). Protein was harvested after centrifugation, quantified
by absorbance reading at 750 nm, and stored at !80"C. 30 mg protein was
resolved on 8%–12% polyacrylamide gels or on MiniProtean TDX Gels (Bio-
Rad) after denaturation at 95"C for 5 min with SDS-PAGE Loading sample
buffer 2X (100 mM Tris [pH 6.8], 4% SDS, 0.2% Bromophenol blue, 20% glyc-
erol, and 10 mM dithiothreitol). For western blot analysis, proteins were trans-
ferred onto nitrocellulose with the iBlot Dry Blotting System (Invitrogen).
Following transfer, membranes were blocked in 5%milk in Tris-buffered saline
(TBS)-T (TBS plus 0.02% Tween20) for 1 hr at room temperature. The primary
antibodies used were rabbit anti-Sox6 (Abcam; 1:1,000), mouse anti-MyHC-I
(Sigma; 1:5,000), mouse anti-b-tubulin (Santa Cruz Biotechnology; 1:5,000),
rabbit anti-Nfix (Novus Biologicals; 1:500), mouse anti-HA (Covance; 1:500),
mouse anti-vinculin (Sigma; 1:1,000), and mouse anti-sMyHC (F59,
Hybridoma Bank) anti-mouse sarcomeric MyHC (MF20, Hybridoma Bank).
Horseradish peroxidase (HRP)-conjugated antibodies (Bio-Rad) were used
as secondary antibodies, and the signal was revealed with the ChemiDoc
MP System (Bio-Rad).
Transfection and Co-immunoprecipitation Assays
For transfection of fetal myoblasts, WT or Sox6-null cells were plated on
90-mm dishes and allowed to reach 80% confluence in proliferating condi-
tions. Cells were transfected with pCH-Nfix2-HA or pCH-HA plasmids with
Lipofectamine LTX (Invitrogen) overnight at 37"C. Cells were kept in DM for
36 hr after transfection, and then nuclear extracts were prepared by collecting
5 3 106 cells in 400 mL ice-cold hypotonic buffer A (10 mM HEPES [pH 7.9],
10 mM KCl, 0.1 mM EGTA, 1 mM DTT, protease inhibitors, 1 mM PMSF,
and phosphatase inhibitors) for 15 min in ice. Then, NP40 was added to a final
concentration of 0.625%, and cells were centrifuged at 5,000 rpm for 5 min at
4"C. The supernatant was discarded as cytoplasmatic extract, while the
pelleted nuclei were resuspended in 100 mL immunoprecipitation lysis buffer
containing 50 mM Tris-HCl (pH 7.5), 1% NP40, 1 mM EDTA, 100 mM NaCl,
and protease and phosphatase inhibitors. Immunoprecipitation was per-
formed using the immunoprecipitation kit Dynabeads Protein A (Life Technol-
ogies). Dynabeads Protein A (50 mL) was incubated for 2 hr with gentle rotation
at room temperature with 5 mg rabbit anti-Sox6 antibody (Abcam), rabbit anti-
HA antibody (Santa Cruz), or non-related rabbit immunoglobulin G (IgG) (Santa
Cruz). Then, the bead-antibody complex was incubated with gentle rotation for
2 hr at 4"C with 1.5 mg total protein lysates per condition. The eluted proteins
were denatured with non-reducing SDS-PAGE loading sample buffer (100 mM
Tris [pH 6.8], 4%SDS, 0.2% bromophenol blue, and 20% glycerol) and loaded
onto a gel.
Chromatin Immunoprecipitation and Reporter Assay
ChIP for Sox6 and luciferase assays were performed as previously published
(An et al., 2011). For the detailed protocol, see Supplemental Experimental
Procedures.
RNA Extraction and Analysis
RNA from homogenized mouse or zebrafish embryos and isolated cells
was extracted with NucleoSpin RNA kits (Macherey-Nagel) following the man-
ufacturer’s instructions. Eluted RNA was checked on agarose gels, quantified
with a Nanodrop spectrophotomer, and stored at !80"C. Approximately
0.5 mg RNA was used with the ImProm-II Reverse Transcriptase kit (Promega).
Real-time PCR was performed on cDNA using SYBR Green Supermix (Bio-
Rad) and the CFX Connect Real Time System (Bio-Rad). After amplification,
relative mRNA expression levels were calculated using standard curves from
cDNA dilutions and normalized on the Gapdh expression levels. For quantita-
tive real-time PCR in zebrafish, we used rpl8 to normalize themRNA levels. The
primers used are listed in Tables S1 and S2.
MO Microinjections
The antisense MOs (Gene Tools) used in this study, sox6-MO1 (von Hofsten
et al., 2008) and nfixa-MO (Pistocchi et al., 2013), were previously described.
MOs, diluted in Danieau buffer (Nasevicius and Ekker, 2000), were injected at
the one- to two-cell stage. Escalating doses of each MO were tested for
phenotypic effects; as control for unspecific effects, each experiment was
performed in parallel with an std-MO (standard control oligo) with no target
in zebrafish embryos. We usually injected 0.25 pmol sox6-MO per embryo.
For combined knockdown experiments, we injected sox6-MO and nfixa-MO
at 0.1 and 0.25 or 0.08 and 0.125 pmol per embryo, respectively.
Statistical Analysis
Values were expressed as means ± SD. Statistical significance was assessed
by unpaired Student’s t test with Prism 5 software. Statistical significance with
a probability of less than 5%, 1%, or 0.1% is indicated in each graph with a
single, double, or triple asterisk, respectively, followed by the number of inde-
pendent experiments (n).
SUPPLEMENTAL INFORMATION
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RhoA-­‐ERK	   axis	   regulates	   secondary	  myogenesis	   through	   the	   control	   of	  
JunB	  and	  Nfix	  expression	  
Summary 
The transition from embryonic to fetal myogenesis is a crucial switch, required for the 
complete maturity of skeletal muscles. Mechanistically, the transcription factor Nfix, 
specifically expressed during fetal myogenesis, is needed for the beginning of fetal 
myogenesis. Here we investigate the mechanisms regulating Nfix expression, showing 
that JunB is both necessary and sufficient for Nfix activation. Moreover, we show that the 
temporal progression of prenatal muscle development is timed by the RhoA/ROCK, which 
maintains the embryonic myogenesis, suppressing JunB and Nfix expression. 
RhoA/ROCK elicit their effects repressing ERK kinases activity, which promote the fetal 
genetic program. In conclusion, RhoA/ROCK/ERK axis constitutes one of the major 
pathway that regulates the progression of prenatal myogenesis through the control of JunB 




Prenatal skeletal muscle development is a biphasic process, which involves the 
differentiation of two distinct populations of muscle progenitors, known as embryonic and 
fetal myoblasts (Biressi et al., 2007b; Hutcheson et al., 2009). The first wave of muscle 
differentiation, named embryonic myogenesis, takes place around embryonic day (E) 10.5-
12.5 in mouse. During this phase embryonic myoblasts are committed to differentiate in 
primary fibers, establishing the primitive architecture of prenatal muscles. Primary fibers 
are mainly slow-twitching fibers expressing high levels of slow Myosin heavy chain (MyHC) 
isoform (MyHC-I, encoded by the Myh7 gene) and embryonic MyHC isoform (MyHC-emb, 
encoded by Myh3 gene) (Schiaffino et al., 1986; Stockdale et al., 1992).   Then, the 
second wave of differentiation is called fetal myogenesis and occurs between E14.5 and 
E17.5. During this latter phase, fetal myoblasts give rise to fast-twitching secondary fibers. 





and glycolytic enzymes, and they are characterized by low levels of slow MyHC (Eusebi et 
al., 1986; Lyons et al., 1990; Daou et al., 2013). The formation of secondary fibers allows 
the complete maturation of prenatal muscles and confers the fiber type diversification, to 
fulfil different functional demands of adult skeletal muscles (Schiaffino and Raggiani, 
2011). 
Embryonic and fetal myoblasts are two intrinsically different population of muscle 
progenitors that differs in terms of morphology, extracellular signal response and gene 
expression profile (Biressi et al., 2007b), indicating that a transcriptional change is needed 
to switch from embryonic to fetal myogenesis. The major regulator of the transition from 
embryonic to fetal gene transcription is Nfix, a transcription factor mainly expressed during 
fetal myogenesis (Biressi et al., 2007b; Messina et al., 2010). The key role of Nfix is due to 
its capability to activate fetal specific markers, such as the muscle creatine kinase (MCK) 
and β-enolase (eno3), and to repress embryonic-specific genes, as Myh7 (Messina et al., 
2010; Taglietti et al., 2016). Moreover, it has been reported that Nfix regulates also 
postnatal muscle homeostasis and the proper timing of regeneration (Rossi et al., 2016). 
Interestingly, the second transcription factor more highly expressed during fetal 
myogenesis is JunB (Biressi et al., 2007b). JunB is a member of activator protein 1 (AP-1) 
family, which maintains muscle mass and prevents atrophy in adult muscles (Raffaello et 
al., 2010), whereas its role during prenatal development is still unknown.  Cellular identity 
during development is known to be defined by intrinsic factors but how the temporal 
progression is achieved is still a matter of research. Moreover, the integration of 
environmental signals is fundamental for the orchestration of prenatal development but, 
although different pathways activated by extracellular stimuli have been described, the 
molecular mechanisms that translate them into gene expression program are not known. 
The Rho GTPase RhoA plays important roles in many intracellular signaling (Kimura et al., 
1996; Amano et al., 1996) through the activation of its major effector, the Rho-kinase 
ROCK. The interplay of the RhoA/ROCK pathway with various signaling molecules, such 
as the ERK kinases (Zuckerbraun et al., 2003; Li et al., 2013), is known to affect the 
proper transduction of extracellular signals, conditioning the gene expression network. 
Here we report that the RhoA/ROCK axis confers the identity of embryonic myoblasts, 
repressing the activation of the ERK kinases and, as a consequence, of JunB. Conversely, 
during fetal myogenesis, the ERK activity is necessary for the expression of JunB, which 
directly activate Nfix, promoting the beginning of fetal myogenesis program and the 







Analysis	  of	  temporal	  gene	  expression	  of	  Nfix	  and	  JunB	  
Although it was demonstrated that Nfix and JunB are highly expressed specifically during 
fetal myogenesis (Biressi et al., 2007b; Taglietti et al., 2016), the temporal profiles of their 
expression are not known. We first analyse the transcript levels of Nfix and JunB on 
Myf5GFP-P/+ myoblasts, freshly isolated by FACS from cellular suspensions obtained from 
Myf5GFP-P/+ embryonic muscles, at E11.5, E12.5 and E13.5 and from fetal muscles at 
E14.5, E15.5, E16.5 and E17.5. Both Nfix and JunB start to be expressed around E14.5 
and their expression drastically increases at E15.5 to remain still high until E17.5 (Figure 1 
A-B). Western blot analysis on total skeletal muscle lysates at different stages showed a 
similar profile of Nfix and JunB expression seen by qRT-PCR (Figure 1 C). These data 
confirm that Nfix and JunB expression occurred only during fetal stages and demonstrate 

















Figure	  1.	  Developmental	  timing	  of	  Nfix	  and	  JunB	  expression.	  A-­‐B)	  qRT-­‐PCR	  analysis	  on	  purified	  Myf5GFP-­‐P/+	  
myoblasts	  dissected	  from	  E11.5	  up	  to	  E17.5	  muscles,	  showing	  the	  expression	  profile	  of	  Nfix	  (A)	  and	  JunB	  (B)	  
at	  different	  developmental	  stages.	  C)	  Western	  Blot	  on	  purified	  Myf5GFP-­‐P/+	  myoblasts	  isolated	  from	  E11.5	  up	  
to	  E17.5	  muscles.	  Vinculin	  was	  used	  to	  normalize	  the	  total	  amount	  of	  loaded	  proteins.	  
 
 
JunB	  is	  sufficient	  for	  the	  induction	  of	  Nfix 
To better characterize the patterns of expression of Nfix and JunB in fetal muscle 
progenitors, we performed immunostaining on Myf5GFP-P/+-purified myoblasts obtained 
from fetuses at E14.5, E15.5 and E16.5. Freshly isolated myoblasts were maintained in 
culture for 2 hours to allow their adhesion and then were stained for Nfix and JunB 
(Supplementary Figure S1). In all the time points analysed, a high percentage of fetal 
myoblasts co-expressed Nfix and JunB (E14.5 = 77.2%, E15.5 = 85%, E16.5 = 82 %), but 
at E14.5 and E15.5 there were some myoblasts which were positive only for JunB (E14.5 
= 10.3%, E15.5 = 10.2%). Conversely, at E16.5 few myoblasts were positive for Nfix but 
not for JunB (13.9%) (Figure 2A-C). Since JunB seems be expressed earlier than Nfix, we 
decided to investigate the possible interplay between Nfix and JunB. With this aim, 
unpurified embryonic myoblasts were transfected with pcDNA3.1X-JunB expressing vector 
and the expression of Nfix was analysed by Western Blot. The analysis revealed that Nfix 
is precociously activated in embryonic myoblasts overexpressing JunB, if compared with 
the embryonic myoblasts expressing a control vector (pcDNA3.1x) (Figure 2D). To further 
confirm this result, Myf5GFP-P/+-purified embryonic myoblasts were induced to express JunB 
upon pcDNA3.1X-JunB transfection and the transcript levels of Nfix were examined by 
qRT-PCR. The pure population of embryonic myoblasts over-expressing JunB expressed 
also Nfix, whereas it was virtually absent in the control myoblasts, suggesting the 
requirement of JunB for Nfix induction (Figure 2E). Interestingly, the embryonic myoblasts, 
which overexpress JunB and Nfix, precociously down-regulate the typical embryonic 
marker MyHC-I, and up-regulate the fetal marker, β-enolase, described to be normally 
respectively inhibited (Taglietti et al., 2016) and activated by Nfix (Messina et al., 2010). 
These results suggest that the induction of JunB in embryonic myoblasts is sufficient for 
the expression of Nfix and the activation of the fetal genetic program. To evaluate whether 
JunB acts as a direct activator of Nfix, we performed in silico sequence analysis of Nfix 





(Chinenov and Kerppola, 2001; Eferl and Wagner, 2003), located about 200 base pairs 
(bp) and 1400bp upstream of the transcription start site (TSS). To address whether JunB 
is responsible for the direct transcriptional activation of Nfix on those two sites, we 
performed a chromatin immunoprecipitation assay (ChIP) for JunB on fetal differentiated 
myoblasts. As shown in Figure 2F, JunB is able to directly bind Nfix promoter in the region 
proximal to the TSS (-200bp) but not the distal one (-1400bp). MyHC-2b promoter was 
used as positive control sequence for the ChIP of JunB (Raffaello et al., 2010). Taken 
together, these results show that JunB is sufficient to directly promote the transcriptional 






Figure	  2.	  JunB	  acts	  as	  a	  direct	  activator	  of	  Nfix	   	  A-­‐B)	  Immunofluorescence	  for	  JunB	  (red)	  and	  Nfix	  (green)	  
on	   freshly	   isolated	  Myf5GFP-­‐P/+-­‐purified	  myoblasts	   at	   E14.5	   (A)	   and	   E16.5	   (B).	   Nuclei	  were	   counterstained	  
with	  Hoechst.	  White	  arrows	  indicate	  myoblasts	  coexpressing	  JunB	  and	  Nfix.	  White	  head-­‐arrows,	  in	  Figure	  A,	  
mark	   nuclei	   positive	   for	   JunB	   but	   negative	   for	   Nfix,	   while	   yellow	   head-­‐arrows,	   in	   Figure	   B,	   indicate	  
myoblasts	  expressing	  Nfix	  but	  not	  JunB.	  Scale	  bars:	  25	  μm.	  C)	  Graph	  showing	  the	  percentage	  of	  JunB+/Nfix+	  
(white	   bar),	   JunB+/Nfix-­‐	   (red),	   JunB-­‐/Nfix+	   (green)	   and	   Junb-­‐/Nfix-­‐	   (black).	   Percentages	   are	   expressed	   in	  
respect	   to	   the	   total	   number	   of	   nuclei.	   D)	   Western	   Blot	   on	   lysates	   from	   unpurified	   embryonic	   (E12.5)	  
myoblasts	   over-­‐expressing	   JunB	   (pcDNA3x-­‐JunB)	   compared	   with	   control	   myoblasts	   (pcDNA3x).	   The	  
Western	  Blot	  shows	  that	  embryonic	  myoblasts	  transfected	  with	  pcDNA3x-­‐JunB	  precociously	  expressed	  Nfix.	  
Vinculin	   was	   used	   to	   normalize	   the	   total	   amount	   of	   loaded	   proteins.	   E)	   qRT-­‐PCR	   on	  Myf5GFP-­‐P/+-­‐purified	  
embryonic	  myoblasts	   (E12.5)	   transfected	  with	  pcDNA3x-­‐JunB	  over-­‐expressing	  vector	  or	  with	  pcDNA3x,	  as	  
control.	   The	   JunB	   over-­‐expressing	   embryonic	   myoblasts	   have	   an	   increased	   expression	   of	   Nfix,	   that	  
correlates	  with	  a	  decrease	  of	  MyHC-­‐I	  expression	  and	  an	  up-­‐regulation	  of	  Eno3	  (*p<0.05,	  **p<0.01;	  N=3).	  F)	  
ChIP	  assay	  with	  anti-­‐JunB	  on	  fetal	  myotubes	   (E16.5)	  on	  positive	  control	   region	  (MyHC-­‐2B	  promoter),	  Nfix	  
promoter	  distal	  region	  located	  1400bp	  upstream	  of	  Nfix	  TSS	  and	  Nfix	  proximal	  promoter	  (-­‐200bp).	  IgG	  were	  
used	  as	  an	  unrelated	  antibody	  (**p<0.01;	  N=3).	  
	  
Nfix	  does	  not	  control	  JunB	  expression	  but	  directly	  activate	  its	  own	  expression	  
We then wondered whether the overexpression of Nfix in embryonic muscles would induce 
the expression of JunB. For this reason we analyzed the mRNA levels of JunB in 
embryonic myoblasts transfected with pCH-Nfix2 vector, which enables the over-
expression of Nfix. Interestingly, the over-expression of Nfix does not induce the 
expression of JunB in embryonic myoblasts (Fig. 3A). To confirm this result, we evaluated 
the protein levels of JunB in embryonic myoblasts purified from a transgenic mice 
overexpressing Nfix, Tg:Mlc1f-Nfix2 mice, under the transcriptional control of the myosin 
light chain1F promoter and enhancer (Jiang et al., 2002; Messina et al., 2010). Western 
blot analysis shows that JunB was virtually absent at E12.5 in Tg:Mlc1f-Nfix2 embryonic 
myoblasts as in wild type (WT) littermates (Figure 3B). As expected JunB was also 
correctly expressed in Nfix-null fetal myoblasts (Fiure 3C-D), indicating that Nfix does not 
control JunB expression. Moreover, to evaluate if Nfix, once expressed, is able to maintain 
its own expression we transduced fetal unpurified myoblasts with a lentiviral vector 
expressing the dominant-negative Nfi-engrailed (NFI-ENG), a fusion protein composed by 





dimerization domain (Bachurski et al., 2003). The over-expression of NFI-ENG causes the 
inhibition of Nfi factor transactivation activity. The NFI-ENG fetal myoblasts show a strong 
down-regulation of Nfix, if compared with fetal myoblasts expressing only the engrailed 
domain (ENG), as control (Figure 3E), suggesting that Nfi factors activate the transcription 
of Nfix. To confirm this data we, then, performed a ChIP assay for Nfix in fetal 
differentiated myoblasts, founding a direct bind of Nfix on its own promoter, in a NFI 
consensus binding site located 1000bp upstream from the TSS (Figure 3F). Overall, these 
results demonstrate that Nfix is not able to control JunB expression, but it is able to 





















Figure	  3.	  Nfix	  does	  not	  regulate	  JunB	  but	  promotes	   its	  own	  expression	  A)	  qRT-­‐PCR	  for	  JunB	  and	  Nfix	  on	  
embryonic	   (E12.5)	  myoblasts	   transfected	  with	  Nfix	  over-­‐expressing	  vector	   (pCH-­‐Nfix2)	  or	  a	  control	  vector	  
(pCH-­‐HA)	   (***p<0.01;	  N=3).	  B)	  Western	  Blot	  on	  WT	  and	  Mlc1f-­‐Nfix2	  embryonic	  muscles	   (E12.5)	  and	  Hela	  
protein	   extracts,	   as	   positive	   control	   for	   JunB	   expression.	   The	  Western	   Blot	   show	   Nfix	   and	   JunB	   protein	  
levels	  and	  Vinculin	  was	  used	  to	  normalize	  the	  total	  amount	  of	  loaded	  proteins.	  C)	  qRT-­‐PCR	  for	  JunB	  and	  Nfix	  
on	  WT	  and	  Nfix-­‐null	  fetal	  muscles	  (E16.5),	  showing	  the	  normal	  expression	  of	  JunB	  in	  the	  absence	  of	  Nfix.	  D)	  
Western	  Blot	  on	   lysates	   from	  WT	  and	  Nfix-­‐null	   fetal	  muscles	   (E16.5).	  Vinculin	  was	  used	   to	  normalize	   the	  
total	   amount	   of	   loaded	   proteins.	  E)	   qRT-­‐PCR	   for	  Nfix	   on	   unpurified	   fetal	  myoblasts	   transfected	  with	   the	  
dominant-­‐negative	  NFI-­‐engrailed	   (NFI-­‐ENG)	   compared	  with	   fetal	  myoblasts	   expressing	  only	   the	   engrailed	  
domain	  (ENG)	  (**p<0.01;	  N=3).	  F)	  Chip	  assay	  on	  unpurified	  fetal	  myotubes	  using	  anti-­‐Nfix	  antibody,	  to	  test	  
Nfix	  binding	  on	  its	  own	  promoter	  (-­‐1000bp;	  Nfix	  promoter).	  Intergenic	  region	  has	  been	  used	  as	  a	  negative	  
control	  and	  IgG	  as	  an	  unrelated	  antibody.	  
 
 
JunB	   is	   necessary	   for	   the	   induction	  of	  Nfix	   but	  not	   for	   the	  direct	   activation	  of	   fetal	  myogenic	  
program	  
Since we observe that JunB is sufficient to promote the expression of Nfix, we decided to 
further investigate whether JunB was also necessary to activate Nfix and thus the fetal 
program (Messina et al., 2010). With this aim, we isolated by cell sorting purified fetal 
myoblasts from Myf5GFP-P/+ muscles and JunB silencing by small hairpin RNA (shRNA) was 
performed. As control Myf5GFP-P/+-purified fetal myoblasts were transduced with a 
scrambled targeting sequence vector. When cultured under conditions that promote 
differentiation, purified fetal myoblasts silenced for JunB display the typical embryonic 
phenotype, characterized by mononucleated differentiated myocytes and multinucleated 
myotubes containing only few nuclei (Supplemental Figure S2A) (Biressi et al., 2007b). 
The selective inhibition of JunB impairs fetal myoblasts differentiation and fusion as 
evidenced by decreased number of nuclei per myotube, decreased fusion index and 
decreased area of each myotubes (Supplemental Figure S2B-D). Most importantly, 
silencing of JunB abolishes the expression of Nfix, as shown in Figure 4A and in Figure 
4B, whereas the typical embryonic marker slow MyHC was robustly induced (Figure 4B). 
As the fetal program was affected, we were wondered whether the effect on fetal 





regulation of Nfix in shJunB fetal myoblasts. For this reason, we transduced shJunB 
purified fetal myoblasts with HA-tagged Nfix2 expression vector (shJunb+Nfix2) 
(Supplemental Figure S2E) and we cultured them under differentiating conditions. After 3 
days in vitro, fetal shJunB+Nfix2 cultures contained larger myotubes than fetal shJunB 
cultures with more nuclei in clusters in the center of the myotubes (Figure 4C). 
Furthermore, the morphology of shJunb+Nfix2 myotubes was similar to what observed in 
both scramble and Nfix2-transduced cultures (Figure 4C), indicating that the over-
expression of Nfix in shJunB myoblasts is sufficient to restore the fetal program. To assess 
whether the fetal morphological restoring is associated with a transcriptional change, we 
examined by Western Blot the expression of the typical embryonic marker MyHC-I. As 
show in Figure 4D, fetal myoblasts selectively inhibited for JunB expressed high level of 
slow MyHC-I after differentiation, but the up-regulation of MyHC-I is lost in shJunb+Nfix2 
fetal differentiated myoblasts, which correctly down-regulate it. Moreover, while wild-type 
(WT) embryonic myoblasts over-expressing JunB down-regulate MyHC-I and activate β-
enolase, as a consequence of Nfix up-regulation, in Nfix-null embryonic myoblasts the 
over-expression of JunB does not leads to any change in MyHC-I and β-enolase, used 
respectively as marker of embryonic and fetal myogenesis (Supplemental Figure S2F and 
Figure 4E).  These data demonstrate that JunB is required for Nfix induction and Nfix, 
acting downstream JunB, is uniquely required for the activation of the fetal program. Thus, 







Figure	  4.	  Silencing	  of	  JunB	  leads	  to	  the	  acquisition	  of	  embryonic	  features	  through	  the	  down-­‐regulation	  of	  
Nfix.	  A)	  Western	  Blot	  on	  shJunB	  or	  control	  (scramble)	  fetal	  differentiated	  myoblasts,	  showing	  a	  decrease	  in	  
Nfix	   activation	   in	   the	   absence	   of	   JunB.	   Vinculin	   was	   chosen	   to	   normalize	   the	   total	   amount	   of	   loaded	  
proteins.	  B)	   qRT-­‐PCR	   on	  Myf5GFP-­‐P/+-­‐purified	   fetal	  myoblasts	   infected	   by	   lenti-­‐shJunB	   or	   scramble	   vector,	  
analyzing	  the	  expression	  of	  Nfix	  and	  MyHC-­‐I.	  C)	  Immunofluorescence	  on	  differentiated	  Myf5GFP-­‐P/+-­‐purified	  
fetal	  myoblasts	  co-­‐transduced	  with	  shJunB	  and	  HA-­‐Nfix2	  lentivectors	  (shJunB+Nfix2)	  or	  the	  single	  and	  the	  
non-­‐targeting	  (scramble)	  vectors	  as	  controls,	  showing	  MyHCs	  (MF20)	  in	  red	  and	  Hoechst	  in	  blue.	  The	  scale	  





scramble+Nfix2,	  shJunB+pCH-­‐HA,	  shJunB+Nfix2),	   showing	  MyHC-­‐I	  expression.	  MyHCs	   (MF20)	  and	  Vinculin	  
were	  used	   to	  normalize	   the	   total	  amount	  of	   loaded	  proteins.	  E)	  qRT-­‐PCR	  on	  WT	  and	  Nfix-­‐null	  embryonic	  
myoblasts	  trasfected	  with	  JunB	  overexpressing	  vector	  or	  with	  a	  control	  vector	  (pcDNA).	  The	  analysis	  shows	  
a	  statistical	  significant	  down-­‐regulation	  of	  MyHC-­‐I	  and	  an	  up-­‐regulation	  of	  Eno3	  only	  in	  WT	  embryonic	  cells	  
that	   overexpress	   JunB.	   The	   regulation	   of	  MyHC-­‐I	   and	   Eno3	   is	   lost	   in	   Nfix-­‐null	  myoblasts	   over-­‐expressing	  
JunB	  (**p<0.01;	  ***p<0.01;	  N=3).	  
 
 
The	  axis	  RhoA/ROCK	  negatively	  regulates	  ERK	  activity	  
It has been described that the Rho GTPases RhoA is required for the myogenic process 
and their activity must be fine regulated in time to allow a proper muscle differentiation 
(Castellani et al., 1996). To understand if the activity of RhoA is timely regulated during 
prenatal muscle development, GST-Rhotekin pulldown assay was performed on lysates of 
E12.5, E14.5 and E16.5 myoblasts and the amount of active Rho GTPases was 
determined by Western Blot. As shown in Figure 5A-B, the amounts of GTP-bound 
activated Rho was higher at E12.5 and E14.5, whereas at E16.5 there is a strong 
decrease of their active state, indicating that Rho GTPases are selectively activated during 
embryonic myogenesis and shuttled down during fetal stage.  RhoA is an upstream 
activator of ROCK kinases and requires ROCK activity for its effects, which impinge 
myogenesis (Nishiyama et al., 2004; Pelosi et al., 2007). For this reason, to confirm the 
activation of RhoA signaling, we examined the phosphorylation of MYPT1 in Thr 696, 
specifically due to ROCK (Seko et al., 2003; Muranyi et al., 2005) during prenatal skeletal 
muscle development. The phosphorylation of ROCK substrate, MYPT1, was detectable 
only during early phase of myogenesis between E11.5 and E13.5, confirming that RhoA 
and ROCK are both active during primary myogenesis. The RhoA/ROCK axis is known to 
regulate many intracellular substrates to orchestrate their signaling, such as the ERK 
kinases (Zuckerbraun et al., 2003; Li et al., 2013). We therefore checked the activity of 
ERK kinesis during prenatal development. The phosphorylation of the ERK kinases, which 
is associated with their activity, is present only during fetal myogenesis, being completely 
activated starting from E14.5 until E17.5 (Figure 5D). Given that RhoA/ROCK signaling is 
engaged in the regulation of ERK activity, we tested whether the RhoA/ROCK axis 
regulates ERK activity. To this aim, unpurified embryonic myoblasts were treated with a 





demonstrates that embryonic myoblasts treated with Y27632 show a strong increase in 
ERK activity, suggesting that ROCK negatively affects the activation of ERKs. Conversely, 
the amount of phosphorylated ERK in fetal myoblasts expressing the constitutively-
activated form of RhoA (RHOV14) was decreased compared with control cells (Figure 5E-
F). Taken together, these results indicate that ROCK mediates the negative regulation of 






























Figure	   5.	   The	   axis	  RhoA/ROCK	   inhibits	   ERK	   kinases	   activity	   during	   embryonic	  myogenesis A)	   Pull-­‐down	  
assay	   on	   lysates	   of	   freshly	   isolated	   myoblasts	   at	   E12.5,	   E14.5	   and	   E16.5.	   The	   precipitated	   active	   Rho	  
GTPases	  were	  detected	  by	  Western	  Blot	   (upper	  panel)	  and	   the	  amount	  of	   input	  was	  shown	   in	   the	   lower	  
panel.	  ß-­‐tubulin	  was	  used	  to	  normalize	  the	  total	  amount	  of	  loaded	  input.	  B)	  Quantitative	  densitometry	  of	  
active	  Rho	  GTPases	  normalized	  on	   the	   ratio	  between	   the	   total	  amount	  of	  Rho	  GTPases	  and	  ß-­‐tubulin.	  C)	  
Western	  Blot	  analysis	  of	  proteins	  isolated	  from	  E11.5	  to	  E17.5	  of	  prenatal	  muscles,	  showing	  ROCK	  activity	  
through	  the	  detection	  of	  MYPT1	  known	  to	  be	  phosphorylated	  at	  Thr696	  by	  ROCK.	  The	  total	  MYPT1	   (Tot-­‐
MYPT1)	  and	  Vinculin	  were	  chosen	  to	  normalize	  the	  amount	  of	  loaded	  proteins.	  D)	  Western	  Blot	  analysis	  of	  
proteins	   isolated	   from	   E11.5	   to	   E17.5	   of	   prenatal	  muscles	   for	   phosphorylated	   ERK	   (pERK)	   and	   total	   ERK	  
(Tot-­‐ERK).	  GAPDH	  was	  used	  to	  normalize	  the	  total	  amount	  of	  loaded	  proteins.	  E)	  Western	  Blot	  analysis	  on	  
unpurified	   embryonic	   (E12.5)	   myoblasts	   treated	   daily	   with	   ROCK	   inhibitor	   (Y27632)	   or	   vehicle	   (control),	  
showing	  an	  increased	  phosphorylation	  of	  ERK	  kinases	  upon	  ROCK	  inhibition	  (left	  panel).	  In	  the	  right	  panel	  
the	   Western	   Blot	   was	   performed	   on	   unpurified	   fetal	   myoblasts	   transduced	   with	   a	   lentiviral	   vector	  
expressing	   the	   constitutively	   activated	   form	  of	   RhoA	   (RhoV14)	   or	   a	   control	   vector	   (PGK-­‐GFP),	   showing	   a	  
decrease	  in	  ERK	  phosphorylation	  in	  RhoV14	  fetal	  differentiated	  myoblasts	  compared	  with	  the	  control	  cells.	  
F)	   Quantitative	   densitometry	   of	   phosphorylated	   ERK	   kinases	   normalized	   on	   the	   ratio	   between	   the	   total	  
amount	  of	  ERK	  and	  Vinculin.	  Vinculin	  was	  used	  to	  normalize	  the	  total	  amount	  of	  loaded	  proteins.	  
	  
	  
The	  ERK	  kinases	  act	  downstream	  the	  RhoA/ROCK	  pathway	  in	  regulating	  the	  fetal	  myogenesis	  
To understand if the RhoA/ROCK axis plays a role in the regulation of JunB and Nfix, we 
analysed the effects of the ROCK inhibitor Y27632 on Myf5GFP-P/+ -purified embryonic 
myoblasts. The ROCK inhibition led to a statistically significant increase of both JunB and 
Nfix expression, while did not affect Myogenin and MyHC-emb expression (Figure 6A). As 
expected, purified embryonic myoblasts treated with Y27632 showed also a strong 
decrease in the expression of MyHC-I, whereas the fetal marker β-enolase (Eno3) was 
precociously expressed in embryonic treated myoblasts (Figure 6A). The precious 
expression of JunB and Nfix and the down-regulation of slow MyHC upon ROCK inhibition 
were evaluated also by Western Blot (Figure 6B). Conversely, Myf5GFP-P/+-purified fetal 
myoblasts transduced with a lentiviral vector expressing the constitutively-activated form of 
RhoA (RHOV14) had a dramatic decrease of JunB and Nfix mRNA levels, while MyHC-I 
was highly expressed, instead of being repressed. Moreover, purified over-expressing 





indicating that RHOV14-expressing fetal myoblasts acquire a more embryonic-like gene 
transcription profile (Figure 6C). Western Blot analysis confirmed that the two fetal 
transcription factors analyzed, JunB and Nfix, were strongly down-regulated in RHOV14 
fetal myoblasts, whereas slow MyHC was robustly induced (Figure 6D). Considering that 
RhoA and ROCK negatively affect the activation of ERK, we wondered whether the ERK 
kinases would regulate JunB and Nfix expression. For this reason, we treated unpurifed 
fetal myoblasts with ERK antagonist, PD98059, and we examine by Western Blot both 
JunB and Nfix protein levels. The immunoblot in Figure 6E reveals that the expression of 
JunB and Nfix were substantially reduced in PD98059-treated fetal myoblasts, indicating 
that ERK kinases positively regulate fetal myogenesis, through the activation of JunB and 
Nfix. Thereafter, we examined whether ERK are the downstream module of RhoA/ROCK 
signaling during myogenesis. As shown in Figure 6F, ROCK inhibition in embryonic 
myoblasts enhanced ERK phosphoylation and activation leading to the consequent up-
regulation of JunB and Nfix, but the co-incubation of Y27632 and PD98059 led to a strong 
reduction of JunB and Nfix, that were not expressed as in control embryonic myoblasts. 
This result indicates that ERK kinases are downstream effectors of RhoA/ROCK during 

















Figure	   6.	   RhoA	   and	   ROCK	   negatively	   regulate	   fetal	  myogenesis	   by	   inhibiting	   JunB	   and	   Nfix	   while	   ERK	  
activity	  promotes	  their	  expression	   	  A)	  qRT-­‐PCR	  on	  Myf5GFP-­‐P/+-­‐purified	  embryonic	  myoblasts	   treated	  with	  
ROCK	  inhibitor	  (Y2763)	  or	  vehicle,	  analyzing	  the	  expression	  of	  embryonic	  and	  fetal	  markers	  following	  ROCK	  
inhibition.	  B)	  Western	  Blot	  analysis	  on	  unpurified	  embryonic	  myoblasts	  upon	  ROCK	  inhibition	  or	  in	  control	  
myoblasts,	   showing	  an	   increased	  expression	  of	  both	   JunB	  and	  Nfix	  and	  a	  consequent	  down-­‐regulaiton	  of	  
MyHC-­‐I.	  MyHCs	  (MF20)	  and	  Vinculin	  were	  used	  to	  normalize	  the	  total	  amount	  of	  loaded	  proteins.	  	  C)	  qRT-­‐
PCR	  on	  Myf5GFP-­‐P/+-­‐purified	  fetal	  myoblasts	  transduced	  with	  the	  constitutively	  activated	  RhoA	  (PGK-­‐RhoV14)	  
or	  control	  (PGK-­‐GFP)	  lentivectors	  to	  check	  the	  expression	  of	  embryonic	  and	  fetal	  markers.	  D)	  Western	  Blot	  
analysis	   on	   unpurified	   fetal	   myoblasts	   over-­‐expressing	   the	   constitutively-­‐activated	   form	   of	   RhoA	   (PGK-­‐
RhoV14)	  or	  control	   (PGK-­‐GFP)	  to	  analyze	  the	  protein	   levels	  of	   JunB,	  Nfix	  and	  MyHC-­‐I.	  MyHCs	  (MF20)	  and	  
Vinculin	  were	   used	   to	   normalize	   the	   total	   amount	   of	   loaded	   proteins.	   E)	  Western	   Blot	   analysis	   on	   fetal	  
myoblasts	   treated	   with	   ERK	   inhibitor	   (PD98059)	   or	   vehicle,	   showing	   the	   inhibition	   of	   JunB	   and	   Nfix	  
expression	   after	   treatment	   with	   PD98059.	   Vinculin	   was	   used	   to	   normalize	   the	   total	   amount	   of	   loaded	  
proteins.	   F)	   Western	   Blot	   analysis	   on	   unpurified	   embryonic	   myoblasts	   co-­‐treated	   with	   ROCK	   inhibitor	  
(Y27632)	  and	  ERK	  inhibitor	  (PD98059)	  using	  as	  a	  control	  not	  treated	  myoblasts	  and	  cells	  treated	  with	  the	  
singular	   inhibitor.	  The	  co-­‐treatment	  blocks	  the	  up-­‐regulation	  of	   JunB	  and	  Nfix,	  observed	   in	  the	  myoblasts	  







Prenatal skeletal muscle development is achieved in two distinct phases to fulfil the 
different needs of a developing embryo (Biressi et al., 2007a; Stockdale, 1992; Tajbakhsh 
and Buckingham, 2000). During the embryonic stage, embryonic myoblasts participate to 
the formation of primary slow-twitching fibers, which form the first architecture of skeletal 
muscles, while, during the fetal stage, fetal myoblasts differentiate in secondary fast-
twitching fibers. Embryonic and fetal myoblasts are heterogeneous populations of muscle 
progenitors, which differ in term of morphology, response to growth factors and gene 
expression, being they intrinsically different (Biressi et al., 2007b). To allow the complete 
maturation of prenatal skeletal muscles a temporal switch from embryonic to fetal 
myogenesis is needed. This transition is accompanied by changes in gene expression; 
indeed embryonic-derived fibers express high level of MyHC-I and MyHC-emb, while fetal-
derived fibers are negative for MyHC-I and MyHC-emb but express glycolytic enzymes, 
such as β-enolase, and fast-twitching isoforms of MyHC, as the neonatal MyHC (Schiaffino 
et al., 1986). Nowadays, there have been some advances in understanding the regulation 
of embryonic to fetal transition, and we know that the gene expression program, that 
establishes fetal myogenesis, is mainly controlled by Nfix (Messina et al., 2010). It has 
been demonstrated that Nfix, is specifically expressed during fetal myogenesis, when it 
drives the activation of the fetal genetic program (Messina et al., 2010; Taglietti et al., 
2016). Intriguingly, the second transcription factor specifically expressed during fetal 
development is JunB (Biressi et al., 2007b), which plays a crucial role in the maintenance 
of postnatal muscle physiology (Raffaello et al., 2010). Our finding that JunB and Nfix are 
co-expressed in fetal progenitors and that JunB target Nfix expression indicate that JunB is 
a direct activator of Nfix at the beginning of fetal myogenesis.  Indeed, the silencing of 
JunB in fetal myoblasts is associated with the acquisition of an embryonic phenotype, 
which is completely rescued with the over-expression of Nfix. Our data demonstrate that 
the fetal genetic program is fully governed by Nfix, being the switch of the two phases of 
prenatal muscle development strikingly dependent on it. Thus, we demonstrate that JunB 
alone is not able to regulate the transition from embryonic to fetal myogenesis. 
Interestingly, in adult muscle, the lack of JunB results in atrophic myofibers, because of its 
inhibitory effect on myostatin expression (Raffaello et al., 2010), and the same phenotype 
were observed modulating Nfix expression (Rossi et al., 2016). Indeed, in postnatal 
skeletal muscles, Nfix-deficiency causes a reduction in the mean cross-sectional area of 





observations suggest that JunB may exert its functions in adult skeletal muscles through 
the activation of Nfix. Starting from the consideration that both JunB and Nfix are 
necessary for the maintenance of adult skeletal muscle mass, to deeper elucidate the 
signalling signalling involved in the temporal regulation of muscle development 
progression, we focused our attention on RhoA GTPases and on ERK kinases. Indeed, 
both RhoA GTPases and ERK kinases have been suggested to impact on myofiber size, 
but, while the inhibition of RhoA signalling leads to increased fiber size (Coque et al., 
2014), the inhibition of ERK cascade elicits in muscle atrophy, with a reduction in fiber 
calibre (Haddad & Adams, 2004; Shi et al., 2009). Interestingly, it was also reported that 
RhoA exerts its cellular effects through the activation of Rho-Kinases, ROCK (Schofield 
and Bernard, 2013), which in turn negatively regulates ERK activity (Li et al., 2013; 
Khatiwala et al., 2009). Although the relationship between the activity of RhoA and ERK 
kinases was not characterized in prenatal skeletal muscle development, we speculate that 
their activity may be involved in the control of JunB and Nfix expression. Time course 
experiments reveal a pronounced enrichment of RhoA and ROCK activity specifically 
during embryonic myogenesis, while ERK kinases are activated only during fetal 
myogenesis. Interestingly, we demonstrate that RhoA/ROCK pathway negatively controls 
the ERK function, which is suppressed when the RhoA/ROCK signaling is activated. Our 
data highlight the importance of RhoA/ROCK/ERK axis during skeletal myogenesis, and 
this let us to study whether JunB and Nfix are affected by RhoA/ROCK/ERK signaling. We 
show that the RhoA/ROCK pathway represses JunB and Nfix expression, leading to a 
change in the transcriptional profile of muscle progenitors. In particular, the constitutive 
activation of RhoA in fetal myoblasts causes a persistence of the embryonic marker 
MyHC-I, due to the down-regulation of JunB and Nfix. Conversely, the inhibition of ROCK 
in embryonic myoblasts provokes an up-regulation of JunB and Nfix, which correlates with 
a down-regulation of MyHC-I and a precocious expression of β-enolase. Based on these 
finding, we decide to deeper investigate also the role of ERK kinases during fetal 
myogenesis, revealing their crucial role in promoting the fetal program through the positive 
regulation of JunB and Nfix. These results display that the RhoA/ROCK/ERK axis 
constitutes, at least, one of the major signaling pathway that regulates the temporal 
progression of prenatal myogenesis. However, it remains unknown the upstream inputs, 
which orchestrate the activation or inhibition of these signaling pathway. Understanding 
how myogenic progenitors are instructed during skeletal myogenesis will be crucial for the 





populations of myoblasts and in the achievement of their respective identities. In 
conclusion, we have identified the RhoA/ROCK pathway as an important regulator of 
embryonic myogenesis, that maintains JunB and Nfix repressed through the inhibition of 
ERK activity. With the progression of prenatal development, the RhoA/ROCK signaling is 
progressively decreased, allowing the activation of ERK kinases, which are necessary for 
JunB and Nfix expression. Finally, we demonstrate that the transition from embryonic to 
fetal is strikingly dependent on Nfix, whose expression is directly regulated by JunB. 
Identification of these signaling pathways may contribute to augment the knowledge of the 









Supplemental Figure S1. JunB and Nfix are co-expressed in fetal myoblasts, with JunB earlier 
expressed than Nfix 
A-D) Immunofluorescence for JunB (red) and Nfix (green) on freshly isolated Myf5GFP-P/+-purified 
myoblasts at E14.5. Nuclei were counterstained with Hoechst. White arrows indicate myoblasts coexpressing 
JunB and Nfix, while yellow arrows indicate myoblasts expressing JunB but not Nfix at E14.5 (A-B) and at 
E15.5 (C-D). Scale bars: 25 µm. E-F) Immunofluorescence for JunB (red) and Nfix (green) on freshly 
isolated Myf5GFP-P/+-purified myoblasts at E16.5. Nuclei were counterstained with Hoechst. White arrows 
indicate myoblasts coexpressing JunB and Nfix, while light blue arrows indicate myoblasts expressing Nfix 





Supplemental Figure S2. Silencing of JunB impairs the differentiation of fetal myotubes 
A) Immunofluorescence for total MyHCs (MF20) on differentiated Myf5GFP-P/+-purified fetal myoblasts 





the non-targeting control vector (scramble). The shJunB-expressing fetal myotubes acquire the typical aspect 
of embryonic myotubes. B) The fusion ability was quantified by counting the number of nuclei for each 
terminally differentiated myotubes. **p<0.01. C) Calculation of the fusion index as the ratio of the number 
of nuclei inside myotubes to the number of total nuclei. ****p<0.0005. D) Quantification of MyHCs positive 
area (MF20) using image analysis software. ***p<0.005. E) qRT-PCR for JunB and Nfix on fetal myoblasts 
(E16.5) following the transduction with scramble or shJunB vector and with control or Nfix2-over-
expressing vector. ***p<0.005; N=3. F) qRT-PCR on wild-type (WT) and Nfix-null embryonic myoblats 





Material and methods 
Mutant Animals 
Myf5GFP-P/+ (Kassar-Duchossoy et al., 2004), Tg:MLC1f-Nfix2 (Messina et al., 2010), Nfix-null, 
obtained from Prof. Richard M. Gronostajski (University of Buffalo) (Driller et al., 2007), and wild-
type CD1 mice (Charles River) were used and their genotyping strategies have been published in 
the references. Female mice were mated with males (2:1) and examined every morning for 
copulatory plugs. The day on which a vaginal plug was found was designated as 0.5 gestation day. 
Mice were kept in pathogen-free conditions and all procedures were conformed to Italian law (D. 
Lgs n 2014/26, implementation of the 2010/63/UE) and approved by the University of Milan 
Animal Welfare Body and by the Italian Ministry of Health. 
 
Cell isolation and Cell Culture 
Myf5GFP-P/+ embryonic muscles, isolated at E12.5, or fetal muscles, isolated at E16.5, were 
mechanically and enzimatically digested for 30 min at 37°C in agitation with 1.5 mg/ml of Dispase 
(Gibco), 0.15 mg/ml of Collagenase (Sigma), and 0.1 mg/ml Dnase I (Sigma) as previously 
described (Biressi et al., 2007b). Dissociated cells were filtrated and collected in DMEM high-
glucose (EuroClone), 20% fetal bovine serum (FBS, EuroClone), 2mM EDTA and 20mM HEPES. 
The GFP-positive myoblasts were sorted using Sorted BD FACSAria and cultured in 20% horse 
serum (HS) medium composed by DMEM high-glucose (EuroClone), 20% HS (EuroClone), 2mM 
L-Glutamine (Sigma-Aldrich) and 1% Penicillin/Streptomycin (Euroclone). Unpurifed embryonic 
and fetal myoblasts were obtained using the same enzymatic and mechanic procedure utilized for 
Myf5GFP-P/+-sorted myoblasts, but after the digestions the obtained cells were pre-plated on plastic 
dish to allow the attachment of fibroblasts. The non-adherent cells were collected and incubated at 
37°C in 20% HS. The differentiation was induced decreasing the serum from 20% to 2% and 
maintaining the cells in 2% HS for 48h or 72h after the medium changing. Embryonic myoblasts 
were treated daily with 10 µg/µL of ROCK inhibitor Y27632 (Calbiochem). Fetal myoblasts were 
treated over night (O/N) with 50 mM of ERK antagonist PD98059 (Cell Signaling).  
 
Plasmids and lentivirus production 
 The following plasmids were used: pCH-Nfix2, pCH-HA (Messina et al., 2010), pLentiHA-





(SHCLNG-NM_008416, Sigma-Aldrich), PGK-RHOV14 and pcDNA3X-JunB or pcDNA3X, as 
control. pcDNA3X-JunB plasmid was obtained by subcloning the JunB cDNA (kindly provided by 
Milena Grossi, University of Rome) in the pcDNA3X vector (ClonTech), whereas PGK-RHOV14 
has been produced by cloning the cDNA of RhoA with a single point replacement of glycine with 
valine at positions 14, RHOV14 (kindly provided by Germana Falcone, CNR Rome), in PGK-GFP 
vector. 
Viral particles were prepared through the co-trasfection of the packaging plasmids pMDLg/p 
(16.25µg), pCMV-VSVG (9µg) and pRSV-REV (6.25µg) together with each of the following 
lentiplasmids: shJunB, pLentiHA-Nfix2, PGK-RHOV14 and the respective controls, as scramble, 
pLentiHA and PGK. Transfection was performed in HEK293T cells by using Calcium Phosphate 
Transfection method. Viral particles were collected 40h after transfection and concentrated with 
Lenti-X Concentrator (CloneTech) in PBS 1X. The concentrated viral particles were stored at -80°C 
until use.  
 
Cell transfection and transduction 
For transfection experiments, embryonic or fetal myoblasts were cultures at a confluency of 70%-
80% and transfected following the Lipofectamine™ LTX (Invitrogen) transfection protocol. 
Myoblasts were harvested 48 h after transfection. Transduction of fetal myoblasts was performed by 
addition of the viral preparation to the cultured cells at the multiplicity of infection (MOI) of 10. 
After O/N incubation, the medium was changed and the cells were maintained in culture for 72 h 
after the medium changing, to allow their differentiation. 
 
Immunofluorescence on cultured cells 
Cell cultures were fixed for 10 min at 4°C with 4% paraformaldehyde in PBS 1X and then were 
permeabilized with 0.2% Triton X-100 (Sigma-Aldrich), 1% BSA (Sigma-Aldrich) in PBS 1X for 
30 min at room temperature (RT). After the permeabilization, the samples were treated with a 
blocking solution composed by 10% goat serum (Sigma-Aldrich) for 45 min at RT and incubated 
O/N at 4°C with primary antibody diluted in PBS. The primary antibodies used are: rabbit anti-Nfix 
(1:200, Novus Biologicals) and mouse anti-JunB (1:100, SantaCruz Biotechnology). After two 
washes with PBS, 1% BSA and 0.2%Triton the samples were incubated for 45 min at RT with 





cells were washed twice with 0.2% Triton in PBS and mounted with Fluorescence Mounting 
Medium (Dako). Images were acquired with Leica-DMI6000B fluorescence microscope equipped 
with Leica DFC365FX camera. And images were merges with Photoshop.  
 
RNA extraction, Retrotranscripion and Real-Time qPCR  
NucleoSpin kits RNA XS (Macherey-Nagel) was used for the extraction of total RNA from cultured 
cells or freshly isolated myoblasts. After quantification of RNA with a NanoPhotometer (Implen), 
0.5 µg of total RNA was retrotranscribed with iScript Reverse Transcription Supermix (Bio-Rad). 
The obtained cDNA was diluted 1:10 in S.A.L.F. water and 5 µl of diluted cDNA was used for the 
Real-Time qPCR. Real-Time qPCR was performed using SYBR Green Supermix (Biorad) and the 
primers are listed in Table S1. Relative mRNA expression levels were normalized on GAPDH 
expression levels.  
 
Protein extraction and Wester Blot 
Protein extracts were obtained from cultured myoblasts lysed with RIPA buffer (10mM Tris-HCl 
pH 8.0, 1mM EDTA, 1% Triton-X, 0.1% sodium deoxycholate, 0.1% SDS, 150mM NaCl in 
deionized water) for 30 min on ice, while total protein extracts from embryonic and fetal muscles 
were obtained from homogenized tissues in Tissue extraction Buffer (50mM Tris-HCl, 1mM 
EDTA, 1% Triton-X, 150mM NaCl). Both RIPA and Tissue extraction Buffer were supplemented 
with protease and phosphatase inhibitors. After lysis, samples were centrifugated at 4°C for 10 min 
at 10000 rpm and the supernatants were collected and quantified using the DC Protein Assay (Bio-
Rad). For the Western Blot assay 30µg of protein extract were denaturated at 95°C for 5 min with 
SDS Page Loading samble buffer (100mM Tris pH 6.8, 4% SDS, 0.2% Bromophenol blue, 20% 
Glycerol and 10mM dithiothreitol) and loaded on 8% SDS acrylamide gel. After electrophoresis 
running, proteins were blotted to a nitrocellulose membrane (Whatman, Protran Nitrocellulose 
Transfer Membrane), which was blocked for 1 h with 5% milk in Tris-buffered saline solution plus 
0.02% Tween20 (Sigma-Aldrich). The primary antibodies were incubated O/N at 4°C in agitation 
using the following conditions: rabbit anti-Nfix (1:1000, Novus Biologicals), rabbit anti-JunB 
(1:500, SantaCruz Biotechnology), mouse anti-Vinculin (1:2500, Sigma-Aldrich), mouse anti-slow 
MyHC (hybridoma Bad5, 1:2, DSHB); mouse anti-total MyHC (hybridoma MF20, 1:5, DSHB), 
rabbit anti-MYPT1 phosphorylated in thr696 (1:500, SantaCruz), rabbit anti-Tot MYPT1 (1:500, 





ERK (1:500, SantaCruz Biotechnology) and mouse anti-GAPDH (1:5000, Sigma-Aldrich). Blots 
after primary antibody incubation were washed and incubated with secondary antibodies (1:10000, 
IgG-HRP, Bio-Rad) for 40 min at RT and washed again. The bands were revealed using ECL 
detection reagent (ThermoFisher) and images were acquired using the ChemiDoc MP System 
(Biorad). 
 
Chormatin Immunoprecipitation (ChIP) assay 
The ChIP protocol was performed on unpurified fetal differentiated myoblasts (E16.5) using 5x106 
cells for each immunoprecipitation. Fetal myotubes were fixed with 1% formaldehyde (Sigma-
Aldrich) in DMEM high-glucose for 10 min at RT. The fixation was quenched with 125mM 
Glycine (Sigma-Aldrich) in PBS 1X for 10 min at RT. The cells were rinsed with cold PBS, 
harvested and centrifugated for 10 min at 2500 rpm at 4°. The cell pellet was lysated and sonicated 
with a Bioruptor Sonicator (Diagenode) for 15 min, with repeated cycles of 30 sec of sonication and 
30 sec of resting. The sonicated suspension was centrifugated for 10 min at 14000rmp at 4°C and 
the supernatant was stored in aliquots at -80°C. Chromatin was precleared with Protein G Sapharose 
(Amersham) and Rabbit Serum for 2 h at 4°C on a rotating platform, while Protein G Sapharose 
was blocked O/N with BSA (10mg/ml) and Salmon Sperm (1 mg/ml) (Sigma-Aldrich).  After 
preclearance, chromantin was incubated O/N at 4°C with 5 µg of antibody: rabbit anti-Nfix (Novus 
Biologicals), mouse anti-JunB (SantaCruz Biotechnology) and normal rabbit IgG (SantaCruz 
Biotechnology). The day after blocked Protein G Sapharose was washed and added to the chromatin 
incubated with the antibodies for 3 h in rotation at 4°C. After incubation, the Protein G Sapharose 
was spun down and repeatedly washed. The elution was performed O/N at 65°C with 10 mg RNase 
(Sigma-Aldrich) and 200 mM NaCl (Sigma-Aldrich) to reverse crosslink. The DNA was purified 
with phenol/chloroform, after treatment with 20 µg of Proteinase K (Sigma-Aldrich). Obtained 
DNA was analyzed by Real-time qPCR and results were plotted as fold enrichment with respect to 
the IgG sample. Primers used are listed in Table S2. 
 
Pull-Down assay 
Active Rho Pull-Down and Detection kit (ThermoScientific) was performed on 600 µg of cell lysate 









Gene Primers sequence Reference 
Nfix F: 5’-CACTGGGGCGACTTGTAGAG-3’ 
R: 5’-AGGCTGACAAGGTGTGGC-3’ 
Mourikis et al. 
2012 
JunB F: 5’-	  CCTGTGTCCCCCATCAACAT-3’ 
R: 5’-	  CAGCCTTGAGTGTCTTCACCT-3’ 












Mathew et al. 
2011 
Eno3 F: 5’-TTCTACCGCAACGGCAAGTA -3’ 
R: 5’-GACCTTCAGGAGCAGGCAAT-3’ 
 
Myogenin F: 5’-CTGGGGACCCCTGAGCATTG-3’ 




F: 5’-	  AGCTTGTGGTAAGACATGCTTG-3’ 
























F: 5’-	  ACACTAGGATTGAGGAAGACTTAGA-3’ 












R: 5’-GTTTTTGGTVTCCAACTGCCG -3’ 
 
Intergenic F: 5’-	  TCGGACCGGAGTGTTAGGAA -3’ 
R: 5’- ACCCTGGAGTCTCAGCATCG -3’ 
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